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ABSTRACT 
Background: 
There is a lack of commercially-available, age-appropriate formulations designed for 
administration to babies and children. This means that medicines may need to be 
manipulated to achieve the dose that is required in paediatric practice. This raises 
concerns about the dose accuracy and safety of the manipulated product. Though 
this is known and accepted as necessary, to date there has been no assessment of 
the evidence relating to these manipulations, the extent and nature of 
manipulations or of any associated practice issues.     
Objective:  
This thesis aimed to determine whether there is an evidence base for drug 
manipulations, to investigate the nature of manipulations, at the point of 
administration, in current clinical practice in neonatal and paediatric settings in the 
UK and to explore drug manipulations in the context of long-term medication 
administration by parents. 
Methods: 
Several methods were used to explore drug manipulations: a wide-ranging 
systematic review, an observation based study of drug manipulations in in-patient 
neonatal and paediatric areas, a UK wide survey of paediatric nurses and an 
interview based study with parents of children taking long-term medications.    
Outcomes:  
Manipulations to administer the required dose occur throughout practice and are 
not supported by evidence. Drug manipulation is intrinsic in neonatal and paediatric 
practice. Manipulations were identified more often in high dependency areas but 
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were found throughout all clinical areas. Manipulations occurred more commonly 
with certain dosage forms, notably with tablets, but were found involving many 
dosage forms. Manipulations were identified involving drugs that are commonly 
prescribed and for prescriptions that had been written for babies and children of all 
ages and with a wide variety of diagnoses. Concerns relating to drug manipulations 
have been raised by those working in these areas. Parents described undertaking 
manipulations prior to administering medications to children, though undertaking 
these manipulations did not appear to cause undue concern.  
Conclusions: 
This thesis has reviewed the limited evidence, scoped out the nature of 
manipulations used in practice and by parents and suggested areas where future 
work would be appropriate. In exploring drug manipulation this thesis has added to 
ongoing discussion about the need for appropriate medication for paediatric use.  
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CHAPTER 1: BACKGROUND TO DRUG MANPULATION IN PAEDIATRIC PRACTICE 
AND NEED FOR THE RESEARCH IN THIS THESIS 
 
1.1 PAEDIATRIC DRUG DEVELOPMENT  
There is considerable use of prescribed drugs by children, it has been estimated 
that in a year 200 million prescriptions for children and adolescents were issued in 
the UK (Costello et al., 2004). Differences in age, maturity and development, 
alongside the possible impact of any illness they may have, mean that the types and 
dosage of medications appropriate for babies and children may vastly vary. 
However, historically clinical drug development has not included clinical trials that 
have investigated the safety and effectiveness of the drug in children. The reasons 
for this include: the cost of studies compared with the size of the potential market, 
difficulties in trial design, time taken to complete studies in children as compared to 
adults, and the unique and complex ethical issues surrounding research with child 
participants, such as concern about obtaining consent from children and their 
parents/guardians and any risk of possible effects of the trial medications on a 
child’s development (Rocchi et al., 2010). Furthermore, for many potential 
treatments the small populations of children that require the medicine mean that 
trials can only be carried out by the recruitment of children from large numbers of 
centres (Waller, 2007). With most studies having been conducted with adults, 
pharmacokinetic and pharmacodynamics studies have produced little data on drug 
effectiveness and safety data relating to children. The results of studies done in 
adults may be extrapolated for use in children in some circumstances (Yewale and 
Dharmapalan, 2012). Extrapolation can be useful and avoid trials but it can be 
misleading if not done carefully. Age dependent changes in physiological factors 
make the data extrapolated from clinical studies in adults inappropriate for children 
and demonstrate the need for paediatric clinical trials (Hsien et al., 2008). There has 
not been sufficient economic incentive for pharmaceutical companies to develop 
and trial medicines specifically for use in children or to extend clinical trials to 
include children. There has also been a trend for UK companies to discontinue 
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licensed paediatric formulations because of low demand (Nunn, 2003). 
Consequently, many medicines have been licensed for use in adults but not for use 
in children. This can lead to situations like those described by (Conroy et al., 2003) 
in which some of the chemotherapy drugs used in children have been 
recommended for use in trials. However the manufacturers state that safety and 
effectiveness in children have not been established and that specific dose 
recommendations for children cannot be made due to insufficient use in 
paediatrics. The licensing process offers reassurance that medicines are safe, 
effective and of acceptable quality. Medicines used as unlicensed or off-label are 
not supported by the reassurance that this system provides (Conroy et al., 2003). 
Consequently evidence-based prescribing for children is compromised by a lack of 
satisfactory data on many drugs. Studies have reported that 50%-70% or 50-90% of 
medicines used in children have not been studied adequately in the paediatric 
population (Yewale and Dharmapalan, 2012). Specialist treatment may be at the 
higher end of these ranges, as it has been reported that more than 80% of 
prescriptions for children with cancer and 90% of those for neonates are for 
medicines which have not been licensed for that use (Turner et al., 1998, Paolucci 
et al., 2008). A review which included UK prescriptions from 2007 found that only 
43% of UK prescriptions were both licensed for children and suitably formulated for 
children (Ragupathy et al., 2010). Accordingly many of the drugs administered to 
children are products which have not been designed for paediatric use. This does 
not only mean that the dose may not be appropriate for paediatric use. It may also 
mean that any impact of organoleptic properties on children may not have been 
considered. While an adult may be able to rationalise taking a bitter tasting 
medicine this may be more challenging for a child. Or a tablet that may appear to 
be of a reasonable size to swallow to an adult may be viewed differently by a child. 
There are additional consequences from this lack of development of paediatric 
formulations such as the non-availability to the paediatric population of therapeutic 
advances (Rocchi and Tomasi, 2011).  
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1.2 PAEDIATRIC DRUG PRESCRIBING  
The provision of appropriate doses of drugs for babies and children is complicated 
by the considerable physiological changes associated with childhood. Virtually all 
pharmacokinetic parameters change with age. Dosing regimens need to take into 
account factors such as growth, organ development and sexual maturation; 
furthermore drugs may directly or indirectly affect childhood development, though 
this may not be apparent for decades (Sinha and Cranswick, 2007a). The frequently 
applied phrase is that children are not small adults and cannot be treated as such. 
The developmental changes throughout childhood affect the responses to 
medications. The way that drugs are absorbed, distributed, metabolised and 
eliminated in children cannot be reliably predicted from adult data (Kearns et al., 
2003; Standing and Tuleu, 2005). Furthermore growth is not a linear process; age 
associated changes in body composition and organ function are dynamic and can be 
discordant during the first decade of life (Kearns et al., 2003). Therefore the size of 
the dose administered may need to be variable throughout childhood, often in 
proportion to body weight, body surface area, or age (Nunn, 2003). In addition 
there can be rapid and dramatic differences in a child’s weight over time, 
necessitating frequent dose recalculations (Conroy et al., 2007). A recent review of 
paediatric gastrointestinal physiology data relevant to oral drug delivery noted that 
stated physiological values in children vary greatly within the literature and 
concluded that improved understanding of measurements of paediatric 
gastrointestinal physiology should help produce a better understanding and 
prediction of drug effectiveness and safety in different age groups (Kaye, 2011). All 
drugs have a therapeutic range below which they do not work and above which 
they are toxic (Yewale and Dharmapalan, 2012). The toxicity of many medicines in 
children is different to that seen in adults and careful consideration of the effect of 
excipients is important, this was demonstrated when some of the major adverse 
drug reactions in children were reviewed (Choonara and Rieder, 2002). As 
knowledge of growth and development has increased so has the recognition that 
developmental changes affect the responses to medications and the need for age-
dependent adjustments in doses (Kearns et al., 2003).    
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1.3 MEASURES TO PROMOTE PAEDIATRIC DRUG DEVELOPMENT  
There has been increasing global awareness of the neglect in drug development for 
children’s medicines. Market forces alone have proved insufficient to stimulate 
adequate research on the specific authorisation of medicinal products for the 
paediatric population (Rocchi and Tomasi, 2011). Therefore regulations have been 
implemented by both the Food and Drug Administration (FDA) in the US and the 
European Medicines Agency (EMA) to incentivise the development and availability 
of medicines for children. The World Health Organisation (WHO) developed the 
‘Better Medicines for Children’ programme to consider research and development 
gaps and factors limiting access and use (Finney, 2011).     
EU regulations have applied since 2007 (Regulation (EC) 1901/2006 as amended) 
and include the early involvement of children in drug development by a 
pharmaceutical company via an agreement on the proposed process for a new 
medicinal product or measures to adapt the formulation of the medicinal product 
for use in paediatrics  –  the Paediatric Investigation Plan (PIP). This involves an 
agreement on the proposed paediatric clinical trials or a waiver if the drug is not 
appropriate for paediatric use (Rocchi et al., 2010). When a PIP is completed an 
extra six months patent protection will be granted, whether or not the data support 
a paediatric indication. The Regulation also established a new type of marketing 
authorisation, the paediatric use marketing authorisation (PUMA), intended to 
stimulate the development of off-patent products for use in children (Rocchi et al., 
2010). The European Paediatric Formulation Initiative (EuPFI) group of paediatric 
formulation experts from industry, academia and clinical pharmacy was founded 
with the aim of raising awareness of paediatric formulation issues (Cram et al., 
2009).    
While this increased focus will encourage future paediatric drug development 
further, there have been some questions raised about whether the impact is 
addressing priority areas for paediatric medicine. Olski et al., (2011) considered the 
impact of three years of the European paediatric regulation, they noted that most 
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of the applications for PIPs or waivers were in areas of economic importance for the 
adult market (such as endocrinology, oncology, infectious diseases, cardiovascular 
disease) and that these do not necessarily match the areas of need within children’s 
medicines. Viergever et al., (2011) reported globally on the collection of 
pharmacokinetic data in clinical trials in children. This report identified that of the 
1081 trials researching medicines in children only a quarter were collecting 
pharmacokinetic data. Additionally the analysis identified supplementary gaps; 
notably that in trials where pharmacokinetic data was being collected only one 
third of the drugs included were on the EMA priority list, furthermore priority age-
groups, such as neonates, were studied less (Viergever et al., 2011). These reports 
have established that while progress is being made, there are still considerable 
issues with the availability of age, dose and condition appropriate paediatric 
medicines. The EMA has yet to publish its experience with supporting the 
development of age-appropriate formulations.         
 
1.4 OFF LABEL AND UNLICENSED PRESCRIBING  
The historical and current situation is that appropriate paediatric drug doses and 
dosage forms are poorly available. This means that decisions have to be made on 
whether to prescribe and administer drugs which are unlicensed or where their use 
will be off-label (off label use involves prescribing outside the product license or 
prescribing a dose that is unlicensed). A number of situations may occur. Medicines 
may not be licensed for use in those under 18 years or may only be licensed for 
some paediatric age-groups. The route of administration required may not be one 
that the medicine has been approved for. It may be licensed for a different 
indication than that for which it is being used or may not be licensed at all (Hill, 
2005; Hsien et al., 2008). Off-label or unlicensed use may be in the best interest of 
the child if no other treatment with a comparable benefit-risk ratio is available 
(Hoppu, 2008). Prescribing needs to be appropriate for the age, developmental 
stage and clinical condition of the child. Several studies have shown that prescribing 
unlicensed and/or off-label medicines is more frequent for children than for adults. 
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A study across children’s wards in the UK, Sweden, Germany, Italy and the 
Netherlands found that 46% (1036/2262) of all drug prescriptions were either 
unlicensed or used off-label (Conroy et al., 2000). A study that considered the use 
of off-label drugs in a paediatric ward in Germany found that 16.4%-75% of off-label 
prescriptions were due to dose, 0%-40.3% were due to indication and 9%-55.8% 
were due to age (Hsien et al., 2008). This use of unlicensed and off label drugs has 
been noted to be at an even higher level within neonatal intensive care areas 
(Conroy et al., 1999). This applies globally. The use of unlicensed and off-label 
medicines in babies and children is common practice in healthcare settings in the 
USA, Europe and Australia (Di Paolo et al., 2006). Choonara (2009) noted that there 
is a growing recognition that the key issues in relation to drug therapy in children, 
such as whether the formulation is appropriate for the age of the patient, are 
similar in high income countries and low and middle income countries.  
The use of off label or unlicensed prescribing may raise concerns about disciplinary 
or litigious action, it is legal and it is currently accepted that this prescribing in 
paediatric practice may be best practice when no suitable alternative is available 
(Conroy and Peden, 2001; Hill, 2005; Sinha and Cranswick, 2007a) . Without such 
prescribing effective treatment would be denied to many children (Sutcliffe, 1999). 
Associations have been made between the use of unlicensed drugs and dispensing 
and administration errors.  In both neonates and children, unlicensed drugs have 
been shown to be significantly more likely to be associated with medication errors 
than licensed drugs (Conroy, 2011), and with an increased risk of adverse events 
(Bush, 2006).    
 
1.5 DRUG MANIPULATION  
As many of the drugs prescribed for children were designed for and tested in adults, 
logically they are predominantly available as single dosage units suitable for adults. 
Many of these are frequently larger than those required for paediatric use. This can 
create a situation where the drug dose is available as a tablet, capsule, sachet, 
suppository or enema but the dose which is required is a fraction of the whole dose 
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available in that single dosage unit. This lack of commercially available, age-
appropriate formulations can make it difficult to administer medication to children. 
Medicines may require manipulation at the point of administration by opening, 
splitting, crushing or dispersing the tablet, capsule, sachet, suppository or enema 
and trying to calculate and measure a smaller dose that is a fraction of the original 
whole dose. Additional difficulties arise as the magnitude of doses required through 
childhood can vary up to 100-fold and the ability of children to cope with different 
dosage forms can also vary considerably (Rocchi and Tomasi, 2011). With 
intravenous drugs this unavailability of appropriately sized doses causes a different 
problem of how to accurately obtain a much smaller dose from what is available. 
This may require several dilutions of the original drug to obtain a volume which is 
sufficient to ensure that the smaller dose can be measured with an acceptable 
degree of accuracy. This need to manipulate drugs to obtain these paediatric sized 
doses has been identified both within the UK and internationally (Bourlon et al., 
2006; Skwierczynski and Conroy, 2008; Kayitare et al., 2009).       
A systematic review of medication errors in paediatric practice noted that there 
were multiple definitions of medication errors used. Within some studies 
definitions were either not included or were vague. This demonstrates that 
terminology is important as the inconsistency limited the ability to draw 
comparisons between studies.  The authors of this review noted the importance of 
standardised definitions (Ghaleb et al., 2006). Recent work by (Ernest et al., 2012) 
on the preparation of medicines for children noted that terminology may mean 
different things to different stakeholders. Therefore it is important to clearly 
describe what is meant for the work in this thesis by a drug manipulation.    
A drug manipulation can be defined as the physical alteration of a dosage form1 for 
the purpose of extracting a proportion of the drug dose (manipulation with the aim 
of achieving the required prescribed dose). The table below (Table 1) details the 
                                                          
1
 A dosage form describes the physical form in which medication is administered, the drug delivery 
system   
8 
 
drug manipulations for each dosage form, these may be necessary in paediatric 
practice where a dose is required which is not easily available. 
Table 1: Definition of manipulation for each dosage form 
Dosage form Manipulation with the aim of obtaining the required dose  
 
Tablets  
 
 Split, broken or cut and a segment given 
 Crushed and a proportion of the powder given 
 Crushed, dispersed in liquid and a proportion of the 
resulting dispersion given  
 Dispersed in liquid and a proportion of the liquid given 
Capsules/  
Sachets 
 Opened, dispersed in liquid and a proportion of the liquid 
given 
 Opened and a proportion of the powder given 
Oral liquids   Diluted and a proportion given (to allow measurement of a 
small dose) 
Nebuliser solutions    A proportion of the vial given 
Suppositories   Cut or split and a segment given 
Enemas  
 
 Proportion of sachet given (the remainder discarded) 
 Proportion of contents removed, the remainder given 
 Proportion of contents removed and administered  
Intravenous  
 
 Reconstituted or ready prepared solution, further diluted to 
allow a smaller dose to be measured 
 Volume of fluid removed from IV bag, drug added for 
infusion (to obtain accurate concentration for infusion) 
 Drug added to infusion bag, portion with smaller dose 
removed and infused 
 
1.6 USE OF DRUG MANIPULATION BY ADULTS  
Drug manipulation is performed frequently by and for adult patients (Verrue et al., 
2011). The need for manipulations can arise due to impaired ability to take 
medicines or the need for individualised dosing. In some cases, however the 
manipulation may not be necessary on clinical grounds. The driver for the 
manipulations may be economic factors, for example to help control drug 
prescription costs and rising healthcare costs (Quinzler et al., 2006; Berg and 
Ekedahl, 2010). There may be little cost difference between tablets of different 
doses of the same drug; for example, the halving of a tablet of twice the strength 
required to obtain two doses means that half of the total number of tablets is 
needed and therefore drug costs may be lower. This has been described by groups 
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such as the Veterans Administration in the USA (Flynn, 2000) and in Sweden (Berg 
and Ekedahl, 2010). Manipulations to achieve a proportion of the original dose has 
also been noted in adult practice, such as in elderly care, in intensive care or those 
receiving enteral feeds (Paradiso et al., 2002; Gerber et al., 2008; Berg and Ekedahl, 
2010; Verrue et al., 2011). Those writing in this area have expressed concerns about 
this practice, such as the difficulties of splitting tablets or the possibility that the 
obtaining of tablet segments may result in unacceptably large deviations from the 
intended dose (Berg and Ekedahl, 2010; Verrue et al., 2011). Although there may be 
some issues which are similar across all age-groups drug manipulations will be 
investigated here solely within clinical neonatal and paediatric practice. As has been 
noted (Section 1.1) assumptions cannot be made about children using adult data 
(or vice versa). Thus the use of manipulations in medicines prescribed for children 
requires dedicated study.    
 
1.7 ALTERING DRUGS TO EASE ADMINISTRATION  
In defining drug manipulations it was evident that similar processes may be used to 
assist with drug administration. For example, tablets may still be split, crushed, or 
dispersed to assist with administration, that is where the whole dose of the tablet is 
given, such as for administration through a nasogastric tube. In 2001 an audit at 
Great Ormond Street Hospital revealed that manipulations such as tablet cutting, 
tablet crushing and opening capsules were necessary to administer 26% of oral 
doses given to inpatients (data unpublished)(Standing and Tuleu, 2005). An 
Australian survey of adult and paediatric solid medication dosage form modification 
(tablets crushed, dispersed or split, capsules opened) found that for children on 60 
(82%) of occasions the inability to swallow the solid dosage form was the reason for 
the modification, on 10 (14%), modification was because the correct dose was not 
commercially available (Nissen et al., 2009). These split, crushed or dispersed 
dosage forms may also be mixed with food or beverages where palatability or the 
ability or willingness of a child to take the drug is an issue. Studies have considered 
the palatability of crushed angiotensin II receptor blockers (Meier et al., 2007) and 
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calcium channel blockers (Milani et al., 2010). The impetus which led to both of 
these studies was the knowledge that, in order to get their children to take their 
prescribed medicines, parents were crushing the tablets and administering them 
with food or beverages. This is not just an issue for younger children. Skwierczynski 
and Conroy (2008) considered manipulation to obtain the required dose and/or to 
help with drug administration and noted that there were similar age ranges of 
children being given manipulated and non-manipulated drugs, suggesting that the 
issues do not solely relate to babies and younger children but span the whole of 
childhood. There are substantial issues relating to the potential impact of altering 
dosage forms to assist with their administration. Standing and Tuleu (2005) noted 
that one important area where research is needed is into children’s ability to 
swallow and their preferences. However, key to the administration of any drug 
must be that the intended dose is given. Therefore, in this thesis, priority is given to 
the consideration of drug manipulation to achieve the required dose, where over or 
under dose and the possible consequences of this, are a concern.        
 
1.8 MANIPULATIONS   
Drugs are designed to enter the body via various routes and using differing 
mechanisms of drug release. While the predominant concerns about efficacy and 
adverse effects are universal to all drug manipulations, the processes of 
manipulating and possible subsequent effects are specific to particular dosage 
forms. Therefore it is important to reflect on the potential issues regarding the 
manipulation of different dosage forms (see Table 1).     
 
1.8.1 Tablet manipulations   
Tablets can be manipulated using different methods; splitting, crushing or 
dispersing. Some potential difficulties with splitting, crushing or dispersing tablets 
have been recognised. There does not appear to have been a systematic attempt to 
scrutinise the relevant literature. Furthermore, it is not known if manipulations are 
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relevant in paediatric practice, which drugs are manipulated, or the clinical areas in 
which they are used.    
1.8.1.1 Splitting tablets 
Where drug manipulations have been previously considered this has predominantly 
been focused on splitting tablets. A number of concerns relating to the tablet 
segments following tablet splitting have been noted. These include differences 
between the halved tablets in weight, drug content and drug stability (Nissen et al., 
2009; Shah et al., 2010). Unequal segmentation may increase the variability of the 
concentration-time profile. This may be particularly relevant for drugs with narrow 
therapeutic ranges, drugs with closely spaced multiple strengths (as even slight 
dose variability may affect clinical outcomes) and those with relatively short half-
lives with respect to the dosing interval (Quinzler et al., 2006; Nissen et al., 2009; 
Shah et al., 2010). Furthermore splitting extended release ((such as the cutting or 
crushing and dispersing of nifedipine modified-release tablets as described by 
(Tuleu et al., 2005) or other formulations with special drug-release characteristics 
may risk toxicity or a lack of effect. An unintended alteration in the formulation can 
lead to an uncontrolled release of the active ingredient or its degradation 
(Breitkreutz et al., 1999; Quinzler et al, 2006).     
When (Verrue et al., 2011) considered the best method for tablet-splitting in 
nursing homes for the elderly they noted that the extant literature reports findings 
in different ways (such as by one splitting method or by type of drug, or by different 
methods of splitting of different tablets), or reported tablet outcomes differently 
(such as by theoretical weight, mean deviations or maximum losses). The accuracy 
of tablet splitting may vary with different devices, users, and tablet shapes (Green 
et al., 2010). This makes comparisons difficult.   
The splitting of tablets may be influenced by the presence or absence of scorelines 
on the tablets. It might be reasonable to assume that tablets which have a scoreline 
can be split as part of a manipulation to get the required dose, scorelines may 
indicate where to segment the tablet. However some tablets are scored to facilitate 
their administration to patients who may have difficulty swallowing them; thus 
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though the tablet has been scored, this is not necessarily intended to reduce the 
dosage of the medication that may be taken (Shah et al., 2010). A scoreline does 
not necessarily signify that there is an even distribution of the active ingredient 
throughout the tablet or that each of the halves can be assumed to contain half of 
this active ingredient (Sayeed et al., 2010). This can be seen in examples such as 
that described by (Sayeed et al., 2010) where a formulation that was initially 
available as un-scored tablets were subsequently marketed as scored tablets 
without any change in the formulation. A review of splitting scored tablets noted 
the potential advantages of scored tablets such as dose flexibility, ease of 
swallowing and cost saving (van Santen et al., 2002). This review concluded that the 
performance of score lines needed to be defined for splitting properties (breaking 
ease) as well for the uniformity of mass of subdivided tablets, and the loss of mass 
by the subdivision (van Santen et al., 2002).  
1.8.1.2 Dispersing tablets 
As with splitting tablets the dispersing of tablets in liquid for the purpose of 
administering a proportion of the dose raises concerns about the accuracy and 
consistency of the doses achieved. Standing and Tuleu (2005) note that insoluble 
drugs are often crushed and dispersed in water to give a proportion of the dose 
without the use of suspending agents. This method may provide highly variable 
dosing, especially if the proportion of the dose volume sought is small. Broadhurst 
et al. (2008) identified that even where dispersible tablets are used inconsistent 
doses were found when sampled from different depths of the container.   
1.8.1.3 Crushing tablets 
As with splitting or dispersing tablets, crushing tablets may be used to obtain the 
required proportion of the original dose. Again there are concerns about the 
accuracy or variability of dosing. Crushing the tablet may make measuring a smaller 
dose difficult. Furthermore, crushing the tablet may leave part of the drug on the 
walls of the container or crushing device and the transfer of the crushed substance 
may also generate loss of the active drug (Best et al., 2011).    
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1.8.2 Capsule and sachet manipulations   
Other oral single dosage forms may be manipulated, such as opening capsules or 
sachets with the aim of obtaining a proportion of the contents, usually by 
dispersing the contents in liquid and administering the proportion. One study 
packed and split capsules and found that when split the weight at the base of the 
capsule was consistently more than the weight of the top portion (Caldwell et al., 
2010). Overall manipulating capsules and sachets appear to have been little 
discussed in the literature. It is not known whether this is because this is not a 
widely used practice or if it is one that has not been investigated. Where the 
contents of the capsule or sachet are dispersed then it will raise similar issues with 
potentially inconsistent dosing apply as described by Broadhurst et al. (2008) for 
dispersing tablets.     
 
1.8.3 Liquid formulation manipulations   
Liquid formulations may be an alternative to tablets, capsules or sachets. They 
provide a wider possible range of doses as they can be easily adjusted by measuring 
the prescribed dose volume (Breitkreutz et al., 1999). However, liquid formulations 
come with other problems. Where designed for adult use they may be presented in 
a concentration which is unsuitable for measuring a small dose and administering it 
to babies or young children (Nunn, 2003). Stability data for many of the drugs used 
in children are lacking making it difficult to provide an appropriate liquid dosage 
form (Nahata, 1999). Oral liquids often require substantially larger amounts of 
excipients to ensure stability and palatability than tablets (Pandit et al., 2010). 
Furthermore, liquid dosage forms may have physicochemical stability issues in the 
medium to long-term and it can be less easy to be sure of the consistent 
measurement of accurate doses (Nissen et al., 2009). Nunn (2003) noted that in an 
unpublished survey of 112 paediatric extemporaneous formulations 54% had 
inadequate data on shelf life. The lack of safety and stability data and inclusion of 
excipients with elevated toxicological risks might hinder the advantages of liquid 
formulations (Pandit et al., 2010). Where a liquid formulation is not readily 
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available, it may be procured from a ‘specials’ manufacturer. ‘Specials’ are special-
order unlicensed medicines which are made to meet the needs of an individual 
patient, they have not been assessed by the regulatory authority for safety, quality 
and efficacy in the same way as licensed medicines (National Prescribing Centre, 
2011). Most ‘special’ liquids are expensive and have short shelf-lives (Standing and 
Tuleu, 2005). The use of ‘specials’ means that there may be little consistency in the 
products used. This can be exemplified by a study by (Mulla et al., 2007) who 
considered the variations in captopril formulations used to treat children, with 
licensed captopril formulations available only in tablet form. This study surveyed 26 
hospitals, in the UK, and found that a variety of unlicensed liquid captopril 
formulations were used interchangeably and that in four of the hospitals, tablets 
were crushed and dispersed. The authors of this study noted that no 
bioequivalence data exists for the liquid formulations identified, so it was not 
possible to be confident that the rate and extent of captopril absorption did not 
vary according to its formulation. This raised concerns about optimal dosing and 
potential toxicity as therapeutic equivalence between differing formulations should 
not be assumed (Mulla et al., 2007).   
Where oral liquids are being used that have not been designed for children or are 
being used off-label there may be issues with achieving the required dose. This may 
necessitate manipulation through dilution of the oral liquid formulation to facilitate 
the measurement and administration of a small dose.       
 
1.8.4 Intravenous manipulations   
With intravenous drugs the unavailability of appropriate dosage forms means that a 
dose much smaller than the dose in the vial is required. A short research report 
considered all of the intravenous drugs prescribed on a neonatal unit, in the UK, 
finding that 404 (31%) of prescriptions were for doses which were less than one 
tenth of the contents of the vial and 16 (4.8%) were for doses which were less than 
one hundredth of the contents of the vial (Chappell and Newman, 2004). Complex 
calculations may be required to facilitate the measurement of suitable doses from 
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ampoules designed for adult patients (Conroy and Peden, 2001). Furthermore there 
are a variety of intravenous solutions available and a lack of consensus regarding 
the ideal premixed solutions for paediatric patients (Sinha and Cranswick, 2007b). 
Dose calculation errors are the most common type of medication error in neonatal 
and paediatric patients (Conroy et al., 2007). A retrospective review of medication 
errors in a paediatric teaching hospital found that 15/195 (8%) of the medication 
errors identified were for intravenous drugs and involved tenfold errors (Ross et al., 
2000). The risk of tenfold errors has also been highlighted by reviews (McIntyre and 
Choonara 2004; Sinha and Cranswick, 2007b). Neonates may be at particular risk of 
medication errors as they have limited reserves to buffer any errors and the 
potential for rapid changes in weight, making appropriate dosing difficult (McIntyre 
and Choonara 2004; Sinha and Cranswick, 2007a). A study by (Allegaert et al., 2006) 
demonstrated improved dose precision in neonates when a smaller paediatric vial 
(50mg) was used in preference to the larger adult vial (250mg) to achieve the 
required dose. McDowell et al. (2010) completed a systematic review on the 
preparation and administration of IV medicines which included nine European 
studies (one of which was in a children’s hospital). This review considered 12 stages 
of drug preparation and administration and found that the stage which contributed 
the most errors was the reconstitution of the drug and diluent. Parshuram et al. 
(2008) reported on a direct observational study in a structured, nonclinical 
environment which considered the preparation of intravenous medication. This 
study found that the errors of the greatest magnitude were made when infusions 
were prepared from small volumes of stock solutions, suggesting that those 
requiring smaller doses, such as babies and children may be at a greater risk than 
larger patients for these preparation-associated errors.         
The noted that the ability to accurately measure small volumes intended for 
newborns and young children is of particular importance. They also note that if 
dilution is required it must be remembered that a significant extra quantity of 
active drug may be contained in the hub of the syringe and that appropriate 
instructions are needed. The flushing of a syringe has been found to deliver more 
than twice the calculated amount of medication when the syringe was filled to the 
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0.05mL mark (Berman et al., 1978). An observational study of intravenous drug 
administration errors described an error identified on a neonatal unit where the 
drug solution contained in the hub of the syringe was also administered to the 
patient (Taxis and Barber, 2003a).           
With intravenous drugs it may be possible to avoid further dilution (thus avoiding a 
manipulation). This may necessitate the measurement of very small volumes to get 
the dose required. A Canadian study evaluated the potential requirements for small 
volumes, finding that in 8% (79) of the 982 indications listed in the formulary the 
recommended dose would require less than 0.1mL of the stock solution (Uppal et 
al., 2011). These authors also completed a clinical study in ICU and found that 7.4% 
(5245) of the 71218 intravenous doses administered required preparation from less 
than 0.1mL, with 17.5% (12439) requiring preparation from less than 0.2mL. Where 
such small volumes are measured there may be a question of accuracy of the dose 
achieved. When dealing with such small doses and volumes then even small 
inaccuracies may represent a concerning percentage of over- or under-dosage.    
This manipulation of intravenous drugs raises questions about the potential of 
increased drug errors relating to the calculations required, the inadvertent 
administration of content of the syringe hub and the measurement of small 
volumes.  
 
1.8.5 Other manipulations – nebuliser solutions, transdermal patches, 
suppositories and enemas    
Nebuliser solutions, transdermal patches, suppositories and enemas are designed 
for a single use of the whole drug dose in the dosage form. The lack of paediatric 
sized doses may also mean that these dosage forms require manipulation. With all 
four of these dosage forms manipulations appear to have been little discussed in 
the literature and, as noted with capsules and sachets, it is not known whether this 
is because this is not a widely used practice or if it is one that has not been 
investigated.     
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1.8.5.1 Nebuliser solutions  
With inhaled drugs there are specific child related issues, the reduced motor 
abilities and low inspiration volume of paediatric patients often limit the proper use 
of drugs and dosage forms for inhalation (Breitkreutz and Boos, 2007). As nebuliser 
solutions are pre-packaged into dose units they may require manipulation where a 
smaller dose than that available in the vial is required.  
1.8.5.2 Transdermal patches  
Durand et al. (2012) considered transdermal drug delivery and noted that as 
patches are available in a limited number of dosage strengths therefore to get a 
different dose an alteration, such as by cutting, may be an option. These authors 
note that in most cases bioavailability studies to determine the effects of cutting a 
patch on safety and efficacy have not been conducted. Furthermore they 
considered that there needs to be attention given to the design of the patch e.g. 
reservoir or matrix system patches (Durand et al., 2012). The use of transdermal 
patches as a delivery route for drugs raises it own concerns for children. With 
transdermal drug administration the varying hydration status of the skin can effect 
drug permeation, in childhood the water content changes significantly due to 
mainly metabolic or anabolic periods during development (Breitkreutz and Boos, 
2007).  
1.8.5.3 Suppositories  
Conroy and Peden (2001) reviewed the use of paediatric analgesia and, using 
diclofenac suppositories as an example, noted that fractions of suppositories may 
be needed to administer a dose small enough for a child. This review also noted 
that the distribution of the drug throughout the suppository is not known and 
therefore the administered dose may not be accurate.  
1.8.5.4 Enemas  
The possibility of manipulation of enemas does not appear to have been discussed 
in the literature.  
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1.9 VARIATION BETWEEN DIFFERING PRODUCTS  
Consistency in manipulations may be further complicated as there may be variation 
because products from different manufacturers behave differently when they are 
manipulated. Sayeed et al. (2010) considered this situation and found that when 
tablets were split there was weight variation, demonstrating that the same tablet 
product from different manufacturers may behave differently. They therefore 
concluded that results about the manipulation of one product should not be 
extended to other drug products. Even within the same tablet of the same drug 
from the same manufacturer may show inconsistencies, van Santen et al. (2002) 
discussed that batch to batch differences such as in hardness, water content, or 
storage time may cause variability in the breakability within the same brand.   
 
1.10 PATIENT PREFERENCE  
It is possible that there may be situations where the patient preference is for a 
manipulated product, though one that does not require manipulation is available. 
Nissen et al. (2009) when considering crushing/dispersing/splitting tablets and 
opening capsules found that there were occasions where tablets were crushed 
though an alternative dosage form such as an oral suspension was available. It 
cannot therefore be entirely assumed that if there is an appropriate formulation 
and dose available that manipulations are not occurring.   
 
1.11 PALATABILITY   
Where drugs are being given orally to a child palatability is liable to have an effect, 
it may cause difficulties with administration to the child and consequently on 
medication adherence. This may be particularly relevant where medication use is 
long-term, such as to treat chronic conditions (Standing and Tuleu, 2005). However, 
palatability studies have been predominantly conducted using adult volunteers and 
there is a lack of formal studies considering this in children (Matsui, 2007). 
Manipulation may have an effect on palatability, such as where tablets which have 
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been coated to disguise the taste of the active ingredient and these are split or 
crushed, similarly where capsules have been opened.   
 
1.12 SUMMARY OF CURRENT SITUATION   
The overriding concerns relating to drug manipulation of all dosage forms are the 
risks of dose inaccuracy. A proportion of the original dose has been administered. 
This may result in subtherapeutic or toxic doses. There may also be adverse effects 
due to dose inaccuracy or changes that the manipulation may cause to the drug 
delivery mechanism.     
The splitting, dispersing or crushing of tablets to obtain the prescribed dose for 
administration raises a number of issues. Concerns about splitting tablets such as 
the possibility of tablets splitting unequally or the possible effect on the drug-
release characteristics of splitting modified-release tablets have been described. 
However, these concerns have been predominantly discussed in general terms. 
Therefore it is clear drugs are being manipulated, into what fractions of the original 
dose and how they are being manipulated in clinical practice is not known. The 
crushing of tablets has been less discussed than tablet splitting and this has chiefly 
been in relation to crushing and administering the entire dose, with the possibility 
of dose loss within the crushing container noted. With dispersing tablets, while one 
study has noted the discrepancies of taking doses of a dispersible tablet from 
different depths of the container involved, there does not appear to have been 
other studies which have considered this manipulation.   
On first consideration, oral liquid formulations may appear to be the solution to 
avoiding the need to manipulate tablets, sachets or capsules. However there are 
issues with this dosage form, such as the varying use of ‘specials’, the larger 
amounts of excipients required, the possible inaccuracies of measuring small 
volumes and the potential rejection by patients of the large volumes and/or the 
taste of oral liquids.   
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Overall, manipulating orally administered drugs may have an impact on the 
palatability and therefore the acceptability of the medications.   
The administration of intravenous drugs to babies or children, where the dose has 
been designed for adults, raises several issues about the methods of achieving the 
required dose, specifically in relation to the calculations of the dilutions required 
and the possibility of error when undertaking these dilutions. A further issue arises 
as to whether it is more appropriate to dilute further or to attempt to measure 
small dose volumes.   
There are four dosage forms where manipulation does not appear to have been 
discussed: sachets, capsules, nebuliser solutions and enemas. The reason for this is 
unknown; it may be that these dosage forms are not manipulated. Or it may be that 
these dosage forms are being manipulated but where and how these manipulations 
are being undertaken is not known. With the manipulation of transdermal patches 
and suppositories manipulation has been mentioned as a possibility but these 
forms of drug manipulation have not been further explored.   
Though the need to manipulate drugs to obtain the doses required for babies and 
children is acknowledged, it appears that this practice has not been further 
investigated, that there has been little research undertaken which considers it. 
Previous studies have identified a paucity of research about paediatric drug dosage 
forms, paediatric pharmacology and paediatric therapeutics (Broadhurst et al., 
2008). Where medication error reduction strategies were investigated a resounding 
lack of paediatric-specific evidence is adduced (Miller et al., 2007). The risk of any 
effect of drug manipulation will be a concern for patients of all ages. The 
vulnerabilities of babies and children to over or under dosing, the increased 
probability of drug manipulations being required due to the need for drug doses to 
change throughout childhood and the historical lack of paediatric specific drug 
development make drug manipulation a particularly pertinent issue in paediatric  
practice.    
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1.13 OVERVIEW AND STRUCTURE OF THIS THESIS  
In summary the literature shows that drug development and the design of 
medicines for children have extensively lagged behind that for adults. The 
developmental changes throughout childhood impact on drug absorption, 
distribution, metabolism and elimination therefore the lack of the availability of 
suitable medicines for children is a substantial concern. While the necessity of 
manipulating dosage forms with the aim of achieving the required dose for 
paediatric use is acknowledged, little is known about the practice, the extent to 
which it is used and which drugs are being manipulated. Despite this 
acknowledgement of drug manipulation there is a lack of guidance for professionals 
or parents/carers about undertaking manipulations.    
The aim of the work in this thesis was to investigate drug manipulation in paediatric 
practice. This is presented in the following chapters: 
Chapter 2 – systematic review of the current evidence. The extant literature has not 
previously been systematically reviewed and where the literature discusses 
manipulation results are inconsistent. This systematic review includes consideration 
of the design of a search where terminology is not defined and approaches used 
where the evidence base includes a variety of types of study design.   
Chapter 3 – observational study. This chapter reports on the identification and 
observation of drug manipulation in inpatient hospital neonatal and paediatric 
settings. This includes the development of the study design, study tools and 
methods of identifying manipulations and reports on the differing types of 
manipulation, dosage forms and drugs involved.   
Chapter 4 – paediatric nurse survey. This chapter reports on a UK wide survey of 
paediatric nurses who are currently working in neonatal and paediatric inpatient 
areas. The design of the questionnaire used the outcomes of the systematic review 
and observational study to further investigate the types and methods used to 
manipulate drugs and to explore the concerns of those undertaking them. 
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Chapter 5 – parent study. This chapter reports on interviews with parents/carers of 
primary school-age children who require long-term medication. This chapter 
reports on an investigation of how the parents/carers of these children assist them 
in taking their medication and within this context the impact of any drug 
manipulations are explored.       
Chapter 6 – discussion of the outcomes of the previous chapters, implications for 
current practice and future research and conclusions.   
Chapter 7 – final conclusions.  
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CHAPTER 2: SYSTEMATIC REVIEW  
From Chapter One it has been noted that manipulations are a known part of clinical 
practice in paediatrics and that they appear not to have been substantially 
investigated. It was important to consider what evidence is available on 
manipulations. Therefore this systematic review aimed to enable the accumulation 
of relevant accessible information, establish the evidence base and clarify where 
research has been completed and where further research may be needed.   
    
2.1 SYSTEMATIC REVIEWS   
Systematic reviews have been used extensively, especially to consider drug 
effectiveness and safety. These reviews often focus on a single drug, or a class of 
drugs, and tend to draw on evidence from randomised controlled trials. Systematic 
review methods have evolved to encompass many other review topics. Indeed it 
has been argued that a systematic review should be completed as a matter of 
course before any new research is undertaken (Harden and Thomas, 2005). 
Without systematic reviews researchers may miss promising leads or may embark 
on studies of questions that have already been answered (Cook et al., 1997). The 
Evidence for Policy and Practice Information and Co-ordinating Centre 
(http://eppi.ioe.ac.uk/cms/) note that a huge variety of types of questions are being 
examined with synthesis of a broad range of study types and that through these the 
flexible nature of systematic review synthesis has been illustrated. A systematic 
review of any area can be carried out providing it attempts to identify and include 
all relevant research, is trustworthy and conclusions are based only on the findings 
of the studies in the review (Harden and Thomas, 2005). There have not been any 
previous extant systematic reviews relating to drug manipulations.   
 
2.2 REVIEW QUESTIONS  
The questions for this systematic review were: 
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1. What is the volume, nature and quality of the research evidence for drug 
manipulations at the point of administration?  
2. What are the effects of manipulating drugs, using methods employed at 
point of drug administration, on: dose accuracy, palatability of the drug, 
safety (of the recipient and/or the person carrying out the manipulation), 
bioavailability and stability of the drug? 
It should be noted that the scope of these review questions has focused on the 
dose accuracy of the resultant proportions of the manipulated drug. Consequently 
it is not specific to the drug or the dosage form involved. This systematic review has 
used a broad scope and aimed to locate and describe the diversity of the available 
evidence relating to any type of drug manipulation.   
 
2.3 SYSTEMATIC REVIEW PROTOCOL  
Within a systematic review all of the decisions used to compile the review should 
be explicit. This allows those who read the review to follow how the review has 
been conducted and consider the quality of the review process (Garg et al., 2008). 
Published protocols serve as a guide to research in progress. The review protocol 
for this systematic review has been published (Richey et al., 2012). The 
development of this protocol ensured that key decisions were identified and 
discussed prior to the review; these included defining the scope of the research 
question, designing the search strategy to identify diverse studies, consideration of 
the methods for assessing the quality of the studies of varying designs and methods 
for synthesising the included studies. This protocol described the process and 
challenges of designing and conducting a systematic review of studies that included 
manipulations across all types and classes of drugs. Protocol publication may 
reduce the likelihood of reviewers introducing bias into their review by making 
major changes which could otherwise remain undisclosed and undetectable (Silagy 
et al., 2002). It should be noted that as a systematic review is dependent on the 
scope and quality of the included studies, the review protocol may need some 
subsequent modification (Sampson et al., 2009).    
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2.4 METHODS  
Overall the methods for the review were rooted within recognised systematic 
review methods and as such were informed by the Centre for Reviews and 
Dissemination (CRD) guidance for undertaking reviews in health care 
(www.york.ac.uk/inst/crd/index_guidance.htm). These methods are well 
established and include; the searching of electronic databases, screening of titles 
and abstracts using inclusion/exclusion criteria, study selection, searching of 
references lists, data extraction using a review designed data extraction table, 
independent quality assessment by two reviewers, data analysis and narrative 
synthesis of the systematic review.     
 
2.4.1 Eligibility criteria for study inclusion  
2.4.1.1 Types of drugs/participants  
This review considers drug manipulation and was not specific to any drug or dosage 
form; consequently studies of any drug could potentially be included. This research 
has arisen from concerns about the manipulation of drugs for paediatric use. Drug 
manipulation has also been highlighted within adult medicine both for economic 
reasons, and in specific clinical areas such as in intensive care or to assist with dose 
flexibility with older adults (Berg and Ekedahl, 2010; Verrue et al., 2011). Therefore 
studies may have been completed where drugs have been manipulated for 
administration to adults that involve drugs that could also be used in paediatric 
practice. Furthermore the outcomes, though in adults, could indicate areas for 
investigation in paediatric practice. Therefore it was decided not to apply age-
restrictions in this systematic review.   
2.4.1.2 Types of interventions 
The manipulations to be investigated are defined as those that can be carried out at 
the point of administration and include:    
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 cutting, breaking or splitting into smaller segments (tablets, 
suppositories, transdermal patches) 
 dispersing tablets or sachets with liquids and taking a proportion 
 crushing tablets or opening capsules, mixing the resultant powder 
with liquid and taking a proportion  
 taking proportions of an enema  
 taking proportions of a nebuliser content 
 further diluting ready prepared or reconstituted intravenous or oral 
solutions (usually to allow a smaller dose to be measured)  
This systematic review was based on the consideration of drug manipulation as it 
has been defined for this research. Where drugs are altered, such as by breaking, 
crushing or dispersing to aid administration, for example where there are 
swallowing difficulties or where administration is through a naso-gastric tube, these 
would be excluded from this review. However modified-release formulations 
provide a particular issue. The design of modified release drug products intends to 
optimise a therapeutic regimen by providing slow and continuous delivery of drug 
over the entire dosing interval (Abdul et al., 2004). If these modified release drug 
products are altered in any way, such as by crushing a tablet, this may affect the 
mechanism of the delivery of the drug involved and could potentially impact on 
both the effectiveness of the drug regimen and/or the possible adverse effects 
associated with that product. Therefore this review allowed for the inclusion of 
studies where modified release formulations had been altered, though the entire 
dose of the original product may have been administered, as the outcomes 
potentially had relevance for drug manipulation.   
The manipulations investigated in this review were those which would be 
completed at the point of administration. Therefore studies investigating 
extemporaneous preparations/compounding by the pharmacist were excluded. 
Extemporaneous preparation describes the manipulation by pharmacists of various 
drug and chemical ingredients using traditional compounding techniques to 
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produce suitable medicines when no commercial form is available (Brion et al., 
2003). The use of these techniques is widespread in paediatric pharmacy practice 
(Brion et al., 2003).     
2.4.1.3 Types of outcomes 
The primary outcomes relate to the aim of drug manipulations, which is to achieve 
a pre-specified dose of drug which is not readily available. The secondary outcomes 
relate to the possible effects of drug manipulation on the medicines, those taking 
the manipulated drug and the person undertaking the manipulation. 
Primary outcomes: 
- dose accuracy of the manipulated medicine as assessed by drug 
content assay or other study specific methods such as weight, 
dissolution or dispersion 
- reproducibility of manipulation assessed by variation in dose 
accuracy  
Secondary outcomes: 
- evidence of safety or harms explicitly attributed by the authors to 
the manipulation of medicines  
- bioavailability  
- tolerability/palatability/adherence (explicitly attributed to the 
manipulation) 
- contamination of the area of the manipulation, healthcare 
professional, carer or patient  
The effectiveness of manipulated drugs was considered, but discarded, as an 
outcome. There are numerous outcomes relating to the effectiveness of drugs and 
these are frequently condition and context specific; therefore to consider 
effectiveness relating to drug manipulation drug specific searches for each drug 
involved would be required.   
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2.4.1.4 Types of studies  
This review aimed to explore and describe the evidence relating to drug 
manipulation across any drug and a range of outcomes. Systematic reviews aim to 
focus on the best available evidence, however where no studies of this level are 
found it does not mean that there is no evidence to assess and the review may 
appropriately consider other evidence (Counsell, 1997; Stroup et al., 2000; Hawker 
et al., 2002). Though systematic review methodologies were initially developed in 
reviews of effectiveness (focusing predominantly on randomised controlled trials), 
interest has been growing in the development of diverse systematic review 
methods to incorporate different types of evidence including other quantitative 
designs as well as qualitative research (Dixon-Woods et al., 2005; Goldsmith et al., 
2007). Reviews in drug manipulation have not previously been completed. It was 
anticipated that there would not be a substantial evidence base for this. It was 
decided that this review would take a broad approach to explore the range of 
evidence available. Accordingly it would not restrict on study design except to 
exclude the evidence considered to be of the lowest quality that is to exclude case 
studies, case reports and letters.   
This review considers drug manipulation across a range of outcomes. These 
outcomes ultimately may impact on patients. However for the primary outcomes 
around dose accuracy the evidence could be considered where the drug has not 
actually been administered. Therefore studies were included in this review, where 
they met the inclusion criteria, which were laboratory-based and considered weight 
and/or drug content but did not include bioavailability. The stated secondary 
outcomes of this review did require the administration of the drug to assess. 
 
2.4.2 Search methods 
The conclusions drawn by any systematic review are going to be determined by the 
appropriateness of the search strategy and its ability to identify relevant studies for 
inclusion. The design of an effective systematic search provided a particular 
challenge with this review. A systematic search is vital to a systematic review 
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(Simunovic et al., 2009). Logically, if the search strategy does not locate the eligible 
studies, the review risks its findings being flawed as the studies that have not been 
located may have provided differing results from those that were included. Within 
searches that, for example, consider drug effectiveness outcomes for one drug used 
for a particular condition, then the design of a search strategy may be more 
straightforward. For this review any drug or dosage form could potentially be 
included.  
A highly sensitive search strategy will retrieve most of the relevant studies but may 
also retrieve many unwanted articles (Goss et al., 2007). Most searches have to 
balance an inevitable trade-off between a highly sensitive search which may yield 
an unmanageably high number of hits and a more precise search that limits the 
retrieval to a manageable yield (Boynton et al., 1998). This may be a particularly 
difficult balance in a review with a diffuse topic area.  Screening references for 
possible inclusion within a systematic review is resource expensive. Therefore this 
review used a considerable iterative process where the search terms were tested 
and modified based on what had been retrieved and the decision as to whether or 
not this was a manageable yield.   
The necessity of having to balance between the sensitivity and the precision of the 
search does raise the risk that there may be studies that have not been identified. 
There were a number of methods used with the aim of ensuring that this review 
was as complete as possible. This included searching the reference lists of included 
studies, contacting experts for any additional studies/grey literature and having the 
list of included studies reviewed by experts.   
2.4.2.1 Resources used  
A thorough search depends on the variety of sources searched as well as the 
sensitivity of the search strategy (Golder et al., 2008). A number of different 
databases were used to increase the coverage of journals, as the use of a wide 
search net increases the likelihood that the studies identified will comprise a 
comprehensive body of evidence (Counsell et al., 1997; Sampson et al., 2009). 
EMBASE is an important electronic resource for pharmacology, pharmacy, 
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pharmacoeconomics, pharmaceutics and toxicology research, whilst MEDLINE 
(internet interface PubMed) is the automatic choice when searching the evidence 
base for medicine. Although overlap exists in their journal coverage, relevant 
information would inevitably be missed if only one of these databases were 
searched (Wong et al., 2006; Garg et al., 2008). Cochrane databases (the Databases 
of Systematic Reviews and of Abstracts of Effects and the CENTRAL Register of 
Controlled Trials), the Cumulative Index of Nursing and Allied Health Literature 
(CINAHL) and the International Pharmaceutical Abstracts (IPA) database that 
indexes articles about pharmaceutical practice and development and use of drugs 
were also searched.  
2.4.2.2 Search strategy development  
In developing a search strategy, standard practice was followed and the review 
question was broken into the relevant sections of a PICO format (that is Participants 
or Population, Intervention, Comparison and Outcomes). PICO components can be 
both searched separately and combined where appropriate (Sampson and 
McGowan, 2006). For this review these components are pharmaceutical 
preparations (P), manipulation methods (I) and the primary and secondary 
outcomes (O). A comparison step was not needed as this review did not include 
comparison between differing drug treatments. There were several main 
considerations when designing the search strategy. Firstly drug manipulation is not 
a term which would feature in the indexing terms in the electronic search 
databases, such as in the MeSH (Medical Subject Headings) thesaurus in PubMed. 
As a result this search needed to consider the use of free text terms and MeSH 
subheadings which may be appropriate. Free text searches are a desirable feature 
because they are database neutral in the sense that they can be applied across all 
databases that use the same language (Goss et al., 2007). This search strategy 
required considerable development of the search terms as they aimed to 
incorporate all possible terms which could be used to describe a manipulation, such 
as split, cut, halve etc.. As drug manipulation does not have a defining description 
these terms were reviewed by pharmacy and formulations experts with the aim of 
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ensuring that the list was as complete as possible. This review aimed to include any 
drug and dosage form included in relevant studies; consequently drug or dosage 
form specific searches were not appropriate.   
Study design filters, such as those for RCTs, can be a useful method of improving 
search precision (Goldsmith et al., 2007). However as the types of study potentially 
eligible for this review was so varied the use of study design filters was not 
appropriate. Throughout the design of the search strategy for this review the non-
specific nature of the terms used caused difficulty in achieving the balance between 
sensitivity and precision. The difficulties of designing an effective, efficient search 
strategy where there is a multiplicity of disciplines involved in the field and the 
heterogeneity of terms used to describe the subject has been previously noted 
(Goss et al., 2007). Following the defining of the P, I and O components an iterative 
process followed. Searches were checked to ensure that they were identifying a 
small number of known papers. There was also the need to ensure that the return 
of the searches was producing a manageable yield of hits. These processes meant 
that there were many cycles and iterations of the search strategies.  Due to the 
overarching challenges of the search strategy many successive iterations of it were 
required using combinations of the P, I and O components. The need to combine 
search terms from all three components (P, I and O) was necessary in this search 
though this risks reducing the recall of potentially eligible studies. This process is 
described in Figure 1.    
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Figure 1: Search strategy development in PubMed 
 
  
Search strings were developed for each of the population (P), intervention (I) and 
outcome (O) components using free text and/or indexing terms where available.  
Within components, terms were combined with the Boolean Operator OR 
An unmanageable number of (mainly irrelevant) references were retrieved when the 
search strings were used alone and when two strings were combined (with Boolean 
Operator AND).  It was therefore necessary to combine the search strategies of all 
three components 
Searches were tested to ensure they were identifying known papers 
Searches were reviewed and re-tested, through many cycles and iterations to balance 
the need for sensitivity with the need for a manageable number of hits   
(P) – index and 
free terms for 
pharmaceutical 
preparations 
were used 
(I) – there are no index 
terms for drug 
manipulation so free text 
terms were complied from 
previous publications and 
expert review 
(O) – identifying 
search terms 
proved 
problematic due to 
the number of 
outcomes in this 
review 
(I) – an 
unmanageable 
number of hits 
were returned 
with use of this 
component alone  
(>70,000 hits 
returned) 
(P) – an unmanageable 
number of hits were 
returned, even when this 
comprehensive search 
string was combined with 
the I or the I and O search 
strings.  A curtailed search 
string comprising index 
terms and relevant sub-
headings was used 
(>100,000 hits returned) 
(O) – due to 
difficulties with 
the search terms 
it was concluded 
that the use of 
this string was to 
be avoided if 
possible   
Additional search strategy development methods which were discussed but could not 
be used in this search: 
• Proximity operators could not be used within the (P) search string as PubMed 
does not allow this across index and free text terms  
• Study design filters could not be appropriately used as the types of studies 
eligible for inclusion are too varied 
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In acknowledgement of the challenges of developing a search strategy in this 
subject area, the search strategy for the PubMed database was reviewed by an 
experienced information scientist and who considered the search strategy to be an 
appropriate one for this review question. The PubMed search strategy is available 
in Appendix 1. The PubMed search was adapted for application in other databases 
to take account of indexing differences and variations in the volume of the indexed 
references. MeSH terms were changed to appropriate indexing terms in EMBASE 
and CINAHL and using free text for IPA. Similarly to PubMed, the IPA search 
incorporated the Population, Intervention and Outcomes search strings. For 
EMBASE and CINAHL a manageable return was obtained using Population and 
Intervention search strings only. 
Subsequent drug specific searches were also devised. Given the necessary iterative 
approach that was required in the search methods it was decided to complete a 
small number of drug specific searches. These were to be completed on drugs that 
are commonly prescribed in paediatric practice and were considered by pharmacy 
experts to be frequently manipulated. These additional searches, as drug specific, 
are more sensitive than the original search, the drug specific terms (P) combined 
with the (I) terms retrieved a manageable yield. If the additional searches identified 
studies which had not been found through the original search then further review 
of the search methods used and the identification of additional search terms would 
have been required. This approach also allowed for an in-depth consideration of 
frequently manipulated drugs. The three drugs selected for additional searches 
were omeprazole, captopril and warfarin. The search strategy for these searches is 
in Appendix 2.   
Update searches were completed in February 2012 prior to completion of the 
review to ensure that the final review is as contemporary as possible.   
2.4.2.3 Additional resources  
Researchers, academics and health care practitioners with a special interest in 
medicines management were identified by a group of clinical and research experts 
and were contacted and asked to provide references to any additional studies or 
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details of any unpublished data. Reference lists of all eligible studies were also 
checked and any relevant studies were identified and included in the overall search 
yield.   
 
2.4.3 Study selection and data extraction  
Due to the considerable number of records identified with the main search strategy 
and with the narrower drug-specific searches the initial screen was undertaken by 
one reviewer, with a 5% random sample of the titles and abstracts screened by a 
second reviewer2. The studies identified from the initial screen were independently 
considered by the two reviewers, these reviewers met to discuss the papers they 
had selected and agreed on which full text studies to obtain. A third reviewer was 
available for any studies where agreement on inclusion could not initially be 
reached. The use of this reviewer was not required.    
Data from the included studies were extracted into data extraction tables by one 
reviewer, these were then independently assessed by the second reviewer and 
changes agreed.     
 
2.4.4 Quality appraisal 
The assessment of study quality is central to the methodology of systematic reviews 
since poor quality studies are more likely to generate inaccurate or biased results. 
The diversity of studies eligible for inclusion in this review posed challenges for 
their quality assessment. There is no widely accepted generic tool that can be 
applied equally across study types (Katrak et al., 2004). Traditional evidence 
hierarchies were developed specifically to address questions of efficacy and 
effectiveness and involved assessing research according to study design (Goldsmith 
et al., 2007). Substantial methodological guidance exists for the conduct of 
systematic reviews of randomised controlled trials (RCTs), and is rapidly evolving for 
                                                          
2
 Throughout the systematic review I was the first reviewer and the second reviewer was Dr Jean 
Craig  
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systematic reviews of other study designs including observational, diagnostic and 
qualitative research (Stroup et al., 2000; Hawker et al., 2002; CRD, 2009; Higgins 
and Green, 2009). Hawker et al. (2002) noted that if all evidence is to be evaluated 
rigorously then the traditional method of systematic review has to be modified and 
assessment criteria developed to encompass all the different types of material, 
while remaining explicit.        
This review included studies that investigated outcomes of drug manipulation such 
as dose accuracy which were purely laboratory based. Other outcomes such as 
palatability, for example, were evidenced from more descriptive studies.   
In general checklists tend to be specific to particular study designs, where reviews 
include more than one study design, separate lists can be used or a combined list 
selected or developed (CRD, 2009). Established quality appraisal criteria from 
checklists that are study design specific (e.g. RCT checklists or checklists for 
descriptive survey studies). Those devised by the Cochrane Collaboration and the 
Centre for Reviews and Dissemination (CRD) were used alongside additional criteria 
specific to this study to devise a customised, review specific, quality assessment 
form. It was important for the applicability of this review to clinical practice that 
this checklist included consideration of how the manipulation had been reported 
within the study. A previous review of paediatric trials noted that authors reporting 
these trials need to give complete pharmaceutical details (drug, formulation, 
manufacturer and administration details) to allow for the application in clinical 
settings (Pandit et al., 2010). What is reported in published studies can be 
considered in how relevant it is to the question of the review. Review specific 
assessments can include the relevance of focus of individual studies in relation to 
the review question. This approach of considering the requirements of the specific 
review in the assessment of the included studies has been used previously, such as 
in a WHO review of maternal morbidity and mortality where it was assumed that 
the presence of definitions of conditions and description of diagnostic methods or 
procedures could be regarded as an indication of higher quality (Gulmezoglu et al., 
2004).    
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Though systematic reviews have been completed on topics such as the diagnostic 
value of laboratory tests (van den Bruel et al., 2011) and therapeutic drug 
monitoring (Touw et al., 2005), it is unusual for a systematic review to consider 
dose accuracy as measured by drug assays/weight/dissolution/dispersion, as used 
to address the primary outcomes of this review. Nonetheless it was important to 
consider the quality of the reported laboratory testing within these studies. In the 
absence of established methods for this, advice was sought from a formulations 
expert who used standardised tests, acceptance limits and validated analytical 
methods as per International Conference on Harmonisation (ICH) guidelines and 
assigned a quality level to this aspect of the studies. The beneficial use of experts or 
external consultants to provide independent appraisal of the quality and relevance 
of particular aspects of the review has been previously described 
(http://eppi.ioe.ac.uk/cms/). This method has been used in previous systematic 
reviews where critical appraisal tools for aspects of the review are not available, 
such as where consensus statements were reviewed (Sinha et al., 2008).    
Inadequate reporting of studies can make quality assessment problematic. If 
insufficient detail is provided than readers are left with an incomplete picture of 
what was done and are not able to judge the reliability of the results (Moher et al., 
2010). The customised form also drew on aspects of the STROBE (Strengthening the 
Reporting of Observational Studies in Epidemiology) checklist 
(www.strobe.statement.org). While STROBE is not a tool for assessing the quality of 
published research it provides guidance on how to report observational research 
well, and does aim to make issues such as confounding, bias and generalisability 
more transparent (von Elm et al., 2008). This bespoke quality assessment form 
facilitated judgement of not only the reported quality of the study but also 
assessment of how it contributes to the answering of the research question 
underpinning this systematic review. This approach has been used previously, as 
the CRD note that separate lists can be used or a combined list selected or 
developed (CRD, 2009). While Hawker et al. (2002) considered that as there is no 
scoring method for the heterogeneous data it was appropriate to develop a 
framework to assess quality across a diverse group of studies. This bespoke quality 
37 
 
assessment form facilitated judgement of not only the reported quality of the study 
(including aspects of internal and external validity) but also assessment of how it 
contributes to the research question. The quality assessment form was reviewed by 
academic and clinical experts, tested using known papers and adjusted prior to 
being applied to all of the included studies.  The form is available in Appendix 3.   
Two reviewers independently completed quality assessments on the included 
studies, acknowledging the possibility of separate reviewers applying and 
interpreting checklist criteria in differing ways (Goldsmith et al., 2007). The 
reviewers met and discussed their decision-making and reached agreement on the 
quality level assigned to each study. A third reviewer was available if there were 
studies where a consensus on the assessment could not be agreed by the two 
reviewers, this reviewer was not required. Overall the following quality levels were 
assigned to the studies using the symbols ++, + and - ; 
 ++ indicates studies where the reported methods and subsequent results 
and conclusions could be considered (with reasonable confidence) not to be 
biased, the process of drug manipulation was at least adequately described   
 + indicates studies where there were some concerns about the reported 
study methods, or the methods were not reported in enough detail to 
permit sufficient assessment 
 - indicates studies where there were considerable concerns about the 
reported methods or there was insufficient reporting of the methods for 
them to be assessed.   
Six (14%) studies were assigned a ++ quality rating, 29 (67.4%) studies a + rating and 
8 (18.6%) a − rating. Throughout the narrative synthesis of this review the quality 
assessment given to the study is included in brackets where that study is being 
described.    
 
 
 
38 
 
2.4.5 Data synthesis  
Synthesis involves the collation, combination and summary of findings of individual 
studies included in the systematic review. The data from each study were extracted 
and tabulated by one reviewer. All of the data extraction was independently 
reviewed by the second reviewer. There was a diverse range of study types that 
could be incorporated in this review. There are challenges with the synthesis of 
different types of studies and data in the same review. However, there is a risk of 
excluding potentially valuable information where only one type of evidence is used 
has also been identified (Roberts et al., 2002; Thomas et al., 2004). While there has 
been some discussion within the systematic review literature about the use of 
quantitative and qualitative studies in the same systematic review, though there is 
little guidance available on combining different studies in reviews (Harden and 
Thomas, 2005). The use of laboratory-based studies in systematic reviews is more 
unusual and has not previously been considered. The heterogeneity of the studies 
included meant that the use of methods of pooling data, such as meta-analysis or 
meta-ethnography was not appropriate. The data was synthesised using narrative 
review with studies grouped using the outcomes defined for this review.      
 
2.5 RESULTS  
The search strategies for this review had the following yield: PubMed 15,042, 
EMBASE 1782, CINAHL 312 hits. Removal of duplicates from PubMed, EMBASE and 
CINAHL resulted in a final search of 16,633. This with the IPA search (13,119 hits), 
means that a total of just under 30,000 hits were screened to identify possible 
studies for inclusion in this systematic review. The narrower drug specific searches 
yielded 4535 hits, there were no additional studies identified from these searches. 
From the update searches an additional 4032 hits were screened for possible 
inclusion with two studies added to the systematic review.     
Forty two studies met the inclusion criteria. The subsequent drug specific searches 
did not yield any additional studies. Figure 2 shows the flow diagram for the 
identification of the included papers. 41 of the 42 studies involved tablets, the one 
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remaining study involved suppositories. 16 of the 41 tablet studies investigated 
weight and/or drug content. There was only one bioavailability study identified 
where drugs were manipulated to obtain a proportion of the dosage form, and that 
proportion administered. Nine further studies investigated bioavailability outcomes 
(of which five also reported adverse effects) following the manipulations of five 
delayed release formulations. In these nine remaining studies all of the dosage form 
was administered. Eight studies reported on patient experience, adherence, taste 
or tolerability outcomes. Eight included a comparison of the methods used for the 
manipulation. Three studies considered tablet characteristics such as whether the 
tablets were scored or unscored.  
Only two studies had child participants including the one bioavailability study where 
a proportion of the tablet was administered and one study which considered the 
taste scores of crushed tablets. No studies were identified that considered 
manipulation of other dosage forms known to be manipulated in practice, or that 
considered physical/chemical/microbial stability or contamination of the areas of 
manipulation. Though adverse effects were reported in five of the bioavailability 
studies there were no studies that specifically considered evidence of the safety or 
harms of manipulating medicines.   
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Figure 2: Flow diagram for the identification of the included papers  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
30,341 records 
identified 
through initial 
database 
searching 
33,872 records screened 
29,839 records 
after duplicates 
removed 
1 record 
identified 
by experts 
4032 records 
identified through 
update searching 
81 full-text articles 
excluded (reasons for 
exclusion; non-
systematic reviews, 
outcomes not 
applicable, letters)   
12 records 
identified through 
searching 
references 
33,760 records 
excluded – did not meet 
the inclusion criteria 
for this systematic 
review   
42 studies 
included in 
analysis 
124 full-text 
articles assessed 
for eligibility    
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2.5.1 Primary outcome: dose accuracy of the manipulated medicines – weight 
and/or drug content outcomes  
Figure 3 summarises the studies that considered weight and/or drug content. The 
dose accuracy of manipulated medicines was assessed by different studies through 
weight, dissolution profiles and/or drug content outcomes. Of the 17 studies 
included in this section 16 were of tablets, with 15 having segmented tablets and 
one study having dispersed tablets.  
In the absence of pharmaciopoeial standards to establish uniformity of split tablets 
when these studies were undertaken, authors have devised tests based on those 
for intact dosage forms. These studies used adapted pharmacopoeial weight and/or 
drug content specifications to assess whether halved tablets were truly halved 
(Footitt, 1983; Rosenberg et al., 2002; Teng et sl., 2002; Polli et al., 2003; Rashed et 
sl., 2003, Tuleu et al., 2005; Hill et al., 2009; Zaid and Ghosh, 2011).   
These eight studies of halved tablets involved 65 products of 33 drugs and found 
that with 64.7% of the outcomes the product did not meet the specifications used 
in the study (for example the product was outwith the specified 85-115% range of 
target half-tablet weight). These eight studies were considered to be of reasonable 
quality with three assessed as ++ and five as +. One of these studies (Tuleu et al., 
2005) also quartered tablets finding that there was wider variability with quarter 
tablet weights than with half tablet weights.   
Additional studies halved and/or quartered tablets and used other weight related 
outcomes measures:  
- One study (+) used the weight variation between tablet parts and found that 
0-75% of halved tablets (of seven differing tablet products) were outwith 
±15% of the desired weight (Horn et al., 1999). This study found that 29-74% 
of quartered tablets were outwith the desired weight.    
- One study (+) used deviations from the theoretical weight of halved and 
quartered tablets (of three differing tablet products), finding that 10-32.5% 
of halves and 37.5-58.8% of quarters were outside the weight limit (Costa et 
al., 2000).   
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- One study (+) quartered tablets and considered them not to be of 
acceptable weight standards (Walker et al., 1978).    
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Figure 3   
44 
 
Three studies (all assessed as +) used dissolution profiles (Shah et al., 1987; Mandal, 
1996; Erramouspe and Javi, 1997). All three considered tablets with a modified-
release mechanism, and identified differences in dissolution profiles between 
halved and intact tablets.   
Table 2 details the drugs involved in the studies above and whether when 
manipulated they did or did not meet the specifications defined in the study. This 
table also demonstrates that many of the included studies had not reported the 
methods of manipulation, and details on the shape, coating and presence of 
scoreline on the tablets. Even where these aspects were reported in many cases 
this reporting was incomplete and lacked detail. 
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Table 2: Summary of the studies that considered dose accuracy or drug content in the manipulated tablets  
 
* G/B = generic/brand medicine 
* M = manipulation (H = halved, Q = quartered),   
* S = scored (Yes or No),  
* Method = method of manipulation (TS = tablet splitter, Kn = knife, Ha = split by hand, Ra = split by razor blade),  
#  
++, +, -  = quality assessment  
 
Drug  Initial 
Strength 
G/
B* 
Specifications  M*  Meth
od* 
S* Shape  (coating – 
where reported ) 
Outcomes summary  Reference
#
 
Amiloride HCL & 
hydrochlorothiazide  
5/5mg B Ph Eur H Ha Y Round (no coating) Did not meet weight variation specifications  (Zaid and Ghosh 2011)++ 
Amlodipine  
 
5mg B Weight variation  H  TS N  77-91% halves within ±15% of desired weight  (Horn, Kuhn et al. 1999) + 
5mg B Ph Eur H Ha Y Oblong (no coating) Did not meet weight variation specifications (Zaid and Ghosh 2011)++ 
5mg B Ph Eur H Ha Y Oblong (no coating) Did not meet weight variation specifications (Zaid and Ghosh 2011)++ 
Aspirin  325mg G Dissolution study  H  TS   Dissolution profile similar for halved and intact tablets  (Mandal 1996) + 
Aspirin (SR) (800mg 
matrix tablets, 650mg 
microencapsulated 
particles) 
800mg B Dissolution study H  TS   Dissolution profile showed higher dissolution for halved 
tablets than intact tablets  
(Mandal 1996) + 
650mg G Dissolution study H  TS   Dissolution profile showed similar drug release profile for 
halved and intact tablets  
(Mandal 1996) + 
Atenolol  
  
25mg B Weight variation  H  TS N  25-95% halves within ±15% of desired weight  (Horn, Kuhn et al. 1999) + 
100mg 
 
B Ph Eur H Ha Y Round (no coating) Did not meet weight variation specifications  (Zaid and Ghosh 2011)++ 
B Ph Eur H Ha Y Round (no coating) Did not meet weight variation specifications (Zaid and Ghosh 2011)++ 
Atorvastatin  
  
10mg B Ph Eur  H Ha Y Oblong (film-coated)  Did not meet weight variation specifications (Zaid and Ghosh 2011)++ 
20mg B Ph Eur H Ha Y Oblong (film-coated) Met weight variation specifications  (Zaid and Ghosh 2011)++ 
40mg B Adapted USP  H  TS N Oval  Met weight uniformity specifications  (Polli, Kim et al. 2003) ++ 
20mg B Adapted USP H Ra N Oval, not flat  Did not meet weight variation specifications  (Teng, Song et al. 2002) + 
40mg B Adapted USP H Ra N Oval, not flat  Did not meet weight variation specifications  (Teng, Song et al. 2002) + 
Buspirone  5mg B Adapted USP  H  TS Y Ovoid-rectangular Did not meet weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
Captopril 
  
 
6.25mg G Adapted USP  H   Y Capsule shaped Did not meet weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
12.5mg B Weight variation H, Q    TS Y  58-100% halves,26-55% quarters within ±15% of desired 
weight  
(Horn, Kuhn et al. 1999) + 
25mg  Theoretical H, Q  Y Round (uncoated) 25% halves, 42.5% quarters outside the weight limit (Costa, Amaral et al. 2000) + 
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Table 2: Summary of the studies that considered dose accuracy or drug content in the manipulated tablets  
 
* G/B = generic/brand medicine 
* M = manipulation (H = halved, Q = quartered),   
* S = scored (Yes or No),  
* Method = method of manipulation (TS = tablet splitter, Kn = knife, Ha = split by hand, Ra = split by razor blade),  
#  
++, +, -  = quality assessment  
 
Drug  Initial 
Strength 
G/
B* 
Specifications  M*  Meth
od* 
S* Shape  (coating – 
where reported ) 
Outcomes summary  Reference
#
 
 weight  Halves met USP dissolution profiles, quarters did not  
 Theoretical 
weight  
H, Q   Y Round (uncoated) 10% halves,37.5% quarters outside  the weight limit 
Halves met USP dissolution profiles, quarters did not  
(Costa, Amaral et al. 2000) + 
 Theoretical 
weight  
H, Q   Y Square (film coated) 32.5% halves, 58.8% quarters outside  the weight limit 
Halves met USP dissolution profiles, quarters did not  
(Costa, Amaral et al. 2000) + 
25mg B Ph Eur H Ha Y Round (no coating) Did not meet the weight variation specifications  (Zaid and Ghosh 2011)++ 
Carbamazepine  100mg B Weight variation H  TS Y  60-93% halves within ±15% of desired weight  (Horn, Kuhn et al. 1999) + 
Citalopram  
 
40mg 
 
B Adapted USP  H  TS Y Oval  Met weight uniformity specifications  (Polli, Kim et al. 2003) ++ 
 Adapted USP  H  TS Y Oblong (non-coated)  Did not meet drug content specifications, met weight 
specifications 
(Hill, Varker et al. 2009) ++ 
Clonidine  
 
0.1mg 
 
B Weight variation  H, Q    TS Y  81-100% halves, 44-71% quarters within ±15% of desired 
weight  
(Horn, Kuhn et al. 1999) + 
G Weight variation  H, Q    TS Y  30-79% halves, 25-49% quarters within ±15% of desired 
weight  
(Horn, Kuhn et al. 1999) + 
Donepezil  5mg B Adapted USP  H   N Round Did not meet weight variation specifications   (Rosenberg, Nathan et al. 2002)+ 
Doxazosin  
 
0.5mg G Adapted USP  H   Y Round Did not meet weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
2mg B Adapted USP  H   Y Oblong Met weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
Enalapril maleate  
  
5mg B Ph Eur H Ha Y Round (no coating) Did not meet weight variation specifications  (Zaid and Ghosh 2011)++ 
5mg B Ph Eur H Ha Y Round (no coating) Did not meet weight variation specifications  (Zaid and Ghosh 2011)++ 
10mg B Ph Eur H Ha Y Round (no coating) Did not meet weight variation specifications  (Zaid and Ghosh 2011)++ 
20mg B Ph Eur H Ha Y Round (no coating) Did not meet weight variation specifications (Zaid and Ghosh 2011)++ 
Fluvoxamine  50mg B Adapted USP  H   Y Elliptical  Met weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
Furosemide  40mg G Adapted USP  H  TS Y Round Met weight uniformity specifications  (Polli, Kim et al. 2003) ++ 
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Table 2: Summary of the studies that considered dose accuracy or drug content in the manipulated tablets  
 
* G/B = generic/brand medicine 
* M = manipulation (H = halved, Q = quartered),   
* S = scored (Yes or No),  
* Method = method of manipulation (TS = tablet splitter, Kn = knife, Ha = split by hand, Ra = split by razor blade),  
#  
++, +, -  = quality assessment  
 
Drug  Initial 
Strength 
G/
B* 
Specifications  M*  Meth
od* 
S* Shape  (coating – 
where reported ) 
Outcomes summary  Reference
#
 
Glipizide  10mg G Adapted USP  H  TS Y Round Met weight uniformity specifications  (Polli, Kim et al. 2003) ++ 
2.5mg G Adapted USP  H   Y Round Did not meet weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
Glyburide  5mg B Adapted USP H Ra, Ha Y Not oval, not flat  Did not meet weight variation specifications  (Teng, Song et al. 2002) + 
Hydrochlorothiazide  
  
12.5mg B Adapted USP  H   Y Round Met weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
50mg B Adapted USP H Ra, Ha Y Not oval, not flat  Did not meet weight variation specifications  (Teng, Song et al. 2002) + 
25mg B Adapted USP H Ra N Not oval, not flat  Did not meet weight variation specifications  (Teng, Song et al. 2002) + 
50mg B Adapted USP H Ra, Ha Y Not oval, not flat  Did not meet weight variation specifications  (Teng, Song et al. 2002) + 
Levodopa  
  
500mg 
 
B Weight 
uniformity    
Q  TS Y  Quarters not of acceptable standards in uniformity of 
weight  
(Walker, Abdulsalam et al. 1978)+ 
B Weight 
uniformity    
Q  TS Y  Quarters not of acceptable standards in uniformity of 
weight  
(Walker, Abdulsalam et al. 1978)+ 
B Weight 
uniformity    
Q  TS Y  Quarters not of acceptable standards in uniformity of 
weight  
(Walker, Abdulsalam et al. 1978)+ 
Lisinopril  
  
 
40mg  Adapted USP  H  TS N Oval (non-coated)  Did not meet drug content or weight specifications (Hill, Varker et al. 2009) ++ 
5mg  Ph Eur  H  Ha Y  Met the specifications for crushing strength, friability, 
disintegration time and mass uniformity  
(Vranic and Uzunovic 2008) + 
10mg  Ph Eur  H  Ha Y  Met the specifications for crushing strength, friability, 
disintegration time and mass uniformity  
(Vranic and Uzunovic 2008) + 
20mg  Ph Eur  H  Ha Y  Met the specifications for crushing strength, friability, 
disintegration time and mass uniformity  
(Vranic and Uzunovic 2008) + 
40mg B Adapted USP   H  TS N Trapezoid  Did not meet weight uniformity specifications  (Polli, Kim et al. 2003)++ 
40mg B Adapted USP H Ra N Not oval, not flat  Met weight variation specifications  (Teng, Song et al. 2002) + 
Lisinopril/ 20/  Ph Eur  H  H Y  Met the specifications for crushing strength, friability, (Vranic and Uzunovic 2008) + 
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Table 2: Summary of the studies that considered dose accuracy or drug content in the manipulated tablets  
 
* G/B = generic/brand medicine 
* M = manipulation (H = halved, Q = quartered),   
* S = scored (Yes or No),  
* Method = method of manipulation (TS = tablet splitter, Kn = knife, Ha = split by hand, Ra = split by razor blade),  
#  
++, +, -  = quality assessment  
 
Drug  Initial 
Strength 
G/
B* 
Specifications  M*  Meth
od* 
S* Shape  (coating – 
where reported ) 
Outcomes summary  Reference
#
 
hydrochlorothiazide  12.5mg disintegration time and mass uniformity  
Lovastatin  40mg B Adapted USP  H  TS N Octagon  Did not meet weight uniformity specifications  (Polli, Kim et al. 2003) ++ 
Lozartan 50mg B Ph Eur H Ha Y Round (no coating) Did not meet the weight variation specifications (Zaid and Ghosh 2011)++ 
Mercaptopurine  
 
50mg B Adapted BP  H  Ha/Kn Y  Did not meet uniformity of weight specifications  (Footitt 1983) + 
10mg G Adapted BP  H  Ha/Kn N  Did not meet uniformity of weight specifications  (Footitt 1983) + 
Methylphenidate (SR),  
 
(Ritalin-SR) 
20mg 
 
G USP dissolution 
profiles 
H  TS   Mean cumulative dissolution profiles showed significant 
differences between halved and whole tablets 
(Erramouspe and Jarvi 1997) + 
B USP dissolution 
profiles 
H  TS   Mean cumulative dissolution profiles showed significant 
differences between halved and whole tablets 
(Erramouspe and Jarvi 1997) + 
Metformin  850mg B Adapted USP H Ra U Not oval, not flat  Did not meet weight variation specifications  (Teng, Song et al. 2002) + 
Metoprolol succinate  
 
200mg  Adapted USP  H  TS N Oval (film-coated)  Did not meet drug content specifications (met when 
weight adjusted). Did not meet weight specifications 
(Hill, Varker et al. 2009) ++ 
50mg B Adapted USP  H   Y Biconvex Met weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
Metoprolol tartrate 
 
50mg G Adapted USP  H  TS Y Oblong  Met weight uniformity specifications  (Polli, Kim et al. 2003) ++ 
25mg  Adapted USP  H  TS Y Circular (non-coated)  Did not meet drug content specifications (met when 
weight adjusted).  Met weight specifications 
(Hill, Varker et al. 2009) ++ 
25mg G Adapted USP  H   Y Capsule shaped Did not meet weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
25mg G Adapted USP  H   Y Round Did not meet weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
Nifidepine M/R  10mg B Ph Eur (halved 
tablets)  
H, Q  TS   38/40halved  tablets did not meet weight specifications, 
wide variability with halved and quartered tablets (SD 
20%& 29% respectively) 
(Tuleu, Grange et al. 2005) + 
Oxybutynin  2.5mg G Adapted USP  H   Y Round Did not meet weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
Paroxetine  10mg B Adapted USP  H   Y Modified oval Met weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
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Table 2: Summary of the studies that considered dose accuracy or drug content in the manipulated tablets  
 
* G/B = generic/brand medicine 
* M = manipulation (H = halved, Q = quartered),   
* S = scored (Yes or No),  
* Method = method of manipulation (TS = tablet splitter, Kn = knife, Ha = split by hand, Ra = split by razor blade),  
#  
++, +, -  = quality assessment  
 
Drug  Initial 
Strength 
G/
B* 
Specifications  M*  Meth
od* 
S* Shape  (coating – 
where reported ) 
Outcomes summary  Reference
#
 
  
 
20mg B Adapted USP  H  TS Y  Met weight variation specifications  (Rashed, Nolly et al. 2003) + 
40mg B Adapted USP  H  TS N  Did not meet weight variation specifications  (Rashed, Nolly et al. 2003) + 
40mg B Adapted USP  H  TS Y Oval  Met weight uniformity specifications  (Polli, Kim et al. 2003) ++ 
40mg B Adapted USP H Ra U Oval, not flat  Met weight variations specifications  (Teng, Song et al. 2002) + 
Propranolol  10mg B Ph Eur H Ha Y Round (no coating) Did not meet weight variation specifications (Zaid and Ghosh 2011)++ 
Risperidone  
  
2mg B Adapted USP  H  TS N  Did not meet weight variation specifications (Rashed, Nolly et al. 2003) + 
4mg B Adapted USP  H  TS N  Did not meet weight variation specifications (Rashed, Nolly et al. 2003) + 
0.25mg B Adapted USP  H   N Oblong Met weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
1mg B Adapted USP  H   N Oblong Did not meet weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
Rofecoxib  25mg B Adapted USP  H  TS N Round  Did not meet weight uniformity specifications  (Polli, Kim et al. 2003) ++ 
Sertraline  100mg 
 
B Adapted USP  H  TS Y Oblong  Met weight uniformity specifications  (Polli, Kim et al. 2003) ++ 
B Adapted USP  H  TS Y  Did not meet weight variation specifications  (Rashed, Nolly et al. 2003) + 
25mg B Adapted USP  H   Y Capsule shaped Did not meet weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
50mg B Adapted USP  H   Y Capsule shaped Did not meet weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
B Adapted USP  H   Y Capsule shaped Did not meet weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
G Weight variation  H  TS Y  90-100% halves within ±15% of desired weight  (Horn, Kuhn et al. 1999) + 
Sertraline  100mg B Adapted USP  H Ra Y Oval, not flat  Met weight variation specifications  (Teng, Song et al. 2002) + 
Sildenafil  50mg B Adapted USP H Ra N Not oval, not flat  Did not meet weight variation specifications  (Teng, Song et al. 2002) + 
Simvastatin  
 
20mg B Adapted USP  H  TS N Shield-like  Did not meet weight uniformity specifications  (Polli, Kim et al. 2003) ++ 
80mg  Adapted USP  H  TS N Oval (film-coated) Did not meet drug content specifications (met when 
weight adjusted).  Met weight specifications 
(Hill, Varker et al. 2009) ++ 
Sulphamethoxy- 500mg B Weight Q  TS Y  Quarters not of acceptable standards in uniformity of (Walker, Abdulsalam et al. 1978)+ 
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Table 2: Summary of the studies that considered dose accuracy or drug content in the manipulated tablets  
 
* G/B = generic/brand medicine 
* M = manipulation (H = halved, Q = quartered),   
* S = scored (Yes or No),  
* Method = method of manipulation (TS = tablet splitter, Kn = knife, Ha = split by hand, Ra = split by razor blade),  
#  
++, +, -  = quality assessment  
 
Drug  Initial 
Strength 
G/
B* 
Specifications  M*  Meth
od* 
S* Shape  (coating – 
where reported ) 
Outcomes summary  Reference
#
 
pyridazine uniformity   weight  
Theophylline (CR) 300mg 
 
B USP dissolution 
profiles  
H     Used 8 different brands; 6/8 had significant  differences in 
dissolution profiles for halved and whole tablets for both 
simulated gastrointestinal fluids used and 1/8 had 
significant  differences for one of the fluids used  
(Shah, Yamamoto et al. 1987) + 
Trazodone  
 
25mg 
 
G Adapted USP  H   Y Round  Did not meet weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
G Adapted USP  H   Y Round  Met weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
Venlafaxine  25mg B Adapted USP  H   Y Shield shaped  Did not meet weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
Warfarin  
  
500mcg B Adapted USP  H   Y Round  Did not meet weight variation specifications  (Rosenberg, Nathan et al. 2002) + 
5mg 
 
B  Adapted USP  H  TS Y Round Met weight uniformity specifications  (Polli, Kim et al. 2003) ++ 
 Adapted USP  H  TS Y Oblong (non-coated) Did not meet drug content  or weight specifications  (Hill, Varker et al. 2009) ++ 
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Overall these studies showed that halving tablets may not be reliable and that 
quartered tablets had substantial variation in weight and less reliably segmented 
than halved tablets.    
Two further studies (both assessed as +)  used other methods to consider dose 
accuracy; (Stimpel et al., 1985) split 34 brands of antihypertensive scored tablets, 
grouping the halved tablets into categories dependent on the weight deviation 
from the theoretical weight of halved tablets. Seven of the antihypertensives were 
considered to have excellent divisibility, eleven had good divisibility, ten had 
moderate divisibility and six had poor divisibility. The second study (Broadhurst et 
al., 2008) dispersed dispersible aspirin tablets in 10mL water and found that 
irrespective of dispersion time the samples taken from the base of the 30 mL 
container were consistently closest to the intended dose (51-95% of the intended 
dose) compared with those taken from the highest zone at 8mL mark of the 
container (23-80% of the intended dose), with a trend for the dose measured to 
decrease as the zones ascended up the beaker.  
2.5.1.1 Non-tablet study 
In the only non-tablet study (-) anaesthetists split six paracetamol suppositories of 
each of three different strengths into half and 2/3 doses (Kim et al., 2005). This 
study identified wide ranges for the resultant segments with yields of between 60-
195% of the intended dose when suppositories were intended to be halved, though 
the authors of the study stated that there was good uniformity of paracetamol 
content in the intact suppository. The authors concluded that the lack of accuracy 
and precision was a reason to use unaltered suppositories.  
 
2.5.2 Secondary outcomes: bioavailability, effectiveness, patient experience, 
adherence/compliance, comparison between manipulation methods   
2.5.2.1 Bioavailability    
Figure 4 summarises the studies that considered bioavailability. Bioavailability is the 
degree and rate to which the drug is physiologically available. While there are many 
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physiological and disease related mechanisms that can effect bioavailability it is also 
influenced by the formulation of the drug product, such as the mechanism of 
release (immediate, delayed), or the excipients added or manufacturing process 
used. The manipulation of a drug product may (or may not) have an impact on 
bioavailability. For example manipulation such as cutting a tablet into segments 
may alter the rate of the drug release or the concentration of the drug available. 
These possible effects of manipulation may mean that the drug dose available 
remains within acceptable efficacy and toxicity ranges, or they could impact 
negatively on both. The difficulty is that these potential effects where drug 
products are designed to have been administered without manipulation are not 
known.   
There was only one bioavailability study (++) identified where a drug was 
manipulated to obtain a proportion of the original dosage form with this portion 
administered to participants and outcomes reported. This study was one of only 
two in this review which specifically included children, it involved 18 HIV-infected 
children who were banded into three weight groups and correspondingly received 
quartered, halved or three quartered generic tablet multiples of lamivudine (3TC) 
300mg, stavudine (d4T) 80mg and nevirapine (NVP) 400mg or a generic liquid or 
trade liquid in a crossover study (Corbett et al., 2010). This study found that overall 
for all dosing groups there were no significant difference in bioavailability between 
the use of quartered, halved or three quartered tablets. Generally the time to 
maximum concentration was delayed for d4T and 3TC for the manipulated tablets 
compared with the liquid formulations. Overall all of the formulations were well 
tolerated.   
There were nine studies, in adults, identified where modified-release tablets were 
split or crushed but the whole dose of the tablet administered. Due to the potential 
to alter the drug release characteristics of the formulation, the bioavailability and 
adverse effects outcomes of these studies are considered to be relevant to 
situations in which a proportion of the dosage form could, potentially, be 
administered. Eight of these nine eligible studies were sustained-release 
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formulations and one study used an enteric-coated formulation. All of these studies 
had adult participants. Two studies involved crushing tablets, the crushing of 
pentoxfylline extended-release (Trental) 400mg and 600mg tablets (Cleary et al., 
1999) (++) and theophylline matrix sustained-release (Theo-Dur) 300mg tablets 
(MacKintosh et al., 1985) (+) did not significantly change the bioavailability, though 
the time taken to reach peak concentration was shorter with crushed tablets than 
with intact tablets.  
Five studies halved modified release tablets. No differences were found in 
bioavailability for halved and intact theophylline sustained-release (Theo-Dur) 
100mg tablets (Simons et al., 1982) (+) and 300mg tablets (Fagerstrom, 1980) (-) 
tablets. One study (+) used theophylline slow-release anhydrous (Uniphyllin) 400mg 
tablets (Primrose et al., 1983) and peak drug levels were significantly higher with 
halved than with intact tablets. Two studies (both assessed as +) used verapamil 
sustained-release (Isoptin SR, Securon SR) 240mg matrix tablets, both studies found 
no differences in bioavailability for halved and intact tablets (McEwen et al., 1989; 
Moreland et al., 1989).  
The final study including modified release tablets (+) involved cutting isosorbide-5-
mononitrate (Monoket Multitab) tablets into thirds and found no significant 
differences in bioavailability though maximum peak concentration was higher with 
the trisected tablets than with intact tablets (Stockis et al., 2002).  
The one study (++) that crushed enteric-coated tablets (pantoprazole 40mg) found 
the resultant suspension to have 25% less bioavailability than the whole tablet 
(Ferron et al., 2003).      
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Figure 4: Studies in the systematic review that considered bioavailability   
 
 
  
10 studies included 
1 study where tablets were 
manipulated and a proportion 
administered 
All studies involved tablets – no studies considered other dosage forms 
1 study crushed 
enteric coated 
tablets  
9 studies where modified-release tablets were crushed or halved, the total dose of the 
original tablet was administered 
2 studies crushed 
modified release 
tablets  
6 studies split modified 
release tablets; 5 into 
halves and 1 into thirds   5 of these 
studies 
reported on 
adverse 
effects  
5 studies did not specify the 
methods of splitting  
1 study split the tablets 
manually  
2 studies crushed tablets with pestle and 
mortar 
1 study crushed tablets between two spoons 
Did not specify the 
methods of splitting  
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2.5.2.2 Evidence of safety or harms, adverse effects 
Adverse effects considered to be related to the drug manipulation were relevant to 
this review. There were adverse effects reported in five of the nine bioavailability 
studies of modified release tablets with nausea/vomiting with theophylline 
(Primrose et al., 1983) and pentoxfylline (Cleary et al., 1999) and headache 
(Primrose et al., 1983; Cleary et al., 1999) and with isosorbide-5-mononitrate 
(Stockis et al.,2002) featuring slightly more often with crushed or split tablets than 
intact tablets. One study reported excellent tolerability with both halved and intact 
verapamil tablets (Moreland et al., 1989). The one study which crushed enteric-
coated pantoprazole tablets found both treatments to be well tolerated and 
considered the adverse effects reported to be related to nasogastric tube insertion 
rather than drug-related (Ferron et al., 2003). The number of adverse effects 
reported was small and reporting was not detailed.   
2.5.2.3 Patient experience 
One study (-) considered the experiences of children taking an oral solution 
compared with those taking a dispersion of crushed prednisolone tablets (Lucas-
Bouwman et al., 2001). Taste assessed by visual analogue scores was significantly 
better for the oral solution than for the crushed tablets. Nine of the 39  children 
taking crushed tablets withdrew due to repeated vomiting while taking the crushed 
tablets compared with none from the oral solution group (p=0.001).    
There were five surveys identified that assessed adult participants’ experiences of 
splitting tablets. Splitting of tablets has been encouraged in some areas for 
economic reasons, though the dose required may be available in an intact tablet. 
(For example, if 5mg of a drug is required half of a 10mg tablet may be used in 
preference to a 5mg tablet as the 10mg tablet may be only fractionally more 
expensive and much cheaper than two 5mg ones.) Three studies used the same 
questionnaire, or an adapted version of it, for tablets split with a tablet splitter. 
Carr-Lopez et al. (1995) surveyed 233 patients splitting lovastatin, Gee et al. (2002) 
surveyed 454 patients enrolled in a statin splitting programme (both -) and Fawell 
et al. (1999) (+) surveyed 47 patients splitting fosinopril. Across the three studies, a 
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small percentage of respondents disagreed with the statement that tablet splitting 
had no effect on their willingness to take their medication; (4% of respondents 
(Fawell et al., 1999), 6.3% (Carr-Lopez et al., 1995), 7% (Gee et al., 2002). Some 
respondents reported missing more doses in a month when splitting tablets 
compared with other medicines where the tablet did not have to be halved, 7% of 
respondents (Gee et al., 2002) and 14% (both (Carr-Lopez et al., 1995; Fawell et al., 
1999).    
One study (+) surveyed 99 patients with hyperlipidaemia using a tablet splitter (55 
participants received financial incentive to split tablets during the study, 54 
participants did not). This study did not find differences between the groups 
regarding willingness to split pills, finding that 87-94% found that tablet splitting 
had not affected their willingness to take their medication and that 7-13% 
responded that they had missed more medication doses because of tablet splitting 
(Choe et al., 2007). In a survey (+) of 28 patients splitting lisinopril (method of 
splitting not reported) (Rindone, 2000) tablet splitting was bothersome ‘most’ of 
the time for 25% of participants. For ‘some’ of the time for 54% of participants 
there were more than two pieces of the tablet following splitting.     
2.5.2.4 Adherence 
Three of the four studies identified considered aspects of adherence; for 47 
participants splitting fosinopril (Fawell et al., 1999), and 111 (Choe et al., 2007) 
(both +) and 3787 splitting statins (Parra et al., 2005) (-) with a tablet splitter. There 
were no differences in adherence between those splitting tablets and those taking 
whole tablets whether self-reported (Choe et al., 2007), measured by  tablet 
counting, refill history and self-reporting (Fawell et al., 1999) or prescription refills 
(Parra et al., 2005). The fourth study (+) included patients with schizophrenia or 
schizoaffective disorder splitting risperidone. This study found that adherence 
increased with tablet splitting (Weissman and Dellenbaugh, 2007).   
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2.5.2.5 Comparison between manipulation methods  
Seven studies compared different methods of manipulation when splitting tablets. 
In general the use of a tablet splitter was found to be better than other splitting 
methods such as using scissors or knives, or splitting manually (Table 3).    
Table 3: Comparison between manipulation methods  
Reference 
(quality 
assessment)  
Manipulation  Outcomes  
 
(Boggie et 
al., 2004) (+) 
100 unscored tablets halved with 
a tablet splitter, 25 split by hand  
No significant difference in weight 
variance between those split with a 
tablet splitter and those split by hand  
(Cook et al., 
2003)  
(+) 
45 round, film coated, unscored 
tablets halved with a tablet 
splitter, 45 split with a kitchen 
knife (split by a pharmacist and 2 
pharmacy doctoral students)  
16% with tablet splitter and 58% with 
kitchen knife deviated from the 
theoretical segment weight by more 
than 15%  
(McDevitt et 
al., 1998)  
(+) 
51 round, scored tablets halved 
with tablet splitter, 876 manually 
halved (if tablets could not be 
split manually the splitter was 
used) (split by 94 volunteers)  
40.2% of those split with a tablet 
splitter and 33% of those split manually  
were within 5% of the theoretical 
weight  
(Teng et al., 
2002)  
(+) 
10 tablets of each of 8 
formulations halved with a razor 
blade  
10 tablets of 3 formulations 
where tablets were soft enough 
to split by hand (split by a single, 
trained individual)  
Halved with a razor blade; 3/11 passed 
the specified weight criteria (2 
unscored, 1 scored), 8/11 failed USP 
weight criteria (5 unscored, 3 scored) 
3 scored drugs split by hand all failed 
the USP weight criteria  
(Verrue et 
al., 2011)    
(+) 
10 tablets of each of 8 
formulations, 4 scored and 4 
unscored, 6 round, 2 oblong,  
halved and quartered (split by 5 
volunteers using each method of 
a tablet splitter, scissors for 
unscored tablets/by hand for 
scored tablets, or with a kitchen 
knife)  
Those split with the tablet splitter had 
significantly lower deviation from 
theoretical weight and significantly less 
weight loss than those split by scissors 
(for unscored tablets) or by hand (for 
scored tablets) or with a kitchen knife.  
There was significantly less weight loss 
with the scissors/hand than with the 
kitchen knife, no significant  difference 
for deviation from theoretical weight  
(Williams et 
al., 2002)  
(-) 
24 round, unscored tablets 
quartered with a tablet splitter or 
cut freehand with a razor blade 
(split by an experienced pharmacy 
technician)  
No significant difference in weight and a 
significantly greater variance with the 
tablet splitter than with the freehand 
split tablets  
(van Vooren 
et al., 2002)   
10 cross-scored tablets of 1 
formulation manually halved and 
Half tablets; the score-up break had the 
lowest residual variance, the score-
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(-) quartered by hand using 4 
different methods or segmented 
with a knife whilst  score side-up 
or score side-down   (split by 3 
individuals)  
down break and the score-up knife had 
the lowest person variability.  Quarter 
tablets; score-down break had 
significantly higher variability than for 
score-up break or score-up knife 
 
One study (+) considered methods of crushing or dispersing whole tablets (10 
tablets of 1 formulation in batches of 2 crushed using pestle and mortar or between 
medicine cups, or dispersed in a syringe (Powers and Cascella, 1990). Suspending 
the drug in the syringe delivered 18% more drug for administration than crushing 
with medicine cups and 36% more than crushing with pestle and mortar. 
 
2.6 DISCUSSION  
This systematic review explores a known and accepted feature of clinical practice. 
Within neonatal and paediatric areas drug manipulation has arisen from necessity, 
where the doses required for administration cannot be readily administered using 
commercially available preparations. This review has demonstrated that there is an 
overall dearth of evidence to support the practice of drug manipulation finding only 
one study where manipulated drug products had been administered. This one study 
(Corbett et al., 2010) reported on the bioavailability of administered quartered, 
halved or three quartered tablets, though it did not specify the methods of splitting 
used and had not completed any analysis on the drug content of the segments 
used. What evidence was available came from a wide-range of studies which used a 
variety of research methods.     
  
2.6.1 Dose accuracy 
When splitting tablets it is reasonable to expect that the weight or drug content of 
segments will vary no more than would be within the defined acceptable limits for 
the intact tablets. Pharmacopoeias such as the European Pharmacopoeia (EP) or 
the United States Pharmacopoeia (USP) provide a legal and scientific basis for 
quality assurance during the preparation of medicines. Pharmacopoeial standards 
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for intact tablets are well established and usually include tests to establish 
uniformity of weight or content. Whilst the detail of these may vary they are 
essentially ensuring low variability of weight and/or drug content of the tablets and 
the absence of outliers. Several authors adapted the pharmacopoeial specifications 
and methodology for testing the uniformity of intact tablets and used these 
adapted specifications to consider segmented tablets. The specifications used 
within these studies were not devised for segmented tablets but were extrapolated 
from those for intact ones. While this may be logical, this approach meant that they 
were using specifications that had not been devised for the purpose they were 
being applied to. There has been recognition that segmented tablets need 
consideration, in 2002 the EP presented pharmacopoeial standards for the 
subdivision of scored tablets. These standards marked the first time this type of 
pharmacopoeial requirement was established and have been subsequently 
reviewed and revised (Green et al., 2010). The use of such standards within other 
pharmacopoeias has been discussed and a stimuli article discussed why such 
standards should be included in the USP (Green et al., 2010).    
Results varied but the majority of included studies indicated a lack of uniformity of 
segment weight or drug content when splitting tablets into halves and that this 
variation is even greater when splitting in to quarters. Tablet splitting did not meet 
the requirements used in the study in two thirds of the tablets tested. Such lack of 
uniformity would be considered of unacceptable quality for intact tablets. The one 
study where tablets were dispersed showed variability in the dose taken from 
different zones in the container. Although there were few comparisons available 
there would appear to be differences in variability of segments between different 
tablet strengths and between branded and generic tablets. As formulations may 
vary, these results can only be applied to the actual drug products involved in the 
study. These findings mean that where tablets are split or dispersed there cannot 
be confidence that the proportion of the tablet that will actually be administered 
contains the dose that the manipulation aimed to achieve.     
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When weight and drug content uniformity were both considered, it is concerning 
that when weight uniformity was compliant, content uniformity often was not. This 
suggests that there is uneven drug distribution within some tablets.  Where tablets 
are scored there may be the assumption that they can be split. However if there is 
uneven drug distribution it may be that splitting is not appropriate. The presence of 
a scoreline does not necessarily signify that there is an even distribution of the 
active ingredient throughout the tablet (Sayeed et al., 2010). Tablets may be scored 
to facilitate administration and though the tablet is scored this is not intended to 
reduce the dosage of medication taken (Shah et al., 2010). The difficulty may be in 
knowing where tablets have been scored to allow a proportion of the total dose to 
be given. A Swiss study screened the Summary of Product Characteristics (SPC) and 
product information leaflets. They reported that the official information available to 
health professionals concerning the fragmenting of scored tablets is incomplete and 
inhomogeneous (Arnet and Hersberger, 2010). This raises the concern that for 
tablets with scorelines there may be insufficient information available about 
whether or not they may or should be segmented. This has been recognised and 
work is under way with the FDA and USP to scientifically define the term functional 
score for tablets and to use it to designate only tablets that can be reliably split into 
equal portions, as described by the American Society of Health-System Pharmacists 
in 2012   
(http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?id=3789#). 
This work will result in a chapter on functional scoring in the USP and The National 
formulary.   
 
2.6.2 Manipulations of non-tablet dosage forms 
The only evidence that was identified relating to other dosage forms involved 
suppositories where one study, which did not report the methods of manipulation, 
showed substantial variation in size of the segments cut from paracetamol 
suppositories, leading the authors to conclude that such suppositories should not 
be split. In a previous review on unlicensed and off label analgesic use in children 
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Conroy and Peden (2001) described that fractions of suppositories are used and 
noted that the distribution of the drug through the suppository may be unknown, 
raising questions about the accuracy of the administered dose.   
 
2.6.3 Bioavailability  
The outcomes from bioavailability studies relevant to this review related to 
situations where modified release tablets were split or crushed and the whole dose 
administered. There were nine studies using ten products. Four of the studies 
indicated that there may be an effect on the intended modified drug release 
mechanism and consequently on bioavailability following manipulation. The 
remaining five studies did not find differences in the outcomes of halved and intact 
tablets. The modified release mechanism is important in determining whether the 
release characteristics will be altered upon splitting. Reduction in the time to reach 
peak concentration was the outcome predominantly affected by the tablet being 
halved or crushed prior to administration. The clinical impact of manipulating 
modified-release tablets is unknown. It has previously been advised that the 
mechanism of the modified-release and the potential impact of crushing a tablet or 
opening a capsule should be considered prior to it being undertaken, though this  
predominantly refers to ease of administration (Williams, 2008; Gill et al, 2012). 
Again the differences between products mean that the results here cannot be 
generalised. Nevertheless, if the dose that is required for an infant or child is 
smaller than is available as an intact modified-release tablet then the decision may 
have to be made whether to manipulate the tablet or not to give the desired drug.   
 
2.6.4 Safety 
In general no adverse events relating to manipulations were reported. Where 
adverse events were reported in the bioavailability studies this was not in detail; 
conclusions cannot be drawn about whether or not manipulated drugs had more 
associated adverse effects.   
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There were no studies identified in this review that reported on the contamination 
of the area of the manipulation or safety of the healthcare professional, carer or 
patient. This supports the view of Crawford (2012) who discussed that splitting or 
crushing medications could be potentially harmful to staff and noted that research 
has not been undertaken on the health and safety aspects of nursing staff exposure 
to small, but repeated, inhalation of medicines.    
 
2.6.5 Patient experience and adherence 
Where adult patients were asked about their experience of splitting tablets they did 
not generally find it had impacted on their willingness to take their medication. 
There was only one study that had paediatric participants and this considered the 
taste and tolerance of crushed tablets, concluding that the oral solution was better 
tolerated than the crushed tablets (Lucas-Bouwman et al., 2001). Again in adult 
studies where adherence was actually measured splitting tablets did not have an 
effect on this.   
 
2.6.6 Comparison between manipulation methods  
Although results were inconsistent, tablets split using a tablet splitter appeared 
more likely to yield segments that had split more accurately than those split using 
other methods, such as scissors, knife or manual splitting. Similarly scored tablets 
tended to provide segments closer to the intended weight. While these results can 
only be considered applicable directly to the products in the studies involved they 
do nonetheless suggest that use of a commercial tablet splitter and scored tablets 
may be beneficial if tablets must be split.        
 
2.6.7 Reporting in the included studies   
Ultimately quality assessment helps answer the question of whether the studies are 
robust enough to guide treatment, prevention, diagnostic or policy decisions 
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(www.york.ac.uk/inst/crd/index_guidance.htm). Within this review quality has 
been assessed though a customised review form specific to the review outcomes. 
This assessment revealed a considerable variety in the quality of the evidence 
relating to drug manipulation. Many of the included studies that considered dose 
accuracy or bioavailability described the use of, or adaption of, recognised 
pharmacopoeial or laboratory methods and as such met many of the quality 
assessment indicators. However often they had not included details that were 
specific to this review such as the methods of manipulation, details on who had 
carried out the manipulation or any methods of ensuring consistency. Some studies 
lacked complete information on the tablets involved such as shape, coating or 
brand name. Though there had been considerable attention given to, for example 
the pharmacopoeial specifications used or the methods of weighing tablets, similar 
attention had not been given to reporting manipulation details. This may echo 
issues found with the reporting of paediatric clinical trials. Pandit et al. (2010) 
reviewed the reporting of formulations information (including how the dose was 
administered) for oral medications in paediatric clinical trials and found that only 
31% of publications provided adequate information. These authors reflected that 
this information is extremely important, particularly where a dosage form may have 
to be manipulated, to restrict the influence administration could have on intra- and 
inter-individual variations. Another marker of quality is that in the individual studies 
where bioavailability was reported any attendant adverse effects were either only 
briefly reported or not reported at all.  
Comparison across studies or synthesis of these studies to suggest conclusions 
about manipulated tablets was made more difficult by the insufficient reporting on 
aspects of drug manipulation in many of the included studies. This makes these 
studies less clinically applicable, as not only are they restricted to the drugs 
involved, if the methods of manipulation have not been clearly stated then even 
the results for these drugs cannot be reliably reproduced.      
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2.6.8 Summary of results  
This review has described the evidence that could be identified. This description has 
highlighted that there are substantial gaps in the evidence both generally relating 
to drug manipulation and specifically with regard to paediatric practice. Though the 
effect of splitting tablets has been investigated in a small number of higher quality 
studies, tablet splitting did not meet the requirements in two thirds of the tablets 
tested. The results can only be seen as specific to the drug product involved. 
Nonetheless this does raise substantial questions about the accuracy of the dose of 
manipulated tablets. These concerns are applicable to the manipulation of other 
tablets and drug products. The manipulated drug was not administered meaning 
that the impact of manipulations on efficacy and safety is not known. There remain 
substantial gaps within the evidence available, for tablet manipulation this has at 
least been explored to some degree. For other dosage forms this has not happened.  
 
2.6.9 Systematic review methods 
The use of a systematic review protocol is acknowledged as important both to help 
guide the review and to help reduce the possibility of introducing bias during the 
review process. Reviews, such as this one, which are not drug or intervention 
specific and which use a wide range of terms not featured in database thesauruses, 
provide additional challenges to their successful completion. The broad range of 
possible types of studies in this review required careful drafting of this protocol. 
This planning assisted with the completion of the review as it ensured that some of 
the main challenges, such as constructing and revising the search strategy, 
assessing the quality of studies and synthesising the data, had been anticipated.   
The retrieval of a high number of irrelevant references was unavoidable given that 
many of the manipulation search terms are commonly used to describe activities 
spanning a broad range of clinical activities. The sensitivity of the searches used had 
to be sacrificed, to some extent, in favour of a more specific search that retrieved a 
manageable number of references. Searchers cannot hope to achieve 100% 
sensitivity while maintaining 100% precision (Boynton et al., 1998). The reliability of 
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the decision process is increased if all papers are independently assessed by more 
than one researcher (CRD, 2009). The overall retrieval of the large number of titles 
and abstracts to be screened meant that it was not possible for two reviewers to 
undertake this. A random 5% were assessed by a second reviewer. In consideration 
of the complexities of the search strategy, and that all abstracts were not screened 
by two reviewers, experts within the field were asked to review the included 
studies list to consider if there were studies that had not been included. One 
additional study was added via this expert review.  
A subsequent search of a small number of specified, frequently prescribed and 
commonly manipulated drugs was undertaken to explore whether there is any 
additional evidence relating to the manipulation of these drugs. Had these 
narrower searches yielded many studies for inclusion then it would have raised 
questions about the original search strategy that may have prompted further 
consideration. These searches did not identify any further papers. This could be 
considered as reassurance about the validity of the original search strategy, it is 
equally reasonable to see this as further evidence of the lack of studies in this area.   
Greenhalgh and Peacock (2005) audited the search method used in a review of 
complex evidence, where broad policy questions were addressed and the synthesis 
involved qualitative and quantitative evidence from disparate sources. This audit 
revealed that reference tracking (scanning the reference list of all full text papers) 
provided 44% of the 495 primary data sources identified, the highest yield of the 
search methods used (this included an electronic database search). With 28% of the 
papers included in this systematic review having been identified from scanning the 
reference lists of already included papers it appears that reference lists may be an 
important source of evidence in reviews where the development of the search 
strategy is complex.   
The difficulties experienced in this review epitomise the importance of a consistent 
nomenclature. Initial work has been completed on this by (Ernest et al., 2012). 
These authors have discussed the confusion that relates to terminology which may 
mean different things to different stakeholders; they explored compounding and 
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manipulation terminology and proposed definitions to provide a hierarchical 
classification.   
This study sought the evidence for an area of clinical practice that could potentially 
include any drug and/or dosage form and therefore may be limited by its complex 
nature. In order to define the scope of the existing research we had specified that 
the only study type restrictions were on case series/studies and letters. 
Consequently the included studies were heterogeneous not only in design and 
quality, but in terms of types of manipulations, drug types, dose forms, participants 
and outcomes investigated. Harden and Thomas (2005) in considering the mixing of 
different study types in systematic reviews noted the strength of diverse methods 
to obtain a more complete picture of a phenomenon and that this diversity allows 
the answering of different aspects of this phenomenon. 
Some review topics can be systematically completed using studies of one study 
type. The importance of presenting evidence, and considering quality, from a 
diverse range of studies has been previously discussed. Lucas et al. (2007) 
integrated findings from systematic reviews of scientific evidence and lay 
perspectives and considered that the comparison of systematic reviews that 
incorporate studies based on scientific paradigms and studies on lay perspectives 
adds additional information that is useful for policy and practice. If this review had 
only assessed data relating solely to dose accuracy and not considered outcomes 
such as patient experience, different manipulation methods or adherence then the 
conclusions of the review, while relevant to clinical practice, would have been 
limited.  
Using evidence from many study types raises further issues within the review, 
notably with quality assessment. Goldsmith et al. (2007) noted that the exact 
function of quality appraisal in reviews of quantitative and qualitative evidence is 
controversial, though it is recognised that reviewers should highlight evidence 
quality issues. Similarly Garg et al. (2008) reviewed the methods used in renal 
systematic reviews and considered that the most common methodological flaw was 
a failure to assess the methodological quality of the included studies. The 
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development of the quality assessment tool for this review allowed the 
incorporation of studies where drug assays were used to consider drug content 
through to studies where surveys considered palatability. The disparate nature of 
these studies provided a particular challenge both with quality assessment and with 
the consideration of the synthesis of the included studies into a review. This is 
notable where the studies involved are solely laboratory based as these do not 
generally feature in systematic reviews and so have not been considered within the 
available systematic review quality tools. This aspect of quality assessment was 
therefore undertaken with the expert input of a formulations expert. The 
development of the quality assessment tool used in this review included the use of 
established criteria for bioavailability, laboratory-based and more descriptive 
studies. It also included study specific additions as it was considered important that 
the process of manipulation was included in the quality assessment. The quality 
appraisal categories used in this review provided an indication of the strengths and 
weaknesses of the included studies. Though this is specific to this review the 
development methods will have relevance for other areas where the evidence base 
is likely to be disparate but where reviewing this base is pertinent to current clinical 
practice.  
This review highlights that quality standards are needed for studies of 
manipulations. The combination of standard approaches to assessment of studies 
with the quality assessment tool described here will provide a foundation for these 
standards.          
Where reviews are broadly focused then they may need to include methods for 
coping with diversity of issues and evidence being considered 
(http://eppi.ioe.ac.uk/cms/). This review has considered this through the review 
protocol, devising an iterative and responsive search strategy, development of the 
quality appraisal process and synthesis of this disparate review. This review 
incorporated a wide range of study types and unusually also included laboratory-
based studies. The limitations of this are acknowledged. However, the methods 
used have been rooted within accepted systematic review methodology and as 
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such have aimed to have the rigour required for a systematic review. This has 
allowed the presentation of evidence from many study types and ensured that the 
evidence can be described and research gaps identified. This has the potential to 
influence planning for future research as clarifying the limits of information in 
current research can assist in defining the research agenda (Choi et al., 2001).  
 
2.7 CONCLUSIONS   
The optimum evidence to meet the aims of this systematic review would have been 
studies where a drug was manipulated to obtain the required dose, compared with 
a control where the drug was not manipulated, administered to participants and 
outcomes, including any adverse effects, reported (Ideally this study would also 
consider the dose accuracy of the manipulated product and test this). Only one of 
the 42 included studies administered manipulated drugs to participants. Where 
evidence was located it almost universally related to the manipulation of tablets for 
the treatment of adult patients. This review has demonstrated that there is an 
overall dearth of evidence to support the practice of drug manipulation. What 
evidence was available came from a wide-range of studies which used a variety of 
research methods. Many questions in healthcare have complex evidence bases and 
are not easily evaluated solely by experimental methods. The studies included in 
this review often investigated the drugs and patient groups that were conveniently 
available. A more planned approach considering the likelihood of the need to 
manipulate and the possible impact of this of dose accuracy, bioavailability, safety 
and patient acceptability would result in more appropriate studies that would have 
direct clinical applicability.      
There is little published information and further work is needed to support what is a 
common practice. All but one of the included studies related to tablets.  It is 
difficult to draw generalisable conclusions as the products and method of 
manipulation varied considerably. Different formulations of each drug may provide 
different results when manipulated. Most segmented tablets did not meet 
standards for variability derived from those for intact tablets. In practical terms, a 
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tablet that has been halved may not result in half of the dose of the whole tablet. A 
consistent nomenclature should be developed and used to facilitate identification 
of data relating to manipulations. Further work should take account of the lessons 
for synthesizing data relating to manipulations that can be drawn from this 
systematic review. Quality standards are needed for studies of manipulations which 
need to report fully on the drug products and methods of manipulation. In 
conclusion, considerable work needs to be done to support what Chapters 3 and 4 
show is a common practice.         
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CHAPTER 3: IDENTIFICATION AND DIRECT OBSERVATION OF DRUG 
MANIPULATION WITHIN WARD AREAS   
 
3.1 BACKGROUND  
Within hospitals the manipulation of drugs with the aim of obtaining the required 
dose prior to administration is predominantly undertaken by nursing staff. In order 
to investigate drug manipulation accurately, the processes that occur in practice 
need to be explored. There is no substantive evidence base underpinning drug 
manipulation (Chapter 2) and it is important to not make assumptions about what 
happens in practice. Zeitz (2005) considered postoperative observation, an area 
where there is a lack of evidence and a variety of practice recommendations. This 
author noted that in endeavouring to achieve best practice it is important to know 
what constitutes current practice.  
With an area that has not been investigated previously decisions need to be made 
about the most appropriate methods to use. The absence of previous data can 
mean that it is not feasible to undertake a study using rigorous sampling methods. 
This is relevant in this case as the absence of information relating to manipulations 
would make designing such a sample difficult. One study by Skwierczynski and 
Conroy (2008) considered how long it took to administer oral medicines to children. 
This study observed 198 administrations of which six had been manipulated. This 
study included only oral administrations and had been designed to time 
administrations, nonetheless it did provide evidence that manipulations could be 
identified and observed in practice. The initial investigations in an area where what 
is occurring in practice is unclear (such as here with drug manipulations) seek out as 
many different aspects as possible so that the data available for future research is 
as rich as possible and the implications for practice can be seen as widely as 
possible. Thus throughout this observational study, the survey of paediatric nurses 
(Chapter 4) and the exploration of parents’ perceptions (Chapter 5) purposive 
sampling was used with the aim of achieving maximum variation and detailed 
description of all aspects of drug manipulation.            
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Consideration of any area of practice requires careful planning to determine how to 
identify and record relevant data, particularly within busy in-patient ward 
environments. Within this study of drug manipulations data needed to be recorded 
on where manipulations are occurring, which drugs and dosage forms are 
manipulated, how the manipulation is achieved and the reasons that a 
manipulation is required. The study completed by Skiwierczynski and Conroy (2008) 
in investigating the time taken to administer oral medicines had indicated that 
manipulations could be identified and observed. This study used long periods of 
observation within ward areas to observe administrations. Methods used to 
describe the details of the mechanism of manipulations occurring in situ has not 
been previously investigated. Though there were no previous studies specifically 
relating to drug manipulations, guidance was sought from studies which had 
observed and recorded prescribing errors, the time taken to administer medicines 
or drug administration errors.  
    
3.1.1 Neonatal and paediatric in-patient areas included  
Previous studies have identified that off-label and unlicensed use of drugs in 
paediatrics may be more pronounced in specialist paediatric areas and that 
different types of manipulations may occur in different clinical areas (Conroy et al., 
1999; Conroy et al., 2003). While it may have been reasonable to speculate that 
manipulations may occur more frequently in the more specialist areas, this could 
not be assumed. Therefore all of the in-patient neonatal and paediatric clinical 
areas in the hospital sites were included. A children’s hospital with a catchment 
area of >7.5 million with care for >200,000 children annually and a regional 
neonatal unit with 54 cots that cares for >1000 babies annually were selected for 
inclusion. A systematic review of medication errors in paediatric areas noted that 
little research had been conducted in nonpaediatric hospitals (hospitals that 
predominantly have adult patients but have a small number of paediatric wards) 
and they speculated that the type, nature and incidence of paediatric medication 
errors may differ between paediatric and nonpaediatric hospitals due to differences 
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in patient population and expertise (Ghaleb et al., 2006). It has been suggested that 
there may be enhanced insight and awareness in prescribing when a service is 
designed to care only for children (Crawford, 2012). Therefore this study also 
included a neonatal (16 cots, 3 ICU cots) and a paediatric ward (30 beds, 2 HDU 
beds) in a district general hospital to allow for possible differences in patient 
population, expertise and access to paediatric sized drug doses that may occur 
between paediatric specialist settings and paediatric care which is delivered in a 
predominantly adult setting.       
 
3.1.2 Estimation of the requirement for manipulation 
Concurrent to this study, a review of all of the in-patient prescriptions, over a 5-day 
period, within the clinical areas used in this study was undertaken (Nunn et al., 
2013). I collected the data (assisted by a research nurse) which I collated for review 
by an experienced paediatric pharmacist (Professor AJ Nunn). This study estimated 
the requirement for the manipulation of medicines (including the measurement of 
small volumes). An experienced paediatric clinical pharmacist assessed the 
prescription data, finding that 10.1% (542/5375) drug administrations required 
either manipulation or the measurement of a small volume (<0.2mL). Of these 
41.7% (226 administrations) involved either the manipulation of intravenous drugs 
or the measurement of a volume of <0.2mL (it was not possible without observing 
the administration to know which had been undertaken), 22.1% (63 
administrations) involved the manipulation of tablets, 3.9% (21 administrations) 
manipulations of nebulisers, 1.1% (6 administrations) manipulations of enemas and 
0.7% (4 administrations) manipulations of suppositories. (29.5%, 160 
administrations, involved the measurement of <0.2mL of an oral liquid – though it 
should be noted that one type of administration (oral dose 0.1 to <0.2mL) 
accounted for 107 of these administrations).     
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3.2 AIMS 
This observational study aimed to:  
- identify the type and nature of drug manipulations occurring in paediatric 
clinical practice 
- where possible, observe manipulations in practice and to describe the 
observed manipulations  
- identify which drugs and which dosage forms are manipulated and in which 
clinical areas  
As there has not been previous research which has considered drug manipulation in 
practice, therefore additionally this study also aimed to: 
- consider the most appropriate methods of describing an aspect of clinical 
practice  
- describe the methodological issues with a direct observation study in clinical 
in-patient settings  
 
 
3.3 DRUG MANIPULATION IN CLINICAL PRACTICE   
 
Clinical practice can be difficult to identify, to record and to describe. All of the 
considerations that contributed to a particular action may not be clear to observers. 
Hospital in-patient wards are busy areas, with many health care personnel involved 
in what can, to the outsider, appear to be a chaotic workspace. Therefore any data 
collection within a clinical area needs to consider how to achieve optimum data 
collection while causing minimum disruption. Research that requires high levels of 
input from already stretched clinical staff is liable to be unsuccessful. Therefore 
how to identify and record the manipulations and how to do this while obtaining 
and retaining the collaboration of clinical staff was fundamental to the design of 
this study.   
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The initial consideration had to be how drug manipulations were going to be 
identified in practice. This required the development of methods that could 
effectively do this but did not require large observation time periods spent in each 
clinical area. As this study aimed to consider manipulation throughout 21 different 
clinical areas it was not feasible to spend prolonged time periods observing drug 
preparation. Nurses within these clinical areas are responsible for the drug 
administration to the patients in their direct care. As such there could be several 
drug preparation and administration episodes occurring in one clinical area at the 
same time, this becomes even more marked in the higher dependency areas such 
as intensive care or the neonatal unit.     
It is possible to predict when some manipulations will occur. Manipulations will be 
necessary where the dose of drug that had been prescribed could not be achieved 
without a manipulation e.g. 5mg of a drug has been prescribed that is solely 
available in a 10mg tablet. This can be predicted from prospective prescription 
review. However there are also likely to be occasions where the drug manipulation 
cannot be predicted. These include where the required dose is temporarily not 
available on the ward, where it may not be evident how the small dose is achieved, 
such as for an intravenous injection, or where patient preference requires an 
individualised manipulation. These episodes cannot be predicted from prospective 
prescription review. Therefore any methods to record data on drug manipulations 
need to be able to identify manipulations both those that were predictable and 
those that may not be.   
 
3.4 OBSERVATION  
 
3.4.1 Previous use of observation in research  
Observation has been substantially used within ethnographic research to observe 
and record human cultures. Time is spent in the field to gain a comprehensive 
understanding of those being studied (Carthey 2003, Baker, 2006). Structured 
observation assigns the behaviour observed to predefined categories (Barker 1980). 
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In sampling and recording data the researcher uses at least one of four basic 
behavioural measures; frequency, duration, percentage of time spent in the 
activity, sequence of activities (Barner-Barry, 1986). This type of observation is not 
subjective as the data are not dependent on the perceptions of those being 
observed or of those recording the data. Barker (1980) noted observation should be 
free of the selective perception of the subject. With any study where behaviour is 
being observed, decisions need to be made about what is to be recorded. This will 
be vital to the validity of the outcomes. Observation is selective, purposive and 
involves decisions about what should be noticed and what should be ignored 
(McCall, 1984).   
 
While collecting data the observer may be a participant in the field which they are 
studying. Alternatively they can be entirely separate, non-participant from the 
situation being observed and present solely in the field for the purpose of collecting 
data. Non-participant observational research is primarily used for descriptive 
research as it enables the researcher to address the question; what did the research 
subjects do? It allows for the study of behaviour in natural settings with the only 
artificially introduced factor being the presence of the data-gatherer (Barner-Barry, 
1986). Barker et al. (2002a) reviewed studies that had evaluated the observation 
method, they considered that the observation technique produced results that 
were more valid and reliable than where self-reporting methods had been used. As 
observation is not retrospective it avoids the potential limitations of methods that 
are dependent on a subject’s memory or willingness to report. Non-participant 
observation is best suited where it is important to study actual behaviour patterns 
of research subjects functioning in settings that are their natural habitats. This 
method also clearly defines the role of the observer to those who are observed. 
However, direct observation is time-intensive. Meyer-Massetti et al. (2011) 
considered that, due to its labour-intensive nature, direct observation must be 
performed over a relatively short period of time which inevitably results only in a 
brief snapshot of what could be observed.   
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3.4.2 Observation and drug manipulation  
Studies have considered how to identify and record medication-related errors in 
practice, these were used as a resource in the development of this observation 
based study. It has been noted that there are three basic methods of identifying 
errors made by people: observation, self-report and study of existing records 
(Barker and McConnell, 1962). Studies of medication errors in paediatric settings 
have compared different methods of collecting the data, such as incident report 
review, chart review and direct observation and the advantages and disadvantages 
of these methods (Flynn et al., 2002; Ghaleb et al., 2006). These studies found that, 
while all of these methods could describe errors, direct observation of clinical 
practice tended to be the most effective. Observation has been used to detect and 
record drug errors since the 1960s and is considered to have demonstrated that it is 
the most valid, efficient and accurate method for this Barker et al, 2002a; Chua et 
al., 2010).  
 
3.4.3 Direct observation – in practice  
Reviewing previous use of direct observation to investigate medication errors 
demonstrated that it was an appropriate and applicable method for considering 
drug manipulation. Nonetheless there were aspects of how to use this method 
within the settings for this study that required further consideration. How these 
have been developed previously and the methods used within this study are 
described below.    
3.4.3.1 Intervention in case of error  
During the observations of drug preparation and manipulation it was possible that 
medication errors would also be inadvertently observed. The observers were 
aiming to be as unobtrusive as possible while data collecting. Nonetheless there is 
both a professional and ethical obligation to intervene should an error be identified. 
An error should not be ignored to maximise the study’s validity (Dean and Barber, 
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2001). In studies where medication errors were detected or observed this was also 
a consideration; those devising these studies had agreed methods of intervening 
where an error was occurring (Dean and Barber, 2001; Taxis and Barber, 2003a; 
Taxis and Barber, 2003b; Cousins et al., 2005; Ghaleb et al., 2006; Haw et al., 2007).   
3.4.3.2 Disguised/undisguised observation 
When disguised observation is used, those being observed are misled regarding the 
purpose of the observer. The argument is made that if those who were being 
observed were aware of the true focus of the study then their behaviour would 
change. Disguised observational techniques have been substantially used in studies 
considering drug errors. A systematic review on intravenous drug errors included 
nine studies all of which used disguised observation (McDowell et al., 2010). Studies 
of medication errors, such as by Dean and Barber (2001), stated that nurses were 
given a partial explanation of the purpose of the observation and that verbal 
consent was obtained from them. This kind of observation raises ethical questions 
as subjects may be consenting to being observed in the belief that the data being 
recorded are different to those which are actually being recorded. Therefore can 
their consent be considered to be truly informed? Due to the arguments noted 
above describing the concern that observation may alter behaviour if nurses were 
fully aware of the purposes of the observation, approval from ethics committees 
has been gained for disguised observation studies, such as in Turnock and Gibson 
(2001). Alongside the ethical concerns, disguising the real reason for the 
observation may risk the completion of the study. If the true purpose of disguised 
observation is discovered the researcher may lose the opportunity to continue the 
study (Barker, 1980). This may further pose complications for future research if 
those who are being asked to participate feel that they cannot trust researchers. 
This possible effect that the observer may have on the behaviour of the person 
being observed (the Hawthorne effect) is one of the apprehensions expressed 
about the validity of undisguised, direct observation (Dean and Barber, 2001; Chua 
et al., 2010). The validity of the outcomes of this current study are reliant on 
recording manipulations being carried out in the same way as they would be if the 
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observers were not present. The importance of being unobtrusive in observing and 
not asking the subject to change normal activities for the convenience of the 
researcher has been highlighted as important in ensuring accurate data capture 
(Barker, 1980). 
3.4.3.3 Observer acceptance into the field  
Direct observation is an effective data collection method but it can raise concerns 
about individual privacy (Baker, 2006). To use direct, structured observation in any 
area requires the accepted entry of a researcher into someone else’s personal or 
professional area. The presence of researchers as observers meant that the support 
of nursing staff for this study was vital to its accomplishment. Several approaches 
were used both prior to and during the study. I and the research nurse assisting 
with the observations attended meetings with senior nurses, nurse prescribers and 
medicines champions during the planning of the observational study. The proposed 
study was outlined to them, any questions were answered and their opinion sought 
on aspects of collecting data in the ward areas.  
Though the observers in this study were non-participant, the support of nurses was 
vital when manipulations were actually being recorded. To ensure the validity of 
the data recorded it was important that the drug manipulation processes recorded 
were true to those that would happen if the observers were not present. The 
potential consequences of mistakes when preparing or administering drugs are 
ingrained in the consciousness of nurses and as such there may be understandable 
apprehension about being observed. There may be some concern about the 
implications for the nurse of undertaking the manipulation. Throughout this study it 
was made clear to nurses that the details of the manipulation were the only data 
being recorded and no details about the nurse undertaking the manipulation were 
recorded.         
 
3.5 SELF-REPORTING  
The self-reporting of manipulations represents the optimum method of identifying 
unpredictable manipulations, as these would be reported via the nurses 
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undertaking them and reporting all of the incidents as they occur. When used in 
detecting medication errors a number of advantages with self-reporting methods 
were noted. These included the rarity of false positive reports; in addition the 
clinical significance of the errors detected was likely to be high (Flynn et al., 2002). 
However the under-reporting of incidents is a substantial limitation with this 
method. It is not possible using self-reporting to make any estimation of 
frequencies (Flynn et al., 2002) or total number of activities.  
 
3.6 METHODS  
3.6.1 Identifying manipulations  
The potentially but not wholly predictable nature of drug manipulations meant that 
a multimodal approach was required to obtain a comprehensive description of the 
range and type of drug manipulations occurring. Self reporting was considered a 
useful approach as it can reveal occurrences which are difficult to predict or identify 
in any other way. However, a lack of awareness or understanding of the research 
study may cause under-reporting when self-reporting methods are used. Therefore 
on each ward, in the week immediately prior to the study (on that ward), time was 
spent during handover periods introducing the study to nursing staff and providing 
the opportunity for questions. A one-page laminated sheet summarising the 
definitions of drug manipulations for each dosage form (and with researcher 
contact details) was also provided and placed on or beside drug preparation areas. 
Researchers (I and the research nurse who supported this study) were frequently 
on the wards throughout the study periods collecting prescription review data and 
the self-report alert cards; they reminded nurses about the study and were 
available to answer any questions. Alert cards were to be completed by nurses 
when they undertook a manipulation. These cards were designed so that they were 
able to provide sufficient information for researchers to further investigate the 
possible drug manipulations but also needed to be brief and easy to complete to 
ensure that they did not impact on nurses’ time. Prior to their use in the pilot study 
these cards were reviewed and discussed by a group of nurses who work within the 
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children’s hospital and form a medicines champions group who provide expertise 
and medicines advice to other nurses.  
Furthermore a second method was used to identify drug manipulations. The use of 
self-report alert cards was supplemented by prescription review. The research 
nurse and I undertook daily prescription reviews throughout the study period on 
each ward to prospectively identify any predictable manipulations. 
 
3.6.2 Sampling  
This study did not aim to obtain definitive numbers of manipulations occurring but 
rather to explore the scope and nature of the manipulations that were being 
undertaken. The only method which could have been used to definitively identify 
unpredictable manipulations would be continual observation of practice. This 
would require a considerable amount of time to be spent on the wards and to use 
this method would have substantially restricted the number of clinical areas which 
could be included; it was considered unfeasible. Studies which investigated drug 
errors have frequently used time sampling methods with the selection of precise 
time periods during which observations occur (Barner-Barry, 1986; Polit and Beck, 
2008). Event sampling uses the behavioural unit of interest to determine the data 
collection. This is not dependent on the time this lasts or the intervals at which it 
occurs (Barner-Barry, 1986). Event sampling is considered to be preferable if events 
are infrequent and are at risk of being missed if time sampling is used (Polit and 
Beck, 2008). As drug manipulations do not occur at specific times (though will 
obviously occur more often at time periods when drugs are frequently given) the 
use of time-sampling would have risked missing the observing of manipulations 
where they did not occur during the time periods specified. Therefore purposive 
event sampling was the most appropriate method for use in this study. 
Manipulations identified through the prescription review and alert cards were 
followed up to see if it was possible to observe and record them. If two 
manipulations were prescribed to be administered at the same time but in different 
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clinical areas and one was of a drug or dosage form that had been previously 
observed then the manipulation not previously recorded would be observed.     
 
3.6.3 Observation units  
The molecular approach to observation uses small, highly specific behaviours as 
observational units and models behaviour as closely as possible to what actually 
occurs. This approach contrasts with a molar approach that involves the 
observation of large units of behaviour which are treated as a whole (Nolan et al., 
1995; Polit and Beck, 2008). The molecular observer records only what is seen and 
no more; as such the interpretation of the observer should be removed from the 
observational picture (Barker, 1980). As drug manipulations are specific, short, 
measured events the molecular approach was used to record what had been 
observed with review and further analysis subsequently completed on the data 
recorded.   
 
3.6.4 Possible drug errors  
Consideration was given to the most appropriate response should a drug error be 
observed. Methods used in studies of drug errors were reviewed and discussed 
with nursing, medical and pharmacy personnel. It was agreed that if an error was 
identified during data collection the observers would ask the nurses involved to 
check their calculation, or measurement, again. If the error was repeated then they 
would identify it to the nurses involved. Should an error be identified during data 
analysis or review, the ward involved would be contacted, made aware of the error 
and advised to ensure that the appropriate hospital procedure and documentation 
for the error was completed.     
 
3.6.5 Consent  
Consideration was given as to the most appropriate form of gaining consent for this 
study. Written consent was liable to be too disruptive within busy clinical areas. 
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Due to the numbers of nurses involved it would not have been feasible to obtain 
this written consent in advance (within the ward areas there are around 15 whole 
time equivalent nurses, often with higher actual numbers of staff when those who 
work part-time hours are included, in the high dependency areas such as in PICU in 
the children’s hospital there are >100 whole time equivalent nurses). Verbal 
consent was sought from all of those who were observed prior to any observation 
taking place. The process of obtaining this verbal consent was; 
 checking if those potentially being observed knew the aims of the study, 
had any questions about it and the purposes of the observation,  
 a reminder that the process of drug manipulation was what was being 
observed not the individuals involved,  
 that no details about the individual undertaking the manipulation were 
recorded,  
 reassurance that the observation and data recording could be stopped at 
any point, and finally  
 the seeking of verbal permission to observe the process of the nurses 
undertaking drug manipulations.   
 
3.6.6 Observation tool development 
This work aimed to observe and capture the details of the practice of drug 
manipulations that are used to obtain the dose required for administration to 
paediatric patients. The observational tools used in this study had to be devised and 
validated.   
 
The observation forms were designed with the aim of categorising each type of 
manipulation that may occur for each dosage form, into recordable sections which 
would provide a standardised description of the process of the drug manipulation. 
Long and Johnson (2000) noted the need for consistency and the importance of 
standardising data collection instruments to ensure that data collection is 
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undertaken in a manner that is free from undue variation. The design of the tools 
for this study aimed to use predominantly closed categories to remove the 
possibility of bias from observer interpretation of what was being recorded. This 
would help to avoid the threat to the validity of observational research from 
researcher bias that may result from selective observation, selected recording of 
information, or the subjective interpretation of situations as described by Baker 
(2006). As these are new tools, it was also important not to exclude the recording 
of categories which had not been anticipated during their design. As Barker (1980) 
cautions, although theoretically a high degree of reliability can be attained using 
small easily observed and recorded units, that this may reduce the behaviour so 
much that it no longer bears resemblance to what it was intended to observe, thus 
losing validity. Observational forms were devised for each possible dosage form 
which may be manipulated. Drug manipulations are known in practice and could be 
theoretically described. They have not previously been recorded in detail and 
therefore there remained the possibility that the designed tools may not capture all 
available data. Skiwierczynski and Conroy (2008) had observed oral administrations 
but other dosage forms had not been included. Therefore several open categories 
were added; these were marked as ‘other’ and were available for the recording of 
additional unpredicted data.  
.      
Measures of validity frequently involve the comparison of the results with those 
obtained from an independent measure (Barker, 1980). With no previous in-depth 
investigation in this area there are no established reference standards for the 
procedures involved in drug manipulation and therefore a comparison with 
previously used tools was not possible. Content validity depends largely on the 
sampling and careful construction of the instrument and refers to the degree to 
which the entirety of the phenomenon under investigation is addressed (Long and 
Johnson, 2000). Therefore the data collection tools within this study needed 
meticulous construction to ensure that there is consistency, completeness and 
reliability in the data collected and that the outcomes can be considered valid. This 
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would provide confidence that the tools were meeting the goal of measuring what 
they are intended to measure. The data collection tools were drafted, reviewed and 
revised by clinical, academic and research experts on several occasions prior to 
their use in the pilot study.   
 
3.7 ETHICS  
The Director of Research at Alder Hey NHS Children’s Trust presented the study 
outline for review to the Liverpool Local Research Ethics Committee. This 
Committee considered that the study met their criteria as a service evaluation 
project involving NHS staff only. This body considered that this study did not 
require review by a NHS Research Ethics Committee. The appropriate permissions 
were obtained from the research committees of the included hospitals.   
   
3.8 PILOT STUDY   
3.8.1 Pilot study aims 
A pilot study was undertaken to ascertain the feasibility of this study and the data 
collection tools. This pilot study aimed to: 
- consider the methods of identifying drug manipulations in clinical in-patient 
areas, 
- test the feasibility of data collection tools for observations of drug 
manipulations, 
- generate preliminary data about the nature of drug manipulations 
conducted on paediatric wards, 
- consider the validity of data obtained with the data collection tools,  
- provide an indication of inter-observer reliability (between the two 
observers, myself and a research nurse) using the data collection 
instruments, and  
- determine the acceptability of the process to those being observed.   
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3.8.2 Pilot study – wards included   
The pilot study was conducted in the paediatric hospital and included five ward 
areas so that the feasibility of the study methods could be investigated in different 
clinical areas. Four general wards (two medical, two surgical) and one specialist 
ward (paediatric intensive care unit – PICU) were included in the pilot study.   
 
During the pilot study the two researchers attended the included wards, initially at 
8am to review prescriptions, remind nurses about the study, answer any questions 
that may have arisen and, where possible, to observe the morning medications 
being prepared for administration. All data collection throughout the pilot and main 
observational study were undertaken by myself or a research nurse who had been 
designated to the study. The researchers visited the clinical areas throughout the 
day (including weekends) to review prescriptions, collect completed alert cards and 
discuss any queries from nursing staff. This also gave the opportunity to plan when 
researchers would return to observe the drug manipulations that had been 
identified.     
 
3.8.3 Pilot study outcomes  
3.8.3.1 Identification of manipulations  
76 nurse alert cards were returned by nurses during this two week pilot study. A 
review of these found that 42 (55%) correctly reported drug manipulations. The 
remaining 45% of alert cards had reported situations where drugs had been altered 
which were outwith the definition of manipulation, such as where dosage forms 
had been crushed, dissolved etc. to assist with administration of the drug and the 
entire dose had been administered, or had reported the reconstitution of 
intravenous drugs as a manipulation. All of these alert cards had been completed 
within the medical and surgical wards (where there are around 15 full-time 
equivalent nurses). None had been completed in PICU (where there are >100 full-
time equivalent nurses). Informal feedback was sought from nurses who had 
completed alert cards which found that nurses considered them quick and easy to 
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complete and as such they did not impact negatively on their time. Furthermore the 
nurses considered that the use of these cards would be acceptable to nurses in a 
larger study. Overall the alert cards were effective in identifying manipulations and 
provided sufficient information that these could be followed up to plan for possible 
observation of the manipulation. Following their use in this pilot study small 
changes were made to ensure that the information required in the various boxes of 
the alert card was entirely unambiguous to those completing them; otherwise the 
alert cards were not changed prior to the main study.   
 
It was evident from the pilot study that attending the wards during periods where 
there tend to be drugs prescribed (such as 8am) would require considerable time 
input by researchers. Although observing drug preparation during these time 
periods did identify manipulations, these could have been found by the use of 
prescription review or via reporting by nurses on the alert cards. It was not possible 
to observe all of the drugs being prepared or administered during these periods as 
there were often several nurses undertaking this role at the same time for different 
patients. This was not an efficient or particularly effective method of identifying 
manipulations. The identification of predictable manipulations via drug prescription 
review was effective. During the study pilot an experienced clinical paediatric 
pharmacist also completed a duplicate prescription review on the wards and in 
PICU. This review did not find any further possible manipulations which had not 
been found through the initial prescription review. 
          
3.8.3.2 Data collection instruments 
Both intra and inter-observer reliability in data collection needed to be optimised. 
Reviewing the reliability of data collection instruments Long and Johnson (2000) 
noted the importance of ensuring that data collection is consistent and free from 
undue variation as this may unknowingly exert an effect on the nature of the data. 
There are methods of increasing inter-observer agreement such as sufficient 
training, using clearly defined and non-overlapping categories, classifying the 
behaviour at the time of observation, demanding little inference from the 
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observers, using a small number of categories, or making certain the investigators 
are observing the behaviour at the same time (Barner-Barry, 1986). Several of these 
methods were used within this current study, notably during the design of the data 
collection tools.   
The data collection forms required the completion of 24 to 34 items, depending on 
the manipulation, as detailed in Table 4. 
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Table 4: Items to be completed on the data collection forms, by type of 
manipulation  
Section on data collection form Number of items 
to be recorded  
Total number of items to be 
recorded for each type of 
manipulation  
Demographic data  7 items   
Drug and prescription details  8 items   
Additional data  4 items   
Tablet cut or broken 15 items  34 items  
Tablet crushed  7 items  26 items  
Tablet dispersed  15 items 34 items  
Capsule dispersed  13 items  32 items  
Oral liquid  12 items  31 items  
Transdermal patch  9 items  28 items  
Suppository  11 items  30 items  
Enema 5 items  24 items  
Nebuliser solutions  9 items  28 items  
Intravenous bolus  13 items  32 items  
Intravenous infusion  11 items  30 items  
 
During the design of the data collection form, boxes were designed so that the data 
to be recorded was unambiguous, where possible tick boxes or score through 
responses (such as Yes/No) were used with the aim of ensuring that the data 
collection was consistent. I undertook the data collection and observation of 
manipulations assisted by a research nurse; both of us had spent time on the wards 
while discussing the study with the ward nurses and had previous observation 
experience.   
 
There were seven manipulations during the pilot study observed by the two 
researchers (a further two were observed by the research nurse alone); four were 
tablets which were cut with a tablet splitter, two were tablets dispersed in water, 
and one was a capsule dispersed in water. It became clear during the pilot study 
that with two observers and all drug preparation checked by two nurses it is 
difficult to ensure that the observers have an unimpeded view without disrupting 
the process. During these seven manipulations, 236 items were recorded. Of these, 
both observers recorded the same data for 196, 83%, of the data collection form 
items. The remaining 40 items were reviewed further.  For 13/236 items, 5.5%, the 
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observers had recorded different data as the form was not sufficiently clear. For 
example, one observer recorded the child’s date-of-birth and the other recorded 
their age or one observer recording the child’s weight from the prescription chart 
and the other taking a slightly different weight which had been recorded in the 
patient notes. For 17/236 items, 7.2%, data had not been recorded by one or both 
observers. For nine items, 3.8%, there were errors in what had been recorded and 
for the remaining one item, 0.4%, there had been a difference in what the 
observers had perceived. As 75% of the items where there were differences 
between the observers were due to either missing data or data which had been 
recorded differently by the observers as they had interpreted differently the data to 
be recorded; these were areas where data collection could potentially be improved. 
Changes were made to the data collection forms with the aim of making it clear 
which data were to be recorded and that all items on the form for that 
manipulation were to have data entered. Furthermore, in consideration of these 
outcomes a guide was devised to ensure that it was clear what was to be recorded 
in each section of the form, this provided a reference source for observers with the 
aim of optimising reliability. Similar guides have been used in previous 
observational studies such that by Barber et al. (2009). This guide to the data 
collection was developed into a detailed reference document (Appendix 4) which 
was taken with the observation forms and could be referred to in the clinical areas 
if there was any uncertainty about the data that were to be recorded. While data 
collection errors cannot be eradicated from any study increasing familiarity with the 
recording tools, improved clarity in the data recording forms and the development 
of a detailed reference document should minimise data recording errors.            
 
Following comments made by nurses during the pilot study about the manipulation 
that they were being observed completing; an additional response box was added 
to the observation forms to allow for the recording of any such comments. Nurses 
were not asked for any views or opinions on manipulations. Observers did not make 
any remarks or ask questions while observing manipulations, but any comments 
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that nurses did make could then be recorded. These unsolicited comments could 
provide some insight into how nurses view manipulations.  
 
Similarly to the alert cards changes were made to the observation forms to ensure 
clarity and consistency in the data recorded but there were no major changes were 
made to the observational tools.   
3.8.3.3 Preliminary data on drug manipulations in in-patient areas  
Data on drug manipulation were recorded in this pilot study. There were few 
changes made in the data collection tools and experts reviewed the collected 
manipulation data and considered the results to be valid. Therefore the data on 
drug manipulations collected in both the pilot and main studies are presented 
together in the results. 
3.8.3.4 The acceptability of the process to those being observed 
Verbal consent was obtained from all nurses involved in the pilot study. Informal 
feedback was sought from nurses who had been observed and they were asked 
how they found the process. During the pilot study set-up period when nurses were 
being introduced to the study they were enthusiastic about the need for the study 
and many provided anecdotes relating to drug manipulations. Nurses who were 
observed undertaking manipulations described that with the knowledge of the 
study objectives they were comfortable being observed.        
3.8.3.5 Validity  
This study was supported by a steering group comprising of nursing, medical, 
pharmacy, research and academic experts. This group reviewed the manipulations 
recorded during the pilot and main studies and considered that the data recorded 
did appropriately described the drug manipulations occurring in practice.   
3.8.3.6 Implications for the main study 
The pilot study demonstrated that drug manipulations could be identified in 
practice. The use of the two methods of identification was shown to be fit for 
purpose. The daily prescription review yielded predictable manipulations and 
expert review did not find any additional data that had not been found in the 
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original review. The use of alert cards was not onerous to nurses and within the 
medical and surgical wards a number were completed. However in the PICU no 
cards were completed. With such a high number of nurses on each shift effective 
communication and reminding nurses about the alert cards was more difficult. 
There are limitations to the use of alert cards and there was a tailing off of their 
return towards the end of the two week pilot. Nevertheless the potential of the use 
of alert cards to identify otherwise undetectable manipulations and thus add to the 
scope of the manipulations described meant that their use in the main study was 
justifiable. The observation of manipulations in practice was feasible and the nurses 
who were observed during the pilot study did not find the process intrusive, were 
not anxious and all approached consented to their practice being observed. During 
the two-week period of the pilot study there were manipulations of some dosage 
forms that were not identified, therefore not all of the observation data collection 
forms were used. For the dosage forms that were observed (tablets, capsules) the 
forms allowed for comprehensive collection of detail on manipulations. The 
devising of a reference guide to support the forms for all dosage forms aimed to 
ensure the clarity of what was to be recorded in the main study. Overall the pilot 
study provided evidence that drug manipulations can both be identified and 
observed in practice and that this is not prohibitively intrusive on the clinical areas 
involved.              
 
3.9 MAIN STUDY  
The main study included 22 different in-patient areas. Data collection was 
conducted in blocks of two weeks over a 6-7month period. Each block was 
dedicated to a ward or small numbers of wards in the neonatal and paediatric in-
patients areas included. Data was collected in each of the wards once, for this two-
week block, during the study. During each two-week block potential manipulations 
for observation were identified prospectively on the relevant ward(s). This study 
used the methods that had been developed and refined during the pilot study. That 
is that time was spent on each ward area prior to the study introducing the study 
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and data collection tools to the nursing staff and responding to any queries. 
Prescription review, collection of completed alert cards and arrangement to 
observe any available manipulations were undertaken daily within each ward 
during the two weeks of data collection. I undertook this data collection aided by 
the research nurse who had participated in the pilot study.  
 
3.10 RESULTS  
There were 310 manipulations that were identified, involving 53 different drugs3. 
The highest proportion of manipulations involved tablets which represented 191 
(61.6%) of those reported. The breakdown of the manipulations by dosage form is 
reported in Table 5. 
Table 5 : Manipulations identified during the observational study, by dosage form  
Dosage form  Frequency reported 
as manipulated   
Percentage  
Tablets  191 61.6% 
Sachets  30 9.7% 
Capsules  4 1.3% 
Oral liquids  0 0% 
Intravenous  65 21.0% 
Nebuliser solutions  4 1.3% 
Transdermal patches  10 3.2% 
Suppositories  6 1.9% 
Enemas  0 0% 
The drugs which were identified crossed the spectrum of possible indications as can 
be seen in Table 6 which shows the manipulated drugs organised on the 
therapeutic classification described in the British National Formulary for Children. 
Though it should be noted that while these classifications indicate a reason for 
prescribing drugs they may not be the reason that the drug has been prescribed 
(for example amitriptyline is classed as an antidepressant but may be prescribed for 
                                                          
3
 Some drugs were found to be manipulated in more than one dosage form e.g. tablet and 
intravenous manipulations of hydrocortisone, or tablet and suppository manipulations of 
paracetamol   
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neuropathic pain). Of the 53 different drugs manipulated during this study 13.2% 
(7/53) were identified only once. 
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Table 6: The drugs identified as manipulated, organised by the therapeutic 
classification from the BNFC, and frequency of manipulation 
BNFC classification   Drugs involved  Frequency 
classification  
reported as 
manipulated   
Percentag
e  of 
manipulati
ons 
identified  
Analgesic Paracetamol, Ibuprofen, Diclofenac  92 29.7% 
Proton pump inhibitor Omeprazole 24 7.7% 
Antimuscarinic Glycopyrronium bromide, Hyoscine 
hydrobromide 
18 5.8% 
Antiemetic  Ondansetron 17 5.5% 
Alginate preparation Gaviscon  16 5.2% 
Antiplatelet  Aspirin  15 4.8% 
Opioid analgesic  Fentanyl, Tramadol, MST 14 4.5% 
Benzodiazepine  Midazolam  13 4.2% 
Antiepileptic  Vigabatrin, Phenobarbitone  12 3.9% 
Antibiotic  Metronidazole, Vancomycin, 
Teicoplanin, Trimethoprim, 
Rifampicin 
11 3.5% 
Neuromuscular 
blocking  
Vecuronium, Suxamethonium 11 3.5% 
Steroid  Hydrocortisone, Prednisolone, 
Dexamethasone  
10 3.2% 
ACE inhibitor  Enalapril, Lisinopril  5 1.6% 
Bronchodilator  Salbutamol, Ipratropium 5 1.6% 
Minerals  Phosphate Sandoz, Zinc 5 1.6% 
Thyroid hormone  Levothyroxine, Liothyronine  5 1.6% 
Vasodilator  Hydralazine, Dinoprostin  5 1.6% 
Diuretic  Furosemide  4 1.3% 
Drugs affecting the 
ductus arteriosus  
Indomethacin  3 1.0% 
Insulin  Insulin  3 1.0% 
Laxative  Glycerine, Movicol  3 1.0% 
Antipsychotic  Levomepromazine  2 0.6% 
Antiviral  Aciclovir  2 0.6% 
Flu prophylaxis  Oseltamivir  2 0.6% 
Hypothalamic & 
pituitary hormone  
Tetracosactide 2 0.6% 
H2 antagonist Ranitidine  2 0.6% 
Inotrope  Digoxin  2 0.6% 
Anticoagulant  Warfarin  1 0.3% 
Antidepressant  Amitriptyline  1 0.3% 
Antihypertensive  Sildenafil  1 0.3% 
Antimotility  Loperamide  1 0.3% 
Pineal hormone  Melatonin    1 0.3% 
Smooth muscle Oxybutynin  1 0.3% 
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relaxant  
Not in BNFC Tetrabenazine  1 0.3% 
 
Within the 191 tablet manipulations identified there were 27 different drugs 
identified, with the most frequent manipulation involving diclofenac 50mg tablets. 
These diclofenac tablets were dispersed and a proportion of the dose administered. 
Overall nine of the tablet manipulations were reported only once during the study. 
The percentage of each drug of the total tablet manipulations identified are 
represented in Figure 5. 
 
Figure 5: Percentage of each drug of the total tablet manipulations, identified 
during the observational study  
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What is also notable from Figure 5 is that several of the drugs manipulated in tablet 
form are available in a liquid formulation, e.g. paracetamol, ibuprofen, furosemide.   
With the 65 intravenous manipulations identified there were 18 different drugs 
identified, the most frequent being midazolam, with three drugs reported only once 
during the study. The percentage of each drug of the total intravenous 
manipulations identified are represented in Figure 6.  
Figure 6: Percentage of each drug of the total number of intravenous injection 
manipulations identified by the observational study 
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The drugs identified for the other dosage forms are detailed in Table 7.  
Table 7: Drugs that were manipulated in the form of sachets, capsules, nebuliser 
solutions, suppositories and transdermal patches during the observational study  
Dosage forms  Total  Number of 
different drugs  
Drugs involved  
Sachets  30 4 Movicol  
Gaviscon  
MST 
Vigabatrin  
Capsules  4 3 Melatonin  
Oseltamivir  
Loperamide  
Nebuliser solutions  4 1 Ipratropium  
Suppositories  6 3 Paracetamol  
Glycerol  
Diclofenac  
Transdermal 
patches 
10 1 Hyoscine hydrobromide  
There were four drugs that were manipulated in two dosage forms. Diclofenac and 
paracetamol were manipulated in tablet and suppository forms and hydrocortisone 
and omeprazole were manipulated in tablet and intravenous forms.   
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Drug manipulations were found across all of the included clinical areas, Figure 7. 
Figure 7: Where manipulations were identified, during the observational study, by 
the main clinical specialities included  
 
 
 
 
Though manipulations were identified throughout all clinical areas, there were 
notable differences in the dosage forms being manipulated. Intravenous 
manipulations were all reported in high dependency areas, with 60% of them 
identified in the specialist neonatal unit, 38.5% in paediatric intensive care and the 
remaining 1.5% in the cardiac unit.   
 
3.10.1 Proportions required  
The predominant proportion required for administration of tablets, capsules, 
sachets, transdermal patches, nebuliser solutions and suppositories involved either 
half or a quarter/three quarters of the original dose. There were manipulations for 
which other proportions were required, notably with tablets, capsules and sachets 
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where dispersion and the subsequent measurement of differing volumes of the 
resultant solution was possible.  
Tables 8 and 9 describe the proportions of the original dose being sought by 
undertaking the manipulations.   
 
Table 8: The proportions, by dosage form, of the original complete dose that was 
being sought by the manipulation      
Dosage form  Half of the original 
dose  
Quarter or three 
quarters of the 
original dose  
Other proportions  
Tablets  58% (129/186) a 11.3% (21/186) a 30.6% (57/186) a 
Capsules  50% (2/4) a 25% (1/4) a 25% (1/4) a 
Sachets  46.2% (6/13) a 23.1% (3/13) a 30.8% (4/13) a 
Transdermal 
patches 
0%   100% (7/7) a 0%  
Nebuliser solutions  100% (4/4) a 0% 0% 
Suppositories  40% (2/5) a 0% 60% (3/5) a  4 
a  Total dosage form manipulation numbers minus those where there was missing/incomplete 
data 
 
Table 9: The proportions of the original dose of intravenous drugs that was being 
sought by the manipulations    
Dosage form  <10% of the original 
dose  
10% to <20% of the 
original dose  
Other proportion 
(45% of the original 
dose)  
Intravenous  drug 
ampoule/vial  
80% (52/65) a 7.7% (5/65) a 3.1% (2/65) a 
 
a number of the total of 65 intravenous drug manipulations identified  
 
                                                          
4
 The suppository proportions that were not either half or a quarter/three quarters of the original 
dose were reviewed and discussed with a senior nurse on the ward that they had prescribed. She 
noted that the doses were close to either a half or a quarter/three quarters, that appropriate dose 
rounding would have been used to administer and prescribers would be requested to change the 
prescription to a more accessible dose.  
101 
 
3.10.2 Observed manipulations 
Of these 310 manipulations 54 (17.4%) manipulations were observed in practice (I 
observed 12, the research nurse 27, and 15 had been observed by both of us).  Of 
the 54 observed manipulations 49 (91%) were observed within the children’s 
hospital and 5(9%) within the neonatal unit. 40 (74%) of the observed 
manipulations were of tablets reflecting the predominance of tablet manipulations. 
Of the remaining 14, 6 were intravenous (11%), 5 were sachets (9%), and 
suppositories, capsules and transdermal patches were each observed once (2%). 
The reasons for non-observation of identified manipulations included: 
 the patient not receiving the drug at the prescribed time (for example 
where there had been changes in the patient’s condition or the patient was 
in theatre),  
 patient discharged from the ward,  
 prescription changes, and  
 difficulties with trying to anticipate when ‘as required’ drugs would be 
needed. 
During the observations no drug errors were observed and therefore there were no 
occasions where the observers had to interrupt the drug preparation.   
 
3.10.3 Patient characteristics 
Manipulations were observed across a range of age groups, the range of patients 
observed went from one day to 19 years. Of the 54 manipulations observed, 6 
manipulations were for patients of <1month, 18 for those 1month-<2years, 21 for 
those 2years-<11years and 9 for those ≥11years). As may have been expected as 
manipulations were found across the range of general and specialist areas there 
was also with a wide variety of diagnoses in the patients who were receiving 
manipulated drugs. 
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3.10.4 Tablets 
Of the 40 tablet manipulations observed 25 (62.5%) were cut to get the proportion 
of the original dose. In all of these, where tablets were split, a tablet splitter was 
used. Three (12%) of these had to be repeated; in two cases the tablet crumbled 
while being split, while with the third the tablet was considered by the nurses to 
have split unevenly. There were three occasions where the tablet had been halved 
and the unused proportion had crumbled, the manipulations had not been 
repeated in these cases. With nine (36%) of these manipulations there was visible 
powder generated when the tablet was split.      
12 (30%) of the tablets were solely dispersed in water, one (2.5%) tablet was 
crushed using a tablet crusher and then added to water for a dose which was three 
fifths of the original dose to be measured, and one (2.5%) tablet was broken by 
hand. For the remaining tablet observation the tablet was manipulated twice, 
initially being halved using a tablet splitter; a half was then dispersed in water with 
the aim of obtaining a quarter of the original dose for administration. In all 12 
observations, where tablets were solely dispersed, the tablet appeared fully 
dispersed. On the one occasion where a half tablet was dispersed to get a quarter 
of the original dose the half tablet did not appear to fully disperse.    
For 29 (72.5%) of these observed tablet manipulations, the aim/purpose of the 
manipulation was to acquire 50% of the original tablet dose, for 7 (17.5%) it was to 
acquire 25% or 75% of that original dose. The remaining four tablet manipulations 
that required neither a half nor a quarter/three quarters of the dose involved 
dispersing the tablet to allow for dose measurement.       
 
3.10.5 Intravenous injections 
Six intravenous manipulations were observed. In each of these an additional 
subsequent dilution was required to reconstitute or administer the drugs. This 
additional dilution was required to allow the measurement of the prescribed small 
dose. Five of these manipulations were observed in the neonatal unit, with the 
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remaining one on the cardiac unit. For all six manipulations there were no occasions 
observed where a volume of the diluent was added to the syringe containing the 
drug solution and this resultant solution administered, thus inadvertently including 
the drug dose that would have remained in the hub of the syringe. Therefore, in all 
observations the initially reconstituted drug was appropriately added to the diluent. 
With these manipulations, which were all found during the main study, it was not 
possible to describe adequately using the boxes on the data collection form and so 
the observers added a narrative account of the manipulation.      
 
3.10.6 Other dosage forms 
For sachets there were five manipulations observed, all of these involved dispersion 
of the sachet contents in water, with 40-80% of the original dose removed for 
administration. There was no visible sediment following dispersion and the dose for 
administration was, in all cases, taken from the bottom of the container.   
For three of the dosage forms there was only one manipulation observed. A 
transdermal patch was cut with scissors and three quarters of the patch applied. 
This proportion was not measured but was judged to be three quarters of the dose. 
A suppository was halved longitudinally with scissors prior to administration. A 
capsule was opened and the contents dispersed in water and a proportion removed 
with the aim of obtaining an eighth of the capsule dose.   
 
3.10.7 Additional comments  
Following the pilot study the decision was made to record any relevant unsolicited 
comments made by nurses undertaking manipulations. These comments reported 
on the challenges of some manipulations with remarks having been made on the 
difficulty of splitting some tablets and of dispersing others or the problems of 
dispersing the contents of some sachets. For one intravenous manipulation the 
reason spontaneously stated for the manipulation was the avoidance of trying to 
measure a small dose (0.1mL), meaning that further dilution was used. For one 
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tablet manipulation the choice of the child was commented on as he preferred to 
take a halved tablet rather than the oral suspension that was available. There were 
also general comments voiced describing concerns about the accuracy of the 
manipulated doses being administered.      
 
3.11 DISCUSSION  
3.11.1 Direct observation 
Direct observation in neonatal and paediatric clinical areas proved to be an 
effective method of facilitating the exploration and description of drug 
manipulation. The need to actually observe has been noted previously. Altmann 
(1974) described direct observation as playing a unique role in behavioural science, 
as the necessary link between laboratory science and real-world behaviour. While 
Zeitz (2005) noted that myths, assumptions and differing perceptions about what 
nurses should be and actually are doing are ever present. While we could theorise 
about how manipulations were being done and how they should be done in 
consultation with clinical and research experts, this could not substitute for the 
actual observations. Drug manipulations provide an exemplar of a clinical practice 
suitable for observation as they meet the requirements for observation specified by 
(Barker et al., 2002a), in that they are events that are visible, predictable, and of 
limited duration. Barker (1980) argues that observation becomes a scientific 
technique when it serves a formulated research purpose, is planned and recorded 
systematically, is related to more general propositions, instead of being presented 
as simply reflecting a set of interesting curiosities, and is subjected to checks and 
controls on validity and reliability. Consequentially, the success of observing and 
recording the resultant data is dependent on the planning of the study.   
The development of the observation data collection tools that were used within this 
study included a substantial process of designing and refining. Decisions need to be 
made about what should be noticed and what should be ignored (McCall, 1984). 
Repeated iterations of the tools being developed were reviewed and discussed 
prior to their use in the pilot study. While this design and review process was time 
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consuming it was effective. Though there were changes made to the data collection 
tools from the pilot to the main study, these changes were made to improve the 
clarity of the tool or to the ease of completion. There were two additional 
alterations made to the data collection tools during the main study. A section for 
the manipulation of sachets had inadvertently been omitted in the initial tool and 
this was not a dosage form observed during the pilot. This became evident in the 
main study and the section on tablet dispersion was adapted for use to record 
sachet manipulations. It was notable that these processes were difficult to 
summarise into short answer boxes or tick boxes and observers had to use a 
narrative description for intravenous manipulation data collection. These tools had 
had a considerable design, review and pilot process and were fit for purpose. 
Nonetheless it is evident that modifications were required during the main study.      
A fundamental feature of observation within clinical areas is the collaboration of 
clinical staff. The nurses who worked in the wards used in this study were 
supportive of the study. Baker (2006) considered that to get rich and in-depth 
information, it is important for the researcher to know when the best times to 
observe are and to meet with those who are actually in the area. During the 
planning period I consulted substantially with senior nurses prior to the pilot study. 
During the study when manipulations were identified the most appropriate time to 
observe them was discussed and agreed with the nurses involved. During these 
discussions it was evident that the nurses could see the relevance of the study to 
their practice and they discussed examples of drugs that they manipulated. All 
three hospital sites are very research active sites with the recruitment of patients 
into relevant studies embedded into the hospital ethos. This may have been an 
influence on the generally positive response that researchers found when asking for 
assistance with the study. Nurses were fundamental to aspects of this study. They 
were asked to both self-report on manipulations and to permit the observation of 
them undertaking them. I undertook substantial preparatory work within the 
clinical areas that were included in this study. Due to the number of different wards 
and sites included in this study this was resource intensive. Nonetheless it was 
considered vital to promoting both the identification of drugs that were being 
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manipulated and ensuring the validity of the recorded manipulations. Despite this 
preparation and my and the research nurse’s regular presence on the wards, the 
numbers of nurses in clinical areas with changing shift patterns made achieving 
effective communication a challenge.     
The alert cards that nurses were asked to report manipulations on were completed 
more in some clinical areas than others. It is reasonable to assume that there were 
manipulations that were not reported. The completion of the alert cards could 
easily be overlooked within busy hospital wards. Though this may not be the only 
reason, van de Mortel (2008) discusses the potential impact of socially desirable 
responding, the tendency for participants to present a favourable image of 
themselves and this is a potential source of bias that has been detected in research 
on many topics. Asking nurses to self-report drug manipulations may not be an 
obvious case where socially desirable responding may arise. However, this is rooted 
in the context of the high-profile that drug prescription errors and administration 
errors have within healthcare and the possible impact on the individuals involved 
that the identification of errors can have. There is a professional onus to report 
drug related errors or other issues that represent clinical incidents. While this has 
obvious patient safety benefits it can also, on occasion, have consequences for the 
individual involved. Donaldson and Grant-Vallone (2002) noted that self-report bias 
is particularly likely in organisational behaviour research where employees often 
believe there is at least a possibility that their employer could gain access to their 
responses. With the considerable organisational and professional focus on reducing 
drug administration related errors there may be an understandable reluctance to 
self-report, even for research purposes, on drug preparation and administration 
related data. This has been identified previously with nurses noting that they would 
be reluctant to report any omissions or wrong-time errors they did become aware 
of, unless a dangerous drug was involved (Barker, 1980). Furthermore, a systematic 
review of drug related issues (including adverse drug events, adverse drug 
reactions, medication errors) noted that with incident report review reasons for 
underreporting include both a perceived lack of time and a fear of the 
consequences (Meyer-Massetti et al., 2011). It is accepted that the numbers of alert 
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cards completed cannot be taken as any indication of the total numbers of 
manipulations occurring. Nonetheless this did find manipulations that it would not 
otherwise have been possible to detect. It is possible that there may have been a 
hesitation from some nurses about self-reporting manipulations, though this was 
not voiced to the researchers. It is also reasonable to assume that where alert cards 
were not completed, though manipulations were occurring, that the priorities of 
patient care took justifiable precedence. In both the pilot and main studies, despite 
reminders from researchers, there were fewer cards completed in the second 
week, suggesting that such self-report methods are unsuitable for long-term use. It 
should be noted that some wards had low patient turnover and this may have been 
an influence on the decreasing number of alert cards completed in the second 
week. An argument could be made that instead of having consecutive weeks that 
there should have been a gap between the weeks in the two-week periods spent on 
each ward. This would have helped to ensure that there would have been more 
turnover in patients, as on some wards the patient population was quite stable over 
the two weeks. This may have contributed to the fewer manipulations that were 
reported in the second week. However, taking this approach may have affected the 
momentum of the study on the wards and may have required further input on the 
wards from researchers.   
This study used methods that identified predictable manipulations and followed 
them up for possible observation. This meant that long periods observing practice 
were not required and so 22 neonatal and paediatric areas could be included. This 
also reduced any likely impact or disruption to clinical areas, as the time episodes 
spent observing practice were discrete. Carthey (2003) evaluated a structured 
observational study in healthcare and concluded that a good observer requires 
interpersonal skills, the ability to keep to the stated objectives and the ability to 
reassure staff who may be concerned about any possible medicolegal and punitive 
consequences of the data. The nurses on the wards were supportive of the study 
and alert cards were completed, nonetheless agreement to being observed and 
what data was being recorded was never assumed. Many of the concerns about the 
effect of the observer on the observed in relation to drug preparation or 
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administration have been rooted in studies that considered drug errors. The 
concern is that the presence of observers would increase awareness, consequently 
fewer errors would occur. Although, the opposite effect has been discussed, that is 
that observation could increase the incidence of errors. The argument being that it 
is possible that being observed could cause unease and so make errors more likely. 
With drug errors it is rational to assume that those being observed do not intend to 
make errors. With drug manipulation the decision to manipulate is intentional. The 
manipulation is a reasoned response to the need to achieve the prescribed dose of 
a drug. Thus manipulation may be unavoidable as the prescribed dose of the drug 
needs to be administered. Therefore while there may potentially be an effect of the 
observer on the how the actual manipulation is undertaken the incidence will be 
unaffected.          
This study used undisguised observation; all who were observed were fully 
informed about the purposes of the study. Nevertheless, it is reasonable to expect 
that a study where any aspect of drug preparation or administration is observed 
may cause concern in those being observed. As Barner-Barry (1986) describes, 
thought should be given in observational research to include the right of privacy of 
those being observed. Barker (1980) noted that if the observer is collecting data 
that has the potential to be embarrassing or damaging to the subject then every 
effort must be exerted to be unobtrusive, non-judgemental and not ask for any 
change to normal activities for the convenience of the researcher. These principles 
were followed and all of those approached and asked to consent verbally to being 
observed undertaking drug manipulations gave consent. 
It may seem reasonable to assume where studies considered drug errors that the 
presence of an observer could decrease the error rate through increased 
awareness. Though it has been argued that this effect could either make the nurses 
more careful and error rates could decrease or could make them nervous and the 
rates could increase (Dean and Barber, 2001). Aspects of this study should have 
reduced this possible effect of the observer. Firstly undertaking a manipulation is 
not a choice of the nurses involved but considered necessary to fulfil the 
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prescription. Secondly those being observed were reminded prior to any 
observation that it was not about the individual involved and that no details of the 
individual were being recorded. Finally as drug manipulation is an accepted part of 
drug administration, the familiarity of the activity and the frequent presence of the 
observers on the wards should minimise the effect of the observers on the 
observation data collected. It has previously been perceived that, with the presence 
of an observer, there is less of a concern where the subjects are doing an activity 
familiar to them and when the observer is unobtrusive and non-judgemental 
(Barker et al., 2002a). Within drug error observational studies the effect of the 
observer has not been considered to have had an effect on the outcomes (Barker, 
1980; Dean and Barber, 2001). Dean and Barber (2001) found no changes in 
omitted doses between observed and unobserved periods and no difference in the 
observed medication administration error rate with repeated observations. These 
findings, alongside those found in previous studies, led them to conclude that the 
concerns about the effect of the observer were unfounded and that the 
observational method was valid.   
Barker (1980) considers that the most common reliability measure in observational 
studies is observer agreement. Ideally a complete assessment of inter-rater 
reliability would be completed where observation is undertaken. The importance of 
both the training of observers and the assessment of consistency has been 
described (Prot et al., 2005).  Previous studies, such as (Nolan et al., 1995; Chua et 
al., 2010) using direct observation have not reported on the reliability of what has 
been observed. Little is known about observer agreement in the context of drug 
administration observation (Dean and Barber, 2001) and this has been highlighted 
as a methodological flaw (Carthey, 2003). One study that did attempt inter-
observer reliability when observing drug errors abandoned the attempt and 
concluded that, due to practical issues, it was too difficult to for two observers to 
record the data (Dean and Barber, 2001). This was also noted within this pilot 
study, ensuring a clear view for the two observers with the two nurse system of 
checking drugs (used in many paediatric settings) while ensuring that the process is 
not disrupted is difficult. Within this study it was not possible to quantify inter-
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observer reliability. There were a small number of manipulations which were 
recorded by two observers. Following the pilot study, the data from the seven 
manipulations which had been recorded by both observers was scrutinised. Three 
quarters of the differences were due to differing data being recorded as the item 
was not sufficiently defined, or where the data had not been recorded at all. These 
findings were used to improve the clarity of the data collection forms and to 
develop a reference document to enable enhanced data collection in the main 
study.   
 
3.11.2 Manipulations 
This study included a wide range of generalist and specialist neonatal and paediatric 
in-patient areas and included three sites within the Merseyside and Cheshire 
localities. This may affect the external validity of the outcomes of the study both 
within the UK and to wider populations. In incorporating all the of available in-
patient areas with the children’s hospital, a separate specialist neonatal centre and 
the neonatal and paediatric areas in a district general hospital this study has 
included both a range of general and specialist areas and given some allowance for 
possible differences in prescribing practice and drug availability. Many of the 
manipulations found involved drugs that are prescribed for indications that mean 
they are liable to be in common use in paediatric practice. Across the UK there may 
be a variety of specials5 ordered and so within hospitals and regions there may be 
differences in the drugs which require manipulation. Mulla et al. (2007) considered 
captopril formulations used in the UK and found that a variety of unlicensed 
captopril formulations are used interchangeably. Additionally there may be 
variance in the preferences between the dosage forms used, for example the use of 
suppositories in children is quite popular in western Europe but uncommon in the 
UK or the US (Breitzkreutz and Boos, 2007). Within Europe there may be diverse 
                                                          
5
 Specials are special-order unlicensed medicines made to meet the needs of an individual patient.  
For children specials may be the only option for the prescriber for some conditions and in some 
circumstances are routinely prescribed (www.npc.nhs.uk/improving_safety/prescribing 
_specials/resources/5_guiding_principles.pdf ) 
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formulations available, again meaning that there may be differences in the drugs 
being manipulated. Notwithstanding that there may be different drugs or drug 
products, methods of manipulation or dosage forms involved, the global impact of 
the historical lack of development in paediatric medicines and need to manipulate 
is acknowledged. Therefore the outcomes of this study can be considered to have 
relevance beyond the geographical area where data were collected.   
It had been suggested that manipulations may occur more frequently in more high 
dependency areas. This study found that, as may have been anticipated, higher 
numbers of manipulations were found in areas where there are likely to be more 
dependent patients and therefore where more drugs are liable to be prescribed. 
However it was evident that manipulations are not solely occurring in these areas 
as they were found throughout all of the included clinical areas.     
The systematic review (Chapter 2) found limited evidence relating to manipulations, 
what evidence there was predominately related to tablet manipulations. This 
current study found that 191 of the total 310 manipulations were tablet 
manipulations. Of the 25 observed tablet manipulations where the tablets were 
split 12% were repeated either due to the tablet crumbling or splitting unevenly. 
The numbers involved in this are small and cannot be considered to correspond to 
other tablet manipulations of different formulations or other drugs.  
In addition, this indicates a potential for considerable waste associated with 
splitting tablets if regular repetition of the manipulation is needed due to the tablet 
crumbling or splitting unevenly.   
With nine (36%) of the observed split tablets there was visible powder produced 
during splitting. Though this may be small and may not impact on the dose 
achieved, further work is needed to explore the implications of this. Even if there is 
insubstantial impact on the dose achieved there are other implications. If tablets 
are split then the dust produced will be drug-containing, this may have unknown 
safety implications for those splitting the tablets. Splitting tablets that contain 
cytotoxic, mutagenic and reproduction-toxic substances could result in the 
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contamination of the domestic environment with hazardous dust (Breitkreutz and 
Boos, 2007).       
30% of the tablet manipulations involved dispersing in water and taking a 
proportion. In all cases the proportion taken for administration was observed to be 
withdrawn from the bottom of the container. The systematic review found a single 
study which had considered the dispersion of tablets. In this study Broadhurst et al. 
(2008) found that when withdrawing proportions of the dose that inconsistent 
doses were found when sampled from different depths of the container, though 
those taken from the base of the container were most consistently closest to the 
intended dose. This gives limited support to the observed practice that doses 
should be, as they were observed to be, taken from the base of the container. 
Though, questions about the actual dose that is contained in the proportion 
administered remain.     
During this current study there were tablets manipulated where a liquid 
formulation was available. This triggers questions about why the manipulation was 
being done. This has been found previously, Skwierczynski and Conroy (2008) found 
that tablets were manipulated where they were available as a liquid; the reasons 
for this included cost (liquid formulation expensive compared to the tablets), 
availability on the ward and the volume of the liquid that was required to achieve 
the prescribed dose. Breitreutz and Boos (2007) considered that the main problem 
with liquid formulations is the palatability of the solution. There may be practical 
reasons for the manipulation (such as availability on the ward). Nonetheless this 
raises a question about preferences, whether some children may prefer tablets 
(even split tablets) that are designed for them to taking large volumes of liquids of 
liquids that they find unpalatable.     
The intravenous manipulations reported involved dilutions beyond those that 
would be expected for the reconstitution of the drug. These were needed to 
achieve a small dose which could not otherwise be measured for administration. To 
obtain the small dose prescribed these extra steps are a necessary addition to the 
drug preparation process. They do add the potential for errors in both calculation 
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and/or measurement. The risk of tenfold error in paediatric practice has been 
previously highlighted (Koren et al., 1994; Ghaleb et al., 2006; Wong et al., 2009) . 
Taxis and Barber (2003b) investigated intravenous drug errors and found that most 
preparation errors were associated with multiple step preparations. Chappell and 
Newman (2004) reviewed nine intravenous drugs administered at doses that were 
less than one tenth of the dose in the vial and four drugs administered at doses that 
were less than one hundredth of the dose in the vial, in a neonatal unit. They found 
that many of these drugs would cause considerable morbidity or mortality in 10-
fold or 100-fold overdose. Of the small number of intravenous manipulations 
observed in this study none mistakenly added the drug dose in the hub of the 
syringe. Though this may be a very small dose, when considering small doses such 
as those prescribed in neonatal units, then this may be a substantial proportion of 
the prescribed dose if inadvertently administered. Taxis and Barber (2003b) found 
that where the volume in the syringe hub was administered on a neonatal unit the 
result was a 2-3 times overdosage. So although not observed in this study the 
administration of the dose in the syringe hub remains a risk where further dilution 
is required to measure the small dose prescribed.                
Though other dosage forms may be manipulated less frequently it is evident that 
tablets are not the sole dosage form manipulated. Manipulations were found for 
capsules, sachets, nebuliser solutions and suppositories. There were no reported 
manipulations involving enemas or oral solutions. As the systematic review 
(Chapter 2) found only one (low quality) non-tablet study (Kim et al., 2005) there is 
not an evidence base to support these non-tablet manipulations.      
The drugs that were manipulated in this study were not the unusual, the 
infrequently prescribed or those where the indication was liable to be to treat a 
rare condition. They were those which could be expected to be used routinely in 
neonatal and paediatric practice, with analgesics representing the largest group 
reported. Manipulations are not therefore an anomaly of clinical practice, only 
applicable to orphan drugs or for unusual diagnoses.  
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Furthermore a substantial number of the drugs being manipulated were identified 
only once during this study. As the aim was to investigate and where possible 
observe the process of drug manipulation absolute numbers of manipulations were 
not being sought. However, this frequent single identification does make it 
reasonable to surmise that there may be other drugs that are being manipulated 
but which were not being used on these ward during the two week data collection 
periods.        
The comments made by nurses undertaking manipulations were unsolicited and 
recorded as they occurred. These comments cannot be considered representative. 
Nonetheless they do provide an indication of the challenges of some manipulations, 
with descriptions given of the difficulties of splitting some tablets and dispersing 
others. Nurses also expressed concern about the impact of manipulations on the 
accuracy of the administered, manipulated dose.    
 
3.12 CONCLUSIONS  
Observation proved to be an appropriate and valid method for considering drug 
manipulations in clinical practice. The limitations of this method, such as the 
possible observer effect on the observation and the difficulties with considering 
inter-rater reliability, are acknowledged. The concurrent use of self-report and 
prescription reviews to identify manipulations proved effective. When exploring a 
topic area that has not been previously investigated, such as this one, then the 
methods of locating manipulations and the observational data collection tools had 
to be designed specifically for this study. Consequently the use of research and 
clinical expertise review and the pilot study were an instrumental part of the 
process to ensure the internal validity of the outcomes.   
This observation based study provides evidence of drug manipulations occurring in 
neonatal and paediatric in-patient areas. These manipulations were undertaken 
across all areas of general and specialist practice and frequently involved drugs that 
are in common use. Undertaking manipulations has the potential to increase 
medication error rates as the extra processes involved may make errors in 
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calculation or in measurement more likely. Aside from an increased risk of errors, 
questions of the dose accuracy of the manipulated product were evident from the 
observations. These questions about dose accuracy are raised where tablets split 
into unequal segments or a segment crumbles; with the potential loss of active 
product where there is residue left after a tablet is split, and whether tablet 
dispersion is sufficiently consistent, that the required dose will be accurate when a 
proportion is withdrawn for administration. Concerns about dose accuracy were 
broached by those undertaking the manipulations.  
The study described in this chapter has confirmed that drug manipulation is an 
aspect of the administration of drugs in neonatal and paediatric in-patient areas. 
This study has explored and described these manipulations. The outcomes of this 
study were used to explore further contextual issues around this practice and the 
thoughts of nurses doing these manipulations in Chapter 4.   
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CHAPTER 4: QUESTIONNAIRE  
4.1 INTRODUCTION  
The observational study (Chapter 3) identified 310 drug manipulation episodes and 
described 54 of them through direct observation. The observational data were 
collected from three sites within Merseyside and Cheshire, including two specialist 
sites and one district hospital. The specialist children’s hospital involved in the 
observational study has large neurosurgery and cardiac units: some of the drugs 
being manipulated were liable to have been specific to some of the conditions 
found in these specialities. Specialities at other sites may require different 
manipulations. Outside of the larger paediatric centres neonatal and paediatric 
units may represent a small number of wards in much larger adult hospitals. This 
may influence the availability of paediatric medicines and consequently influence 
the manipulations in these areas. Throughout the UK there may also be an 
influence from differences that may occur in prescribing practice. Porta et al. (2012) 
considered antibiotic use across children’s hospitals in Europe and noted that there 
have been few studies that compare this. Within the two UK sites included they 
found variation in use. Therefore the data from the observational study may not 
have captured the scope of manipulation practice across the UK.        
It is important to consider the setting in which manipulations occur. Drug 
manipulations may themselves be discrete actions but cannot be considered as 
independent actions. There are a number of contextual issues which may influence 
practice. These include: 
- Manipulation may be an unlicensed or off-label use of the drug product. As 
such they will not be included in any information from the pharmaceutical 
companies and may not be available in other reference sources. Therefore 
where do those undertaking the manipulation seek information or advice 
relating to them from?   
- Tablet manipulations were found in the observational study where a liquid 
formulation is available; suggesting that achieving the dose required may 
not be the sole reason for the manipulation, there may be other influences.     
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Additionally, the 5-day quantitative review showed that for both intravenous 
injections and/or oral liquids two methods could have been used to try and achieve 
the prescribed dose. That is either a manipulation in the form of a further dilution 
or a measurement of a small volume (<0.2mL), could have been used to obtain the 
final dose for administration (Nunn et al., 2013). Volumes of <0.2mL may be difficult 
to measure accurately. The perceptions of nurses about the need to measure very 
small volumes have not been described.     
The observational study identified issues that could not be addressed within it. 
Within that study the observers aimed for impartiality and were present only to 
record the data of the observation. Questions were not asked except where 
required for clarification. Nonetheless there were spontaneous comments made by 
nurses doing manipulations, these were recorded. These provided some insight into 
the views of those undertaking manipulations, suggesting that nurses have 
questions and concerns relating to them.   
Therefore there were several areas relating to drug manipulation where additional 
data would provide context for drug manipulations. In order to address these issues 
a further study was designed and conducted. The areas included were the variation 
in prescribing practice and therefore the nature and type of drug manipulations 
occurring, further details of manipulations that may occur less commonly, including 
whether they are considered to be applicable to current practice, the use of sources 
of supportive documentation, possible variation in the reasons why manipulations 
were undertaken, the use of the measurement of small volumes and any concerns 
that those undertaking manipulations have.  
In deciding to seek this additional data there was also the opportunity to ask about 
the dosage forms where there had been limited data found during the 
observational study (Chapter 3). This specifically included suppositories and enema 
manipulations.      
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4.2 AIMS  
This questionnaire study aimed to: 
- Elicit complementary data (to the observational study, Chapter 3) about the 
nature and type of drug manipulations occurring in neonatal and paediatric 
in-patient areas and to investigate the process of manipulations in dosage 
forms that were not observed 
- To consider how and where any reference materials about undertaking 
manipulations is located   
- To explore if nurses are measuring small volumes of liquids (<0.2mL)  
- To identify if nurses use any methods to avoid drug manipulations  
- To elicit the views of nurses undertaking manipulations  
 
4.3 STUDY DESIGN  
On review of the study aims it was clear that questions relating to many of them 
could be distilled into short and direct questions, therefore fitting a questionnaire 
based method. Surveys are considered to be well suited to descriptive studies, but 
can also be used to explore further aspects of a situation or to seek explanation 
(Kelley et al., 2003). Furthermore a questionnaire can be appropriate if used within 
a mixed methodology study, such as to extend and quantify the findings of an initial 
exploratory phase (Boynton and Greenhalgh, 2004). Both of these aspects apply to 
the aims underpinning this questionnaire. The use of a survey provided the 
opportunity to investigate across a wider geographical area and had the potential 
to include many more participants than would be possible with other methods. 
Additional open ended questions could be used within the questionnaire to explore 
those questions where, either a closed question would be inappropriate, or as 
supplementary to a closed question to gain further insight.   
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4.4 QUESTIONNAIRE DESIGN  
Literature on questionnaire design resonates with warnings about poorly designed 
questionnaires and the inherent consequences of this on the outcomes resulting 
from the questionnaire. With the design of this questionnaire, as with many 
questionnaires, a balance was required between gaining as much relevant and 
sufficiently robust data as possible whilst ensuring that the questionnaire is not 
considered too onerous by participants. Williams (2003) noted that the temptation 
with designing a questionnaire may be to delve into a wide range of issues which 
are interesting but not directly relevant to the study. The use of previously 
administered questionnaires in similar topic areas can help to guide the design of 
future questionnaires. This was not a resource available in designing this 
questionnaire. Questionnaire design methodologies were reviewed to ensure that 
this questionnaire would meet the principle described by (Gendall, 1998) of letting 
the respondent tell us what they mean without imposing responses on them. It is 
much more difficult than it seems to prevent a questionnaire becoming an 
instrument of the designer’s perceptions, values and language, which is then 
inflicted on the respondent (Gendall, 1998).    
Within questionnaire design the respondent defines what can be done. One of the 
criticisms of questionnaires is that they assume that the researcher and respondent 
share assumptions and interpret the wording of a statement in a similar manner 
(Rattray and Jones, 2007). However, a survey of a specified group can, and should, 
be a different proposition to a survey of the general public (Gendall, 1998). As all 
potential respondents were nurses, it could be assumed that potential respondents 
familiarity with clinically related statements and terminology existed. Nonetheless 
this did not diminish the importance of designing a questionnaire that ensured that 
the perceptions or views of the researchers were not transmitted to respondents. 
In tandem with this is the need to ensure the intelligibility of questions, that they 
are clearly comprehensible. Questionnaires have the potential for error where 
respondents misunderstand the question or response categories (Tourangeau, 
1984; Stone, 1993). This may have a negative impact on the response rates as it has 
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been shown that low response rates are can be due to participants being unable to 
read or follow the questionnaire (Boynton and Greenhalgh, 2004).     
 
4.4.1 Overall questionnaire design 
Gendall (1998) considered a questionnaire to be a structure of layers which must be 
integrated into an entity whose properties are greater than the individual layers 
(question design, question wording, and formatting or layout). Relevant aspects of 
this structuring were reviewed in planning and designing the questionnaire for this 
study.   
4.4.1.1 Question choice  
Many questionnaires consist of predominantly closed questions making them 
relatively rapid to complete and providing data that lends itself to coding and 
analysis. Closed questions provide the same context for all respondents, though 
outcomes are dependent on the answer set presented (Gendall, 1998). These 
questions, by their nature, restrict the pool of answers. Consequently overall the 
richness of potential responses is lower with closed questions (Boynton and 
Greenhalgh, 2004), though the questions will usually aim to include the range of 
possible answers. It has been proposed that within closed question design that 
there should always be the option for respondents to not give an opinion through, 
for example, the use of ‘don’t know’ or ‘not relevant’ or ‘other’ options. It has been 
opined that a ‘no opinion’ option should be offered (Gendall, 1998). Though this is 
debated, as it has been argued that including the ‘don’t know’ may lead to many 
non-committal responses (Williams, 2003), some respondents may choose to 
provide a non-committal response when they actually do have an opinionated one 
(Stern et al., 2012). The removal of the choice of a neutral answer forces the 
respondent to select a response (Rattray and Jones, 2007). Respondents have to 
either pick an option that they may not agree with or not complete the question. As 
(Stone, 1993) argued human uncertainty and indecisiveness may be an irritating 
inconvenience but it cannot be ignored.   
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The addition of open questions allows participants to express their views. The 
respondent must formulate an answer rather than selecting from pre-existing 
answers (Tourangeau, 1984). Open-ended questions allow for a large number of 
possible answers where it is important to capture all of the detail in the information 
provided (Edwards, 2010), the driver behind them is often a concern about missing 
an important issue (O’Cathain and Thomas, 2004). However, open-ended questions 
may take longer to complete meaning that they are left unanswered. Respondents 
may short-circuit the process, deciding to not complete the question rather than to 
retrieve facts from the memory or to review what they think about an issue 
(Tourangeau, 1984; Williams, 2003). The decision of respondents on whether or not 
to complete open-ended questions may mean that the views expressed may not be 
comprehensive. Those who choose to answer the general open questions could be 
different from overall respondents, either being more articulate or having a greater 
interest in the survey topic (O’Cathain and Thomas, 2004). 
 4.4.1.2 Question wording, question order and layout  
For the data resulting from a questionnaire to be valid, participants must be able to 
correctly understand the question and what is being asked of them. The design, 
wording, form and order of questions can affect the responses obtained; careful 
design is needed to minimise bias in the outcomes (Kelley et al., 2003). The wording 
of questions can be an influence, in general questions should be short, simple and 
specific (Williams, 2003). Unfamiliar or difficult words should be avoided, as should 
asking two questions within one (Gendall, 1998). The aim should be to reduce the 
opportunity for misinterpretation with the avoidance of unambiguous words. 
Boynton and Greenhalgh (2004) noted that words that are often used 
inappropriately in closed questions are “frequently” and “regularly” and further 
recommends avoiding “commonly”, “usually”, “many”, “some” and “hardly ever”. 
Words like these are open to individual interpretation of their meaning.       
There are some differences in the views on question order. Some consider that it is 
better to start with easy, factual, non-personal questions and that any questions 
that may involve some research from the respondent should come later when the 
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respondent will hopefully have developed an interest in the subject and feel 
ownership of the questionnaire (Williams, 2003). Traditionally many questionnaires 
have started with demographic questions though there is also a view that these 
questions are asking more personal information and should be placed at the end 
(Stone, 1993). The HTA review on the design and use of questionnaires considered 
that question order effects may not be ubiquitous, but that the evidence suggested 
that general questions should precede specific ones (McColl et al., 2001).    
The importance of visual aspects of questionnaire design has been highlighted, with 
a caveat that researchers rarely spend sufficient time on the layout of their 
questionnaire (Boynton and Greenhalgh, 2004; Edwards, 2010). Visual design 
theory notes that even the formal visual elements of a self-administered 
questionnaire can be assumed by respondents to be meaningful (Stern et al., 2012). 
Additionally, designing a questionnaire that is easy to navigate is considered to 
increase response rates (Williams, 2003).     
When it comes to questionnaire length there is insufficient evidence to suggest an 
optimal questionnaire length in terms of number of questions or pages (Nakash et 
al., 2006). Overall findings with respect to questionnaire length are equivocal 
(McCall, 1984). There is, however, an inevitable trade off between making the 
questionnaire comprehensive enough to answer the question adequately, and 
making it so long that it may have an adverse effect on response (Nakash et al., 
2006).    
 
4.4.2 Response rates 
Postal questionnaires are notorious for the difficulty this method poses in attaining 
adequate response rates. Response rates are a potential source of bias; the 
potential differences between responders and non-responders should be explored 
and any implications discussed (Kelley et al., 2003). This study aimed to obtain 
participants to include a range of types of units, such as large specialist paediatric 
hospitals and paediatric wards based in district general hospitals, throughout the 
UK, and across general and specialist paediatric areas. While the individual practice 
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and experience of participants may differ, all participants were nurses working in 
paediatric in-patient areas and were asked about their professional practice, 
lessening the potential differences between responders and non-responders.  
Cover letters have not emerged as substantial predictors of response rates. It is 
difficult to assess if this is because the content of the cover letter is not important 
or because it has been difficult to predict or measure the impact (Redline et al., 
2004). Theories of individual motivation that have been used to attempt to increase 
response rate and have argued that the cover letter should link the survey topic and 
possible motivational concern of the respondent (McColl et al., 2001).  
 
4.4.3 Saliency  
It seems reasonable to infer that where potential participants are interested in the 
topic area then they are more likely to complete the questionnaire. Overall theory 
and empirical research suggests that respondents are predisposed to respond to 
questionnaires with more salient topics or issues that are relevant to them 
(Williams, 2003; Stern et al., 2012). This may even have relevance throughout the 
questionnaire questions. Stern et al. (2012) noted that there has been some 
discussion as to why certain questions show response effects while others do not 
and deemed item saliency6 to be a plausible explanation. However determining 
saliency is difficult. Direct measures of people’s interests are difficult to obtain, so 
indirect measures or proxies, such as membership on a list that suggests an 
interest, are a logical compromise (Groves et al., 2004; Stern et al., 2012). In this 
situation, the selection of nurses who are currently working in neonatal and 
paediatric hospital areas allowed some assumption that a questionnaire that asked 
them to provide information on clinical practice would be salient to them. A 
previous survey of nurses that aimed to measure the knowledge, practice and 
attitudes of nurses found that many respondents were positive about participation 
and reported comments such as ‘I welcome any means to assess my clinical 
                                                          
6
 Item saliency is the degree to which any topic of any given question resonates with the respondent  
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effectiveness’ and ‘in order to be effective clinically it is important to be self-critical’ 
(Upton and Upton, 2006). Though influential, topic is not the sole feature of a 
saliency. Other aspects such as the length of the survey, the sponsor of the study or 
poor visual design of the questionnaire may also have an effect and may need to be 
considered (Groves et al., 2004; Stern et al., 2012).    
 
4.4.4 Anonymity 
The argument has been made that assuring respondents of anonymity can increase 
response rates. The evidence from this appears to be equivocal with some 
concluding that stressing the anonymity of the survey could increase response rates 
(Williams, 2003), while a Health Technology Assessment review considered that 
assurances of anonymity did not improve response rates (McColl et al., 2001).      
Medication errors are a particular focus within the NHS. With patient safety a 
paramount consideration is understandable that medication errors are given 
substantial prominence. In relation to the causes of drug errors the influence of 
other factors is acknowledged, nonetheless attention is often focused on the 
individual involved in the error (Smith, 2004). As described in Chapter 3 when 
planning the observational study, it was necessary to be aware of the importance 
attached to drug errors and whether participants would be cautious due to this, 
and consequently reluctant to report on drug manipulations. As Crawford (2012) 
describes, with the administration of medicines there needs to be an ethos of 
transparency and responsibility, if it is felt that there is a blame culture then nurses 
may be less likely to report incidents.  
There is the potential that a survey of nurses, which asks about their practice, may 
cause participants to feel constrained by their being a registered health care 
professional. They may be tempted to provide what they consider to be 
professionally acceptable responses. Edwards (2010) noted that when exploring 
aspects of practice of health care professionals that there may be a perception that 
there are responses that they should give. The use of self-administered 
questionnaires should mean that there is less susceptibility to response desirability 
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bias Edwards (2010). Akram and Mullen (2012) considered that some of the 
difficulty they had with getting paediatric nurses to agree to participate in the 
interview stage of their study was a reluctance to discuss their practice with 
another health colleague, that assurances of anonymity were not sufficient. The 
distance from researchers provided by self-administered questionnaires will help 
avoid any potential bias due to interviewer effects. Participants may respond more 
truthfully to sensitive questions, and may make more critical and less socially 
acceptable responses to a questionnaire than when face-to-face with an 
interviewer (McColl et al., 2001).   
 
4.4.5 Retrospective recall of recent drug manipulations 
Relying on the memory of questionnaire respondents provides its own 
complications. This retrospective approach to data collection can be prone to bias 
due to inaccurate recollection. Imposing a time frame in question wording can both 
be helpful and pose difficulties. It is considered unwise to ask about things that 
have happened more than six months ago (Williams, 2003). With retrospective 
recall it is likely that there will be episode omission, respondents may fail to recall 
an event that falls within the specified time-frame (McCall, 1984).  
 
4.5 STEERING GROUP  
An expert steering group was used to support the development of this 
questionnaire based study development. This group had initially conceived the 
need to investigate this area and had sourced the research funding for the 
Manipulation of Drugs Required in Children (MODRIC) research group. The steering 
group used comprised medical, pharmacist and nursing members alongside 
formulations and research expertise, this group were consulted with repeatedly 
during the questionnaire development. I completed the initial design and drafting 
of the questionnaire which was reviewed by this group, they provided advice for re-
drafting of the questionnaire and face validity for the questionnaire.  
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4.6 ETHICS  
This study outline was reviewed by the Liverpool Local Research Ethics Committee 
and met their criteria as a service evaluation project involving NHS staff only. This 
body considered that this study did not require review by a NHS Research Ethics 
Committee.  
 
4.7 METHODS  
This study used a paper based postal questionnaire. Paper based questionnaires 
were selected ahead of using an electronic based distribution. Consultation with 
ward based nurses found that there tends to be a small number of computers 
available in ward areas. These computers are often predominantly used for 
updating records and notes and access for any other purpose may be more difficult. 
Questionnaires were distributed via unit/ward based nurse managers.  
 The questionnaire used in this study was designed following a review of 
questionnaire design literature and in consultation with study steering group. 
Throughout the design of this questionnaire questions were repeatedly assessed 
and reviewed specifically considering their relevance, clarity and lack of ambiguity. 
Advice and assistance on layout and general aesthetic design was taken from a 
clinical audit unit with considerable experience in questionnaire administration.   
 
In relation to issues that the review of questionnaire design had shown to be 
potential sources of bias the following decisions were made. Throughout the 
questionnaire no opinion or not applicable options were generally included. 
However there were a small number of questions where this option was not 
available. These questions asked specifically practice related questions where not 
having a ‘no opinion’ option was logical, such as when asking whether or not they 
take steps to avoid manipulations. Where participants were asked to 
retrospectively recall data this was for the time period of the previous month. 
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Within the design of this questionnaire supplementary open questions were used 
to allow respondents, if they chose to, to expand on answers given to closed 
questions. A small number of additional open-ended questions were used to ask 
about any concerns relating to manipulations and any further information that 
respondents may wish to give. The questions such as those relating to steps to 
avoid manipulations or about concerns needed to be open-ended as they aim to 
elucidate what the respondents think and did not want any possibility of biasing 
answers by using closed question categories. The aim of the cover letter sent with 
this questionnaire was to explain clearly the purpose of the questionnaire and to 
ensure that the nurses would feel that this questionnaire was salient to them, thus 
increasing the likelihood that the questionnaire would be completed. Nonetheless 
measures were taken with the aim of maximising the response rate. This included 
this use of several relatively easy to achieve practical suggestions which have been 
considered to potentially improve questionnaire response rates (Williams, 2003). 
These included using white stamped envelopes, pre-paid addressed envelopes for 
replies and using official headed paper for all correspondence.    
For the outcomes of this survey to be valid the honesty of participants was 
necessary. With the aim of ensuring that respondents would not be concerned 
about providing full details questionnaires were anonymous. Participants were 
asked only to report the town/city that the hospital they work in is located and the 
type of hospital and clinical area they worked in. The provision of complete 
anonymity, and therefore no possibility of their responses being individually 
questioned, aimed to make certain that participants would not feel obliged to give 
professionally standard answers.  
The questions that asked for retrospective recall of recently undertaken drug 
manipulations were placed at the end of the questionnaire following the previous 
18 questions relating to manipulations, as this should assist with the recall of recent 
occurrences. Questionnaire respondents were asked to recall data of recent 
manipulations they had undertaken. A time frame of one month was used. While 
acknowledging the potential drawbacks, the recall by respondents of recent drug 
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manipulations could still supply valuable data about manipulations currently being 
used in clinical practice throughout the UK.   
 
4.7.1 Sampling  
This study did not aim to find a representative sample of paediatric nurses in the 
UK. Purposive sampling was used with the aim of ensuring both that there was a 
geographical spread throughout the UK and that there was a range of sizes of 
paediatric units included, encompassing both large specialist centres and smaller 
units, which are often located in larger, mainly adult, hospitals.. 
Neonatal/paediatric ward or unit managers in 42 neonatal and paediatric centres 
across the UK were contacted via email. This contact initially was made by Professor 
Nunn representing the MODRIC group as he is a known expert within paediatric 
medications related research and it was considered that this may assist with 
response rate. Once they had replied to him he forwarded the emails on to me and 
I completed all further contact including questionnaire distribution. The use of ward 
managers allowed questionnaires to be distributed personally within a work place 
environment but also preserved the anonymity of respondents. The study was 
described to the managers and they were asked if they would agree to distribute 
questionnaires to the nurses working in neonatal and/or paediatric areas. Thirty of 
the 42 sites responded and agreed to participate, relative to the size of the units 
they managed 10, 20 or 30 questionnaires were sent to the managers for 
distribution. All questionnaires responses were anonymous. There was no direct 
communication with the potential questionnaire respondents.  
Reminder emails were sent to all participating managers of participating centres 
two weeks after the initial distribution of the questionnaires. 
 
4.7.2 Pilot study   
The questionnaire was piloted with a group of paediatric research and clinical 
nurses. On collating their comments a few questions were reworded to ensure that 
129 
 
the questions were sufficiently concise, and clear in what was being asked. Major 
revisions were not required. Participants in the pilot process were also asked 
specifically about the table used within the questionnaire to define manipulations 
for each dosage form to ensure that these definitions were unambiguous. Changes 
to this table were not considered necessary by those completing the pilot.               
 
4.8 ANALYSIS  
The data from the closed-questions were analysed descriptively. Although the data 
from the open questions are qualitative it can be difficult to analyse using 
qualitative analysis techniques. The data from open questionnaire questions often 
lacks some of the key strengths of qualitative research, with a lack of conceptual 
richness as the data often consist of a few sentences or less (O’Cathain and 
Thomas, 2004). The data from the open-ended questions were content analysed to 
report the concerns that were raised by those who chose to answer these 
questions. Further analyses of this was limited by the brevity of many of the 
responses, as these were not in-depth but were short comments or sentences.   
 
4.9 RESULTS  
560 questionnaires were distributed to 30 hospital sites. Of these 153 (27%) were 
returned. There were respondents from 22 of the 30 hospitals where managers had 
agreed to distribute questionnaires. This included hospitals in Northern Ireland, 
England, Scotland and Wales. There was a spread of hospital types with 11.8% 
(18/153) of respondents working in children’s hospitals, 51.6% (79/153) in teaching 
hospitals with paediatric and neonatal beds and 25.5% (39/153) in district general 
hospitals with paediatric and/or neonatal beds.  11.2% (17/153) respondents did 
not specify the type of hospital where they worked.   
Four respondents worked in hospitals with only neonatal cots.  The number of 
paediatric beds in the remaining units ranged from 14 to 400 beds (mean 50 beds). 
Eleven respondents worked in hospitals with no neonatal beds.  The number of 
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neonatal beds in the remaining units ranged from 6 to 60 beds (mean 20 beds). The 
largest groups of respondents were working in general paediatric and neonatal 
areas, nonetheless respondents worked across many differing specialities (Figure 
8).     
Figure 8: Main speciality of the ward/clinical area that questionnaire respondents 
worked in. 
 
4.9.1 Drug manipulations 
There were 258 manipulations reported to have been undertaken in the previous 
month by 68% (104/153) questionnaire respondents (within the two largest groups, 
62% of those working in neonatal areas and 80% of those working in general 
paediatrics completed this question and reported manipulations). All of these drug 
manipulations were evaluated to ensure that they met the criteria to be considered 
a manipulation to achieve the required drug dose. This evaluation was reviewed by 
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an experienced paediatric clinical pharmacist. Where there was doubt as to 
whether the reported manipulations met the criteria, usually where the data was 
not complete enough (the proforma given to provide details of the manipulation 
was incomplete) for this to be assessed, these data were removed from any 
analysis. This resulted in 188 manipulations that could be considered further with 
70 (27%) of the 258 reported manipulations being removed.    
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Table 10: The drugs identified as manipulated from the questionnaire using the 
classifications from the BNFC  
BNFC classification   Drugs involved  Frequency 
this 
classification 
reported as 
manipulated   
Percentage  
of 
manipulatio
ns identified  
Analgesic Paracetamol, Ibuprofen, Diclofenac  33 17.6% 
Proton pump 
inhibitor 
Omeprazole 24 12.8% 
Bronchodilator Salbutamol, Ipratropium 23 12.2% 
Antimuscarinic Glycopyrronium bromide, Hyoscine 
hydrobromide 
20 10.6% 
Steroid Prednisolone, Hydrocortisone, 
Dexamethasone  
12 6.4% 
H2 antagonist Ranitidine 8 4.3% 
Antibiotic Metronidazole, Amoxicillin, 
Gentamicin, Clindamycin, 
Vancomycin 
7 3.7% 
Antiepileptic Phenobarbitone, Topiramate, 
Clobazam, Gabapentin, Phenytoin  
6 3.2% 
Osmotic laxative Phosphate enema  6 3.2% 
Antiemetic Aprepitant, Cyclizine, Domperidone  5 2.7% 
Laxative  Glycerine suppository 4 2.1% 
Immunosuppressant  Tacrolimus 4 2.1% 
Antimotility Loperamide  3 1.6% 
Antiplatelet Aspirin 3 1.6% 
Sedation  Secobarbital, Chloral hydrate 3 1.6% 
Benzodiazepines  Diazepam, Midazolam  2 1.1% 
Alginate preparation Gaviscon 2 1.1% 
Anticoagulant  Enoxaparin 2 1.1% 
ACE inhibitor  Captopril, Lisinopril  2 1.1% 
Calcium channel 
blocker  
Nifedipine  2 1.1% 
Cytotoxic  Allopurinol 2 1.1% 
Minerals  Potassium chloride  2 1.1% 
Opioid analgesic  Codeine, Morphine  2 1.1%  
Pineal hormone Melatonin  2 1.1% 
Vitamin Folic acid, Vitamin K 2 1.1% 
Antipsychotic Levomepromazine  1 0.5% 
Antihypertensive  Sildenafil 1 0.5% 
Antiviral  Aciclovir  1 0.5% 
Beta-blocker  Atenolol 1 0.5% 
Skeletal muscle 
relaxant  
Baclofen  1 0.5% 
Thyroid hormone Levothyroxine  1 0.5% 
Vasodilator  Glyceryl trinitrate 1 0.5% 
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Respondents were asked to identify how frequently they considered they had 
undertaken the manipulation that they had provided details of in the last month 
prior to completing the questionnaire;  
- 54.8% (103/188) considered that they were undertaking the manipulation 
they described daily,  
- 19.1% (36/188) weekly,  
- 9.0% (17/188) monthly, and  
- 14.4% (27/188) did not know.  
Overall there were 188 manipulations identified. Manipulations reported by dosage 
form are described in Table 11. 
Table 11: Manipulations reported by questionnaire respondents, by dosage form  
Dosage form  Number of manipulations 
identified via questionnaire 
respondents 
Number of different drugs 
involved  
Tablets 86 30 different drugs 
Capsules 15 8 different drugs  
Sachets  2 1 drug  
Nebuliser solutions 22 1 drug  
Transdermal patches 20 2 different drugs  
Suppositories  15 4 different drugs  
Enemas  6 1 drug  
Intravenous injections  22 13 different drugs  
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Within the largest two groups of respondents the breakdown of manipulations by 
dosage group can be seen in Table 12. 
Table 12: Manipulations, by dosage form, reported by questionnaire respondents in 
neonatal and general paediatric areas  
Dosage form  Manipulations, by 
dosage form, all 
manipulations 
reported  
Manipulations, by 
dosage form, 
reported by those 
working in general 
paediatric areas  
Manipulations, by 
dosage form, 
reported by those 
working in neonatal 
areas  
Tablets 86 (45.7%) 31 (46.3%) 6 (17.6%) 
Capsules 15 (8.0%) 5 (7.5%) 0 
Sachets  2 (1.1%) 0 2 (5.9%) 
Nebuliser solutions 22 (11.7%) 15 (22.4%)  0 
Transdermal 
patches 
20 (10.6%) 5 (7.5%) 6 (17.6%) 
Suppositories  15 (8.0%) 4 (6.0%) 6 (17.6%) 
Enemas  6 3.2%) 3 (4.5%) 0 
Intravenous 
injections  
22 (11.7%) 4 (6.0%) 14 (41.2%) 
Total  188 (100%)  67 (100%) 34 (100%) 
 
4.9.2 Proportions of the original dose required  
Of the 86 tablet manipulations, 46 (53.5%) were dispersed, 31 (36.0%) were cut and 
9 (10.5%) were crushed to get a proportion of the original dose. 36% of these tablet 
manipulations were reported by nurses working in general paediatrics, 11.6% in 
oncology, 9.3% in paediatric surgery and in paediatric surgery/HDU, 8.1% in liver 
units, and 7.0% in neonatal areas.   
For 40.7% (35/86) of overall tablet manipulations half of the original dose was 
required, for 14% (12/86) a quarter or three quarters of the original dose was 
required. For all of the reported tablet manipulations where tablets were cut or 
crushed the dose required was a half, quarter or three quarters. Where tablets 
were dispersed there was a wider range of proportions of the original dose 
required. For 29.1% (25/86) of all of the tablet manipulations and 54.3% of the 
manipulations where tablets were dispersed the proportion of the original dose of 
the whole tablet was not half, a quarter or three quarters of the original dose. With 
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these manipulations where tablets were dispersed the doses required were; 7%, 
19%, 65%, 66%, 90% (one manipulation each), 20% (two manipulations), 40% (six 
manipulations), 60% (eight manipulations), and 80% (four manipulations). Table 13 
describes the proportions of the original dose required from the manipulations of 
other dosage forms.   
Table 13: The proportions of the original dose of the whole dosage form required 
for the manipulations reported by questionnaire respondents for capsules, sachets, 
nebuliser solutions, transdermal patches, suppositories and enemas (where the 
data is incomplete in this table it was missing in the questionnaire response) 
Manipulations  Half of the 
original dose 
required  
Quarter/three 
quarters of the 
original dose 
required  
Other proportions of the original 
dose required  
Capsule 
manipulations  
33.3% (5/15) 13.3% (2/15) 33.3% (5/15) 
For each of these 5 manipulations 
the dose required was 6.7% (one 
manipulation each) 
Sachet 
manipulations 
50% (1/2) None  None  
Nebuliser 
solution 
manipulations  
59.1% (13/22) 31.8% (7/22) None  
Transdermal 
patch 
manipulations  
25.0% (5/20) 55% (11/20) 5.0% (1/20) 
For this manipulation the dose 
required was 12.5% 
Suppository 
manipulations  
46.7% (7/15) 6.7% (1/15) 13.3% (2/15) 
For each of these 2 manipulations 
the dose required was 66.7% (one 
manipulation each) 
Enema 
manipulations  
83.3% (5/6)  None  None  
 
With intravenous manipulations 68.2% (15/22) were for doses of <10% of the 
original dose (the smallest proportion was for 0.7% of the original dose), 13.6% 
(3/22) were for between 10% and 20% and 13.6% (3/22) were for 40% to 70% of 
the original dose.    
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4.9.3 Methods of manipulating suppositories, enemas and transdermal patches  
Within suppository and enema manipulations there had been limited opportunity 
to observe them during the observational study (Chapter 3). Questionnaire 
respondents have provided further data; the 15 suppository manipulations 
reported involved four different drugs (glycerine, paracetamol, diclofenac, chloral 
hydrate). When asked about the manipulation method for cutting a suppository, 
45.4% (69/152) of those who completed this question reported that they had 
‘never cut a suppository’. Of 82 of those who would cut suppositories 50 (61.0%) 
would cut longitudinally (from the pointed end to the blunt end) while 32 (39.0%) 
would cut transversely across the suppository, one respondent reported that they 
would use either method.  
With enemas there were six manipulations described by respondents all were of 
the same drug (phosphate enema), 47.7% considered that a question asking for 
details about enema manipulations were ‘not applicable’. Of the 77 of those who 
would manipulate enemas 51(66.2%) would discard an unwanted portion from the 
original pack to leave the dose to be administered, 15 (19.5%) would administer the 
required portion from the original pack and discard the remainder and 9 (11.7%) 
would withdraw the required portion and administer it (the remaining two 
respondents said they would manipulate enemas but did not specify the method 
they would use). 
A similar question involving transdermal patches (20 manipulations reported 
involving two different drugs, glycerol trinitrate and hysocine hydrobromide) found 
that 24.8% considered this type of manipulations ‘not applicable’ to them. Of the 
113 who would manipulate transdermal patches 73(64.6%) would cut the patch and 
apply a segment, 31 (27.4%) would cover the segment of the patch not to be used 
and 7 (6.2%) would use either method (the remaining two respondents said they 
would manipulate enemas but did not specify the method they would use). 
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4.9.4 Reasons for the manipulation 
For each manipulation for which they provided details, respondents were asked to 
provide the reason for the manipulation. For some manipulations respondents 
provided more than one reason for the manipulation:  
- 75% (141/188) of respondents included no suitable preparation or strength 
of the drug available as a reason for manipulation  
- 11.2% (21/188) of respondents included patient preference as a reason for 
manipulation 
- 31.4% (59/188) of respondents included usual practice as a reason for 
manipulation 
 Table 14 details the reasons given for undertaking the manipulations. 
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Table 14: The reasons for the manipulations that 
they had undertaken in the previous month by 
questionnaire respondents, by dosage form  
Reasons for manipulation 
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No suitable preparation or strength available  103 
(54.8%) 
46 
(53.5%) 
9    
(60%) 
0 4 
(18.2%) 
11  
(55%) 
18 
(18.1%) 
10 
(66.7%) 
5 
(83.3%) 
Patient preference  13 
(6.9%) 
13 
(15.1%) 
0 0 0 0 0 0 0 
Usual practice  23 
(12.2%) 
8   
(9.3%) 
1   
(6.7%) 
1    
(50%) 
9  
(40.9%) 
3    
(15%) 
0 1   
(6.7%) 
0 
No suitable preparation or strength available & usual 
practice  
32 
(17.0%) 
7   
(8.1%) 
2    
(13.3%) 
0 1   
(4.5%) 
0 0 0 0 
No suitable preparation or strength available, usual 
practice & patient preference  
2   
(1.1%) 
2   
(2.3%) 
3    
(20%) 
1    
(50%) 
8   
(36.4%) 
5    
(25%) 
3   
(13.6%) 
4  
(26.7%) 
1  
(16.7%) 
No suitable preparation or strength available & 
patient preference 
4   
(2.1%) 
4   
(4.7%) 
0 0 0 0 0 0 0 
Patient preference & usual practice  2   
(1.1%) 
2   
(2.3%) 
0 0 0 0 0 0 0 
Other  6   
(3.2%) 
3   
(3.5%) 
0 0 0 0 0 0 0 
Missing  3   
(1.6%) 
1    
(1.2%) 
0 0 0 1      
(5%) 
1   
(4.5%) 
0 0 
Total  188 
(100%) 
86 
(100%) 
15  
(100%) 
2  
(100%) 
22   
(100%) 
20  
(100%) 
22  
(100%) 
15  
(100%) 
6  
(100%) 
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4.9.5 Policies, guidelines, procedures or worksheets 
Respondents were asked if the hospital they work in has policies, guidelines, 
procedures or worksheets (set of instructions) on how to carry out specific 
manipulations. Respondents overall, and those working in general paediatric areas, 
gave similar answers with 58.8% and 54.5% respectively saying that there were 
policies, guidelines, procedures or worksheets (Table 15). Those working in 
neonatal areas reported higher availability of these resources with 88.1% 
responding that they had these forms of supportive documentation available.      
 
Table 15: Availability of supportive documentation (policies, guidelines, procedures 
or worksheets) on how to carry out manipulations, reported by questionnaire 
respondents  
 All questionnaire 
respondents  
General paediatrics 
respondents  
Neonatal 
respondents  
Yes  58.8% (90/153) 54.5% (24/44) 88.1% (37/42) 
No  22.2% (34/153) 25.0% (11/44) 7.1% (3/42) 
Don’t know 17.0% (26/153) 18.2% (8/44) 4.8% (2/42) 
Missing 2.0% (3/153) 2.3% (1/44) 0 
Total  153 44 42 
 
Similarly respondents were asked when faced with measuring small volumes (i.e. 
less than 0.2mL) of liquid medicines for any route of administration, does the 
hospital they work in have policies, guidelines, procedures or worksheets. Again 
respondents overall and those in general paediatrics gave similar answers while 
those in neonatal areas reported higher availability of the supportive 
documentation, Table 16.   
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Table 16:  Availability of supportive documentation (policies, guidelines, procedures 
or worksheets) on measuring small volumes, reported by questionnaire 
respondents 
 All questionnaire 
respondents  
General paediatrics 
respondents  
Neonatal 
respondents  
Yes  28.1 (43/153) 15.9% (7/44) 59.5% (25/42) 
No  35.9% (55/153) 36.4% (16/44) 21.4% (9/42) 
Don’t know 33.3% (51/153) 47.7% (21/44) 14.3% (6/42) 
Missing 2.6% (4/153) 0 4.8% (2/42) 
Total  153 44 42 
 
4.9.6 Reference sources 
Following the question relating to supportive documentation for manipulations 
respondents were asked what publications and reference documents they would 
consult, if any, prior to manipulating a medicine. The BNF/BNFC was the most 
consulted reference source (Table 17).   
 
Table 17: Reference sources that would be consulted by nurses prior to undertaking 
a drug manipulation, reported in the questionnaire  
 All questionnaire 
respondents  
General paediatrics 
respondents  
Neonatal 
respondents  
BNF/BNFC 80.6% (104/129) 86.8% (33/38) 66.7% (24/36) 
Documents 
produced by the 
hospital and/or 
pharmacy 
department  
62.0% (80/129) 63.2% (24/38) 75% (27/36) 
Internet  6.2% (8/129) 5.3% (2/38) 5.5% (2/36) 
Manufacturer 
instructions 
11.6% (15/129) 15.8% (6/38) 2.8% (1/36) 
Guidelines  4.7% (6/129) 7.9% (3/38) 2.8% (1/36) 
Journals  0.8% (1/129) 0 0 
Total (respondents 
who answered the 
question) 
129 (24 respondents 
did not complete 
this question) 
38 (6 respondents 
did not complete 
this question) 
36 (6 respondents 
did not complete 
this question) 
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4.9.7 Measurement of small volumes 
Questionnaire respondents were asked to list the drugs for which they had to 
measure small volumes of liquids (<0.2mL) and to indicate which route of 
administration they referred to.  65.4% (100/153) of respondents chose to answer 
this question, describing 306 cases where these small volumes were used. This 
question did not ask for further details; therefore the responses could not be 
further evaluated (as the manipulation data had been to ensure that it met the 
manipulation criteria). Nonetheless two small volumes responses were removed as 
they referred to transdermal patches. This left 304 cases of small volume 
measurement, details of which are found in Table 18. Of the 100 who provided 
answers to this question 35% worked in neonatal areas, 26% in general paediatrics, 
5% in each of oncology and ICU, the remaining areas respondents worked in all 
represented <4%. The most frequent route of administration for drug doses that 
have required a small volume to be measured was intravenous. In 10.5% 32/304 
drugs where a small volume is measured respondents reported that this could be 
for >1 route of administration (Table 19).       
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Table 18:  The drugs where volumes of <0.2mL have been measured, as reported by 
questionnaire respondents  
BNFC classification   Drugs involved  Frequency  
this 
classification 
reported as 
having small 
volumes 
measured >5 
occasions   
Percent
age   
Vitamins  Vitamin K, Folic Acid, Vitamin D 40 13.2% 
Opioid analgesic  Morphine, Diamorphine, Oromorph, 
Fentanyl 
34 11.2% 
H2 antagonist  Ranitidine  30 9.9% 
Heparins  Enoxaparin sodium, Heparin, 
Dalteparin sodium 
26 8.6% 
Antibiotics  Gentamicin, Erythromycin, 
Vancomycin, Clindamycin, 
Flucloxacillin, Benzylpenicillin, 
Cefotaxime, Trimethoprim 
23 7.6% 
Diuretic  Furosemide, Amiloride, Chlorothiazide  23 7.6% 
Benzodiazepine Lorazepam, Midazolam, Diazepam   19 6.3% 
Insulin  Insulin  13 4.3% 
Aldosterone 
antagonist 
Spironolactone 11 3.6% 
Steroids  Hydrocortisone, Dexamethasone  9 3.0% 
Immunosuppressant  Tacrolimus, Ciclosporin, 
Mycophenolate mofetil 
8 2.6% 
ACE inhibitor Captopril  7 2.3% 
Calcium channel 
blocker  
Nifedipine  7 2.3% 
Drugs used in 
neutropenia 
GCSF 6 2.0% 
Other – BNFC 
classification 
reported 5 or fewer 
times  
Ondanestron, Omeprazole, 
Suxamethonium, Pancuronium, 
Levothyroxine, Diaxoide, Octreotide, 
Ursodeoxycholic acid, Domperidone, 
Adrenaline, Dinoprostin, Sodium 
phosphate, Calcium supplements, 
Potassium supplements, 
Phenobarbitone, Cyclizine, Dopamine, 
Caffeine, Vasopressin, Desmopressin, 
Digoxin, Somatropin, Paracetamol, 
Atropine, Hyoscine hydrobromide  
48 15.8% 
Total   304 100% 
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Table 19: The routes of administration for small volume doses, as reported by 
questionnaire respondents  
Route of administration  All questionnaire 
respondents  
Neonatal 
respondents  
Intravenous  33.2% (101/304) 43.9% (50/114) 
Oral  29% (88/304) 27.2% (31/114) 
Subcutaneous  9.5% (29/304) 1.8% (2/114) 
Intramuscular  2.6% (8/304) 3.5% (4/114) 
Buccal  2% (6/304) 0 
Intranasal  1% (3/304) 0 
Intravenous or Oral 5.9% (18/304) 7.9% (9/114) 
Intravenous or Intramuscular  1.6% (5/304) 3.5% (4/114) 
Intravenous or Subcutaneous  1.3% (4/304) 0.9% (1/114) 
Intravenous or Intranasal  1% (3/304) 0 
Intravenous, Subcutaneous or Intramuscular  0.3% (1/304) 0 
Intravenous, Oral or Subcutaneous  0.3% (1/304) 0 
Missing  12.2% (37/304) 11.4% (13/114) 
Total small volume measurements reported  304 114 
 
4.9.8 Open-ended questions 
The questionnaire ended with open-ended questions, aiming to ascertain the views 
and opinions of the nurses undertaking the manipulations.   
Participants were asked if they took steps to avoid manipulations or to make them 
easier to achieve. 70.6% of those who completed this question (126/153) 
responded yes, with 100 participants providing further details. Of these 100: 
- 55% would consult with a pharmacist. The reasons given for this included to 
get advice, to discuss whether more appropriate preparations or doses were 
available, or to see if the drug could be extemporaneously prepared in 
pharmacy  
- 21% would consider using further dilution to allow the measurement to be 
made  
- 16% would seek changes to the prescription so that the manipulation may 
not be necessary, such as seeing if it is possible to prescribe a different dose 
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or to use dose rounding or considering if the use of another drug is 
appropriate  
- 10% would check if the drug is available in a more appropriate dose or 
dosage form  
- 4% would consult the BNF/BNFC 
- 4% would consult hospital based documents/intranet  
The second open-ended question asked respondents if they had any concerns 
about the manipulations to obtain the required dose. 53.6% (82/153) chose to 
complete this question. Of these the largest group of respondents, 31 (37.8%), were 
concerned about the accuracy of the manipulated dose. Other concerns mentioned 
by respondents included those relating to possible errors in calculations for 3.7% 
(3/82), difficulties with getting some products to disperse for 3.7% (3/82), and 
concerns about the measurement of small doses or the impact of the dead space in 
syringes for 4.9% (4/82). Respondents also used this question to mention other 
aspects of manipulation. 20.7% (17/82) noted that they used colleagues (nurses, 
doctors, pharmacists) to consult with and the importance of this support. The 
importance of documentation such as guidelines, protocols, procedures, policies as 
reference sources was highlighted by 7.3% (6/82) of those who answered this 
question.  
Finally respondents were asked for any additional information that they would like 
to give. Ten respondents chose to add comments. These mainly echoed points 
found in the data from the previous question about concerns they had, with 
comments relating to the need for clear guidance, difficulties with dispersing 
tablets and the importance of consultations with pharmacists. There were two 
further comments from respondents who worked in district general hospital 
children’s wards. They considered that they had difficulty in obtaining paediatric 
medications as they were not working in a children’s hospital.   
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4.10 DISCUSSION  
4.10.1 Questionnaire design  
The use of ward/unit managers to distribute the questionnaire preserved the 
distance and anonymity between the researcher and participant while still allowing 
for personal distribution. Anonymity was assured for respondents; potential 
respondents were not contacted by researchers to request participation and they 
were asked no personal details beyond establishing the type of clinical area they 
worked in, their qualifications and the town/city that the hospital they worked in 
was based. This aimed to ensure the validity of their questionnaire responses. The 
administration of the questionnaire within a work place environment would help 
facilitate the recall of work based data. This relied on the managers to distribute 
the questionnaires and may have impacted on the response rate as the completion 
of a questionnaire may be a low priority in a busy clinical area. The 153 
questionnaires returned enabled the exploration of the aims of this survey. The 
pilot study and steering group had been utilised to ensure that the questionnaire 
was both comprehensible and not onerous to complete.             
The limitations associated with purposive sampling, notably the possible 
introduction of bias, are acknowledged. Furthermore it is acknowledged that 
requesting retrospective recall of data is prone to bias. While the sampling used in 
this approach precludes generalisation of the results it did ensure a range of 
neonatal and paediatric units throughout the UK were represented. Although the 
largest groups of respondents worked in neonatal or general paediatric areas there 
was a wide range of general and specialist areas represented by respondents across 
children’s hospitals, teaching hospitals and district general hospitals with 
neonatal/paediatric beds.   
Many of the studies and experts who have written on questionnaire design make it 
evident that with many aspects of questionnaire designs their impact on response 
rate and questionnaire outcomes are equivocal. Nonetheless some aspects that 
were particularly pertinent to this questionnaire were implemented. With any 
questionnaire it is necessary to refine what can and should be included. It is 
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tempting to include many aspects of the topic area; however this can have a 
negative effect on the outcomes. Therefore, although there were many aspects of 
drug manipulation that could have been explored, the priorities were distilled into a 
small number of main aims that were used in the process of developing this 
questionnaire.  
 
4.10.2 Drug manipulations reported  
There were 188 manipulations reported that were considered to provide sufficient 
detail or data that met the definitions of a drug manipulation. As had been found 
within the observational study (Chapter 3), the drugs reported as manipulated by 
questionnaire respondents were predominantly those which are liable to be 
prescribed regularly in neonatal and paediatric settings. Again it was evident that 
drug manipulations are not applicable solely to drugs prescribed for rare childhood 
conditions.   
Over 50% questionnaire respondents indicated that they were undertaking the 
manipulation they had just provided details of, on a daily basis, with a further 
almost 20% considering that the manipulation was undertaken weekly. This 
indicates that drug manipulations are a customary part of in-patient drug 
preparation and administration. Yet outcomes from the systematic review chapter 
(Chapter 2) revealed that there are substantial evidence gaps relating to drug 
manipulation.   
Manipulations of tablets, sachets, capsules, nebuliser solutions, transdermal 
patches, suppositories, enemas and intravenous drugs were reported by 
questionnaire respondents. As anticipated, tablets were the most frequent 
representing 45.7% of those reported, with 11.7% for intravenous drugs and 
nebuliser solutions, 10.6% transdermal patches, 8% capsules and suppositories, 
3.2% enemas and 1.1% sachets.   
Comparison of the drugs manipulated from the observational study and the 
questionnaire found that there were 24 drugs found to have been manipulated in 
147 
 
both studies; while 30 drugs were reported only in the questionnaire and 29 found 
in the observational study but not in the questionnaire. Of the 53 drugs found as 
manipulated in the observational study 7 were noted only once; similarly with the 
54 manipulations described in the questionnaire 7 were noted only once. Six of the 
drugs that had been included in papers within the systematic review were 
manipulated in the observational study (aspirin, enalapril, furosemide, lisinopril, 
oxybutynin, and warfarin) and four were manipulated in the questionnaire (aspirin, 
captopril, lisinopril, nifedipine). Both the observational study (Chapter 3) and this 
questionnaire took a cross-section of the drugs that were currently prescribed in 
the included clinical areas. As the questionnaire responses required retrospective 
recall it was not expected that it would return a complete list or even complete 
information on individual manipulations. These studies did not aim to provide a 
comprehensive list of manipulated drugs but to explore the scope of drug 
manipulation. The number of drugs that were identified as having been 
manipulated on only one occasion suggests that there are likely to be other drugs 
that require manipulation. Nevertheless what the outcomes from both this 
questionnaire and the observational study show is that there are evidently a variety 
of drugs being manipulated in practice. Consideration is needed to decide which of 
these should be prioritised for future research, for example should there be a focus 
on those with a narrow therapeutic index or on those that are most frequently 
manipulated.  
For many of the manipulations the doses required were either half, a quarter or 
three quarters of the original complete dose of the single dose unit. However, there 
were a number of manipulations where other proportions were required. For the 
intravenous manipulations proportions from 0.7% to 70% of the dose in the vial 
were required. Dose calculation errors have been highlighted as a substantial cause 
of drug errors. This combined with what appears to be piecemeal local access to 
supportive guidance documentation may increase the risk of drug errors occurring 
alongside drug manipulations. Variation in the proportions required may add to 
errors with differing doses being calculated from the original dose.  
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One suppository and no enema manipulations were observed during the 
observational study (Chapter 3). The one study Kim et al. (2005) included in the 
systematic review (Chapter 2) which considered suppositories did not stipulate how 
that manipulation was done. These outcomes raised the question as to whether 
these dosage forms are not manipulated or if they are but there is a lack of 
information about them. Almost half of the questionnaire participants considered 
that suppository and/or enema manipulations were not applicable in their practice. 
Thus more questionnaire respondents considered that these manipulations were 
applicable to their practice than did not. So although they may occur less frequently 
there are drugs in these dosage forms that are manipulated. There were 15 
suppository and six enema manipulations reported. The results of this 
questionnaire suggest that there is a lack of standardisation in practice. Of the 
respondents who would manipulate suppositories 61% would cut them 
longitudinally and 39% transversely, while with those who would manipulate 
enemas 66% would discard a portion and administer the remainder, 20% would 
administer the required portion and discard the remainder and 12% would 
withdraw the required portion from the pack and administer. The evidence base for 
this practice is known to be lacking and there is an inconsistent approach to the 
manipulation of these dosage forms. This raises further questions both about how 
these manipulations should be undertaken or if they should be being carried out at 
all? If these dosage forms are to continue being manipulated then how they are 
carried out needs to be further considered, with an aim of standardising practice. 
Similar inconsistency was found with the manipulation of transdermal patches, with 
65% reporting that they would cut a segment from the patch and 27% that they 
would cover a segment. Again methods of manipulating these patches need further 
consideration and practice standardised. 
 
4.10.3 Reasons for drug manipulations occurring   
Outcomes from the observational study (Chapter 3) found that there are occasions 
where manipulations may be undertaken that are not necessary. There may be an 
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alternative preparation available which does not require manipulation. Patient 
preference for a halved tablet over an oral liquid was noted. Either a lack of access 
to the alternative preparation when required or the usual practice being to 
administer the manipulated medicine were also suggested as reasons why 
medicines may be manipulated where alternatives are available. This questionnaire 
further investigated this. Patient preference was given as the only reason or among 
the reasons for manipulation in 11% of the manipulations described by 
questionnaire respondents. All of these manipulations were of tablets, representing 
almost a quarter of the tablet manipulations reported. With 15% of the tablet 
manipulations patient preference was the only reason given for the manipulation. 
There has been little work previously completed on the preferences of children on 
how they take their medicines. Palatability reviews have noted that assumptions 
about children have been made using adult based data or based on very limited 
evidence (Davies and Tuleu, 2008). Reviewing what has been previously written 
about the ability and age at which children can swallow tablets shows little 
consensus (Yeung and Wong, 2005). Liquid based preparations may be easier to 
swallow but these outcomes suggest that there may be a preference from some for 
tablets, even where a proportion of them are required. Skwierzcynski and Conroy 
(2008) noted that though liquid preparations may be available they are not always 
of a useful strength. It may be that the focus on developing liquid formulations may 
be appropriate for many drugs and the preferences of the majority of children, or it 
may be that the focus should be more on the development of solid dosage forms 
that are acceptable to children. The production of various products of the same 
drug that meet the differing preferences of children may not be reasonable for 
many drugs. It needs to be acknowledged that drug manipulations may occur to 
meet patient preference. Nonetheless the lack of a suitable preparation or 
strength, cited by 75% of respondents, remains the predominant reason for the 
drug manipulation.   
For 31% of the manipulations described usual practice was included as one, or the 
sole, reason for the manipulation. Usual practice was the sole reason given for 12% 
of the manipulations, this included tablet, intravenous, transdermal patch, capsule, 
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sachet and suppository manipulations. While usual practice may be a logical and 
reasonable approach to some practice it does raise the question of how much this 
is accepted and whether usual practice should be questioned more. Nilsen et al. 
(2012) reviewed the role of habit in clinical practice, they considered that much 
clinical practice occurs in stable healthcare contexts and can be assumed to be 
habitual, making it unlikely to be spontaneously reconsidered. There is a current 
substantial emphasis in healthcare on the use of evidence to base decision-making 
on. This emphasis may encourage more spontaneous questioning of clinical 
behaviour that may be due to usual practice, as these questionnaire responses 
suggest that some drug manipulations are. This further reinforces the need for the 
provision of and the regular revision of existing policies 
 
4.10.4 Reference documentation  
Consideration of the sources of supportive information used by nurses undertaking 
manipulations revealed that a substantial proportion (around 40%) either did not 
have access to, or did not know if they had access to, relevant local documentation 
(policies, guidelines, procedures or worksheets). Those working in neonatal areas 
had more access to supportive documentation with 88% reporting that they had 
access to local documentation. This may be related to the considerable use of 
intravenous drugs in this area as with intravenous injections there is drug policy 
documentation available in most hospitals. 
This lack of local supportive documentation is concerning as nurses who returned 
this questionnaire principally reported that they access the BNF/BNFC if they 
consulted any reference source prior to manipulating a medicine. As described 
previously (Chapter 1) many of the medicines given to babies and children are 
unlicensed or are being used off-label. Even where the original medication may be 
licensed for use in children, manipulation will often not be recommended by the 
pharmaceutical company. Therefore sources of information available to healthcare 
professionals for the licensed use of medicines, for reference purposes, may not be 
applicable. Those who prepare the BNFC note that many drugs used in children are 
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used outside their licence and may not have been studied in adequate detail in 
children. The BNFC includes information on drugs when there is sufficient evidence 
for the drug to be considered relatively safe and effective in children 
(http://www.bnf.org). However for some drugs information is very scarce and their 
use may be limited to specialist centres, by clinicians with specialist expertise and 
knowledge of these drugs. In such cases, until the evidence is better established, 
the BNFC omits information about the drugs (http://www.bnf.org). Therefore for 
some manipulations, the BNFC may be an appropriate and useful source of 
reference. It is likely that for others the required information may not be available. 
This may mean that there is more reliance on local documentation which makes it 
more of a concern if such documentation is not available or when there is a lack of 
awareness of what is available.     
 
4.10.5 Measurement of small volumes  
This questionnaire has identified that there are a considerable number of drugs that 
those working in neonatal and paediatric practice consider they measure in doses 
of <0.2mL. This was not initially included within the investigation of the 
manipulations but arose during the quantitative review of prescription data that 
was completed concurrently with the observational study. A recent study of 
paediatric drug administration identified that 7.4% of 71 218 intravenous doses 
evaluated required less than 0.1mL of drug to be measured (Uppal et al., 2011). 
Previous studies have shown that the accuracy of small drug volumes drawn up by 
clinical staff is inconsistent (Parshuram et al., 2008; Isaac et al., 2010). Proposed 
reasons for this inconsistency include inaccuracies in the equipment (Bhambhani et 
al., 2005; Erstad et al., 2006) and human error (Taxis and Barber, 2003a;2003b). The 
answers to the open question asking for examples of small volume measurement 
indicated that this measurement may go beyond intravenous injections with several 
other routes of administration also mentioned. Further consideration is needed as 
if the measurement of these small volumes is inaccurate and/or inconsistent then 
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there is the risk that the dose of drug administered to a child following the 
measurement of a small volume may be inaccurate.   
 
4.10.6 Concerns about manipulations  
Comments were made by nurses during the observational study (Chapter 3) that 
had illuminated some concerns that they may have about manipulations. Although 
these comments had been noted, the question relating to concerns was designed 
as an open-ended one so that all possible responses could be represented and that 
there could be no risk of influencing the answers. It is accepted that those who 
choose to answer open questions may not represent all respondents (O’Cathain 
and Thomas, 2004). The chief concern reported by nurses related to the possibility 
that the dose that is administered following the manipulation is not accurate, that 
the manipulation did not successfully achieve the desired proportion of the original 
dose. Other concerns described included the risk of dose calculation errors, the 
measurement of small doses and the difficulties with dispersing some drug 
products. That there is awareness of possible dose inaccuracies shows that though 
manipulations may be an accepted feature of paediatric practice they are not 
instigated without thought about the outcomes. What are perhaps notable are the 
other possible consequences that were not mentioned, such as the effect that a 
manipulation could have on efficacy or any potential changes in adverse effects of a 
manipulated drug. A survey on off-label prescribing among GPs found that 50% of 
respondents were concerned about the lack of paediatric dosage information and 
appropriate formulations (Ekins-Daukes et al., 2005). As with the respondents to 
this questionnaire there was a lower rate of concern about other aspects of this 
with 15% reporting specific concerns about side-effects or unevaluated efficacy 
(Ekins-Daukes et al., 2005).           
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4.11 CONCLUSIONS      
That drug manipulations are a feature of clinical practice has been established. This 
questionnaire study provides insight into the nature of drug manipulations. These 
do not solely involve tablets, the dosage form at least discussed if not methodically 
investigated in previous research, but are found across all dosage forms. 
Furthermore manipulations are a usual feature of practice with over half of those 
describing manipulations having noted that these were events that they undertake 
daily. However, supportive or reference documentation on conducting drug 
manipulations is often lacking. This questionnaire has revealed several areas for 
future research. These include; consistency in the practice of manipulating 
suppositories, enemas and transdermal patches; that manipulations may occur for 
reasons other than the lack of the required strength of the drug, and the 
measurement of small volumes.  
This questionnaire study and the observation based study (Chapter 3) have 
described the range of the use of drug manipulation in paediatric in-patient 
practice. The results of these studies have been published (Richey et al., 2013).  
However, for many children taking medications will be based at home. Therefore in 
investigating drug manipulations and identifying areas for future research it is 
important to consider manipulations that will be undertaken in the community 
setting.     
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CHAPTER 5: PARENT STUDY  
5.1 INTRODUCTION   
Through the legalisation introduced by the EMA and FDA and the development of 
organisations such as the European Paediatric Formulation Initiative (EuPFI) there is 
an increasing focus on the need for appropriate paediatric formulations to be 
available. Attention needs to be given to what this means to those children who are 
actually taking the medications. This will be particularly pertinent for those children 
who are likely to need to take prescribed drugs for a prolonged period, for whom 
there is no definite end point when they will no longer need to take medications. 
The incidence of chronic illness in children has increased; approximately 14% of 
children in Britain now have some form of chronic illness (Fisher, 2011). Not all of 
these children will require long-term drug treatment; nonetheless the need to 
administer on-going medication to a child for a chronic condition is not an unusual 
occurrence. Though there may be periods spent as hospital in-patients, for many of 
these children their predominant treatment will be as an out-patient. Furthermore 
there is a shift towards providing home-based care for children with chronic illness 
(Ziaian et al., 2006). Consequently for many children the administration of the 
majority of their prescribed drugs will take place at home. For these children 
adhering to long-term medication regimens may be challenging. Dimatteo (2004) 
reviewed the role of effective communication in fostering adherence to paediatric 
treatment regimens. This author noted that paediatric chronic disease treatment 
regimens can be prolonged and stressful, and can adversely affect quality of life 
both of paediatric patients and their families. With the administration of 
medications to children at home there is reliance on both the commitment and on 
the understanding of their parents (Breatkreutz and Boos, 2007). A lack of research 
has been noted relating to the understanding of parents’ views about giving 
medicines to children. Sweis and Wong (2004) described that little is known about 
parental attitudes and the extent of their knowledge regarding medicines for their 
children. These authors further commented that the lack of knowledge is unsettling 
and a possible solution may be found through qualitative research with parents.     
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5.2 CHRONIC CHILDHOOD CONDITIONS   
The impact of having a chronic condition on children has been previously 
researched. A systematic review of qualitative studies of children’s experiences of 
living with juvenile idiopathic arthritis identified six themes. These were: an 
aversion to being different, striving for normality, stigma and understanding, 
suspension in uncertainty, desire for knowledge and managing treatment (Tong et 
al., 2012).      
Furthermore, there is widespread recognition that the presence of a child with a 
chronic condition can be a source of stress and distress among family members 
(Herzer et al., 2010). The nature and process of parenting has to be restructured to 
raise a child with a chronic health condition and this has consequences for the 
entire family (Ray, 2002). Studies that have investigated this have found many 
aspects can be affected, such as the effect on intrapersonal and interpersonal 
relationships, medicalising parents, disrupting family norms, coping strategies and 
support structures (Tong et al., 2008). Research findings have been mixed. The 
literature has highlighted the variability in family functioning across chronic 
paediatric conditions (Herzer et al., 2010). A systematic review on the needs of 
parents with chronically sick children found that, following diagnosis, parents 
needed to regain a version of normalcy, required information regarding their child’s 
condition, and wanted to be regarded as partners in the care of their child (Fisher, 
2001). For many families living with a child with a chronic condition uncertainty is a 
constant, even if the disease is under control or in remission parents know this can 
change (Cohen, 1995).   
Studies have often not addressed any medication-related issues or considered the 
methods used to administer medications at home to children. While many studies 
have considered the impact of treatment, especially in relation to the need for 
knowledge and information (Tong et al., 2008; 2012), they have not actually 
addressed administration or have reviewed administration only in the context of 
non-adherence (Schultz et al., 2012). A study that addressed supporting parents in 
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managing drugs for children with cystic fibrosis had to draw on studies with 
informal carers of adults to review problems that have been experienced with 
medication-related activities (Slatter et al., 2004). A model was developed around 
family-centred models of care-giving for children with chronic illness or disability 
and medical care was one of its six major sections (Ray, 2002). This medical care 
section included technical aspects (such as tracheostomy care or gastrostomy use) 
and symptom control but did not feature any reference to drug preparation or 
administration. Walsh et al. (2011) noted that there has been little attention paid to 
medication errors occurring in the home and they investigated this in parents of 
children with sickle cell disease and seizure disorders. They concluded that home 
visits and observation highlighted the complexity of the home medication use 
process and the numerous ways things can go wrong, such as medication 
preparation problems, and communication failures in the doctor’s office and at 
home. This study also found that parents would sometimes alter the technique for 
administration from what the physician had told them to do either because they did 
not have the proper equipment at home or because the technique they were told 
to follow did not work at home (Walsh et al., 2011). These authors concluded that 
systems for medication use at home are complex and error prone and that indeed 
they may be more error prone than systems in the hospital.   
Where the support needed by parents in managing drugs for children with cystic 
fibrosis was considered it was found that medication was described by parents as 
conferring a degree of ‘controllability’ to a disease and a certain amount of 
protection (Slatter et al., 2004). This was considered to be balanced with more 
negative views, such as concerns about side-effects, some distrust of the 
medication, practical problems (such as unpleasant taste), problems of obtaining 
supplies, sheer quantities of medications and time-consuming regimens. Overall the 
benefits were commonly perceived to outweigh the concerns (Slatter et al., 2004).  
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5.3 MEDICATION ADHERENCE  
5.3.1 Medication adherence – general   
Adherence involves the accurate observance by a patient of a prevention or 
treatment regimen set out by a health professional (Dimatteo, 2004). Medication 
adherence refers to the degree to which the medications taken reflect the 
prescriber’s intention (Dean et al., 2010). Non-adherence to medicines is known as 
a substantial difficulty within all aspects of healthcare with an obvious potential 
impact on the efficacy of treatments, poorer patient outcomes and the use of 
scarce healthcare resources (Dean et al., 2010; Clyne et al., 2012). Poor adherence 
to medication regimens is considered to be a common problem with life-
threatening disorders (Zindani et al., 2006). With chronic conditions the long-term 
maintenance of adherence is critically important as disease management maybe 
life-long and can pervade every aspect of daily life (Dimatteo, 2004). Reasons given 
for poor adherence include extended treatment duration, multiple medications, 
and periods of symptomatic remission (Gardiner and Dvorkin, 2006). Much of the 
evidence and most existing reviews on adherence has been derived in adult 
populations (Dean et al., 2010; WHO, 2010). In describing medicines adherence in 
Europe, (Clyne et al., 2012) reflected that there are numerous gaps in knowledge 
about reasons for non-adherence (both intentional and non-intentional) and 
evidence of how to reduce non-adherence remain elusive. Costello et al. (2004) 
noted that with the advances in medical therapeutics during the past two decades 
it seemed reasonable that non-adherence studies or research on effectiveness 
strategies would flourish. However, Gardiner and Dvorkin (2006) considered that, 
on the contrary, the literature concerning interventions to improve medication 
adherence remains surprisingly weak, and that this contrasts with the rigor applied 
to drug trials.     
 
5.3.2 Medication adherence – children   
Adherence to medicines in children provides particular challenges, requiring both 
compliance from the child and a committed parent or caregiver (WHO, 2010). 
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Estimates of non-adherence or non-compliance range from 25% to 60% of children 
or adolescents, figures considered to be greater than those reported in adults 
(Costello et al., 2004). Reasons suggested for non-adherence within children include 
an inability to swallow tablets, an aversion to taste, feeling unwell and subsequent 
refusal to co-operate (WHO, 2010). Other reasons that have been suggested 
include the influences of parents, such as parents’ lack of understanding of the 
diagnosis, concerns about drug therapy effectiveness, and fear of medication side 
effects (Gardiner and Dvorkin, 2006).       
Where adherence has been investigated in children studies have focused on 
whether or not the medication was taken. The impact of achieving adherence has 
not been considered. Furthermore, any actions that may mean that the medication 
has not been taken as it was designed to be taken have not been investigated. 
These actions include the use of drug manipulation, or the addition of the 
medication to food or drinks. Where these have been considered it has tended to 
be a feature of general discussion.   
 
5.4 PALATABILITY  
5.4.1 Palatability – general   
Palatability is likely to have an effect on adherence to medication regimens. The 
ability to take medicines and/or palatability of the medicines may be particularly 
relevant where they are used in the treatment of long term conditions as this may 
impact medication adherence (Standing and Tuleu, 2005). Palatability of paediatric 
oral medicines is considered to be crucial in influencing adherence to therapeutic 
regimens and consequently therapeutic outcomes (Cram et al., 2009). Though it 
should be remembered palatability can be affected by more than taste as 
somatosensory modalities such as touch, temperature, appearance and perhaps 
most importantly smell may be significant (Davies and Tuleu, 2008).  
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5.4.2 Palatability – children   
A literature review on interventions to improve the use of medicines in children 
found that evidence specific to paediatrics is limited and considered that available 
compliance and adherence studies were insufficient to allow conclusions to be 
drawn (Costello et al., 2004). This review noted that ensuring that the child has a 
convenient, palatable, easily administered medication with minimum effect on 
lifestyle is intuitively attractive, but the contribution of various influences on this 
requires further study. Furthermore, Ziaian et al. (2006) discussed that studies on 
health related quality of life, in patients with chronic conditions, have largely 
focused on the relationship with clinical status alone and have not considered the 
relationship with treatment time and treatment hassle. 
Difficulties with the palatability of medicines and/or with the child’s adherence to a 
medication regimen can put parents in a problematic situation. Their wish to ensure 
their child takes their prescribed medications may be in conflict with their sympathy 
for their child’s preferences. Parents may deploy a range of strategies to ensure 
that the medication is taken. However, the practical ways that parents deal with 
this problem have not been described. This current study, by considering the actual 
process of drug administration and drug manipulation, will add to previous work 
relating to children and add to the discussion on methods of improving adherence.   
 
5.5 DRUG MANIPULATION  
With the manipulation of drugs to obtain the dose required for administration to 
children there has been a decision made to perform a manipulation. If the 
manipulation was not done then the child would either not get the prescribed drug, 
have an inappropriate (potentially either less effective or harmful) dose or have a 
different (possibly less appropriate for the purpose required) drug. There may be an 
effect on the efficacy and a risk of changing side effects with manipulating a drug, 
but these are balanced against the need for the child to receive the drug. It has 
been assumed in all of these considerations that the drug will be actually taken by 
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the child. What actually occurs within the home situation, where long-term 
medications are prescribed for children, is unknown.   
There are no published reports about how parents describe manipulations, how 
they are supported (or not supported) by health care professionals or about the 
impact of manipulations.   
 
5.6 STUDY OBJECTIVES   
There is a lack of paediatric drug related research; specifically that work that has 
investigated children with chronic conditions has not investigated any impact of the 
ongoing medication regimens. Therefore, this study will be exploratory, and in 
considering the administration of drugs to children by their parents/carers, will help 
to clarify areas that may be appropriate for future research.     
This study aims to explore the methods parents/carers use to assist them to 
administer medications that are being prescribed for long-term use to their 
child/children. This will include where the child may be reluctant to or has difficulty 
in taking the medicines and where manipulation of the medications is required to 
get a dose which is a proportion of the dose in the intact dosage form.  
This will include exploration of the following issues relating to taking long-term 
medication: 
 skills/methods developed to administer medicines 
 issues relating to the ability of the child to take medicines, including dosage 
form preferences  
 where manipulation is required; 
- how it is undertaken 
- the issues that parents have relating to the manipulation 
- any supportive information or advice that was helpful or would have 
been helpful if given 
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 relationships with any HCPs which may have proved beneficial, who advice 
is sought from, and the type of advice which proved useful 
 any effect on the child/parent relationship 
Approaching parents to investigate how they undertake manipulations, and their 
views on them, provided the opportunity to additionally explore how they 
administer medicines to their child. This allowed the framing of manipulations 
within the real-life context that occurs for children and parents, that is that if drugs 
are being manipulated by parents then this will be within all other medicine-related 
aspects of their child’s condition.   
 
5.7 PARTICIPANTS AND RECRUITMENT  
5.7.1 Participants  
Children cannot be treated as a homogenous group. Varying developmental 
capacities of children and adolescents may influence medication adherence (Dean 
et al., 2010). Adolescents have psychosocial and lifestyle issues, adolescent non-
adherence has to be seen in the context of adolescent development (Rianthavorn 
and Ettenger, 2005). The differences between younger children and adolescents 
have been acknowledged in previous studies, such as where adherence to 
treatment in cystic fibrosis was considered using two groups, those less than 12 
years old and those 12 and over (Zindani et al., 2006). Their analysis showed that 
there was a non-significant higher rate of adherence with the younger group. It has 
been intimated that while solid dosage forms are more accepted by older children, 
that younger children and their carers tend to prefer liquid formulations (Cram et 
al., 2009).      
Previous work has suggested that drug manipulation occurs across all ages of 
children (Skwierczynski and Conroy, 2008) and the outcomes of the observational 
study (Chapter 3) have supported this. Nevertheless it was important to select the 
age of children to be included in this study. Adolescents were excluded in 
recognition of the differences between them and younger children. With the 
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changes that occur in this age-group adolescents, as a group, should be considered 
separately. Children of primary-school age were included as, at this age, the child 
will be able to express opinions about taking their medications but will be 
predominantly reliant on their parents/carers. Children’s use of medicine at this age 
is still controlled by their parents (Hameen-Anttila et al., 2011). According to 
observation and previous experience the medication intake of those younger than 
twelve was expected to be supervised closely by their parents (Zindani et al., 2006). 
Studies have indicated that when considering any issues relating to the 
administration of medicines to younger children that parental/carer involvement 
within any research is imperative (Matsui, 1997). The involvement of carers in the 
management of medication potentially introduces a third party to the consultation 
who have their own, and differing views regarding the need for medication (Slatter 
et al., 2004). Children are in a unique situation, in that they are dependent on their 
parents for medication administration, but can display oppositional behaviour 
when medication is being delivered (Schultz et al., 2012). Therefore, the current 
study involved interviews with parents/carers of primary school aged children 
where the child (or children) requires long-term medication.  
As has been used previously (Ziaian et al., 2006), to ensure the focus is on chronic 
rather than acute management; all children had their condition for at least one year 
prior to the study. Furthermore all of the children had to be taking medications 
orally, those having medications administered via nasogastric or gastrostomy tubes 
were excluded. Those who are having medications administered in this way may 
well require manipulated medications; however this group are liable to have their 
own specific manipulation related circumstances and merit their own investigation.    
 
5.7.2 Sampling   
Purposive sampling was used to identify potential participants. This study aimed to 
act as an initial exploration of this area; as such it does not make any claim to 
representativeness. Participants were selected on their ability to provide data 
relevant to the area under investigation. This approach to sample recruitment will 
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provide rich data that addresses the research objectives (Horsburgh, 2003; Shaw et 
al., 2006).   
Potential participants were identified by the clinical teams reviewing them at 
rheumatology and renal out-patient clinics in a specialist tertiary children’s hospital. 
These particular clinics were selected as they are likely to include children who have 
considerable medication needs and are often managed predominantly on an out-
patient basis (this was confirmed following a discussion I had with a paediatric 
consultant). They were asked to initially approach parents/carers, describe the 
study to them and provide them with information leaflets. These parents were then 
contacted, invited to ask any questions about the study and asked if they wished to 
participate. Parents were offered their choice of interview location either at home 
or at the hospital; all chose to be interviewed in their own homes.      
 
5.8 METHODS  
This study used semi-structured interviews. This allowed for a core set of topics to 
be used in the interview with the flexibility for the exploration of additional topics, 
experiences and perceptions that may arise during the interview. I devised an 
interview prompt guide (Appendix 5) for the interviews that was reviewed by 
clinical and research experts. This guide was also reviewed during the study as part 
of the process of constant comparison (see section 5.10.2). This allows for the 
exploration of topics that arose during the analysis, as described in previous studies 
using this method, such as (Shilling et al., 2011a; 2011b). I completed brief field 
notes immediately following the conclusion of each interview. These detailed what I 
considered to be the key points of the interview and any overall impressions about 
how the parents found the interview. All interview recordings were transcribed 
verbatim for analysis, transcription undertaken externally.   
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5.9 ETHICAL APPROVAL   
I applied for and obtained ethical approval for this study was provided by a UK 
National Health Service research ethics committee (NRES Committee West 
Midlands - The Black Country, Rec Reference 12/WM/0267). Written informed 
consent, including consent to be audio-recorded, was obtained from all participants 
prior to their interview. The protocol and interview prompt guide for this study 
were reviewed and approved by the Alder Hey NHS Children’s Foundation Trust 
research review committee (Reference: 12/24/RE).   
Participants were assured of the confidentiality of the interviews and that they 
could withdraw from the interview at any time. Though participants were identified 
through their child’s attendance at out-patient clinics they were assured that the 
interviewer was entirely independent of the clinical team and that their interview 
responses would be treated confidentially.   
As the interview centred around drugs prescribed for the child involved, it was 
possible that interviews could reveal that these were not being administered. It was 
agreed within the ethics approval that if the interviewer had any concerns relating 
to this then these would be discussed with a paediatrician, who was independent of 
the child’s clinical team, and a judgement made about safeguarding.   
Following explanation of the study and an invitation to ask any questions, 
participants were asked to sign an informed consent form that included consent to 
audio-record the interview.   
Parents were provided with the choice of whether to be interviewed at home or in 
the hospital research unit. The hospital lone worker policy was consulted and 
followed for all home-based interviews. This involved ensuring that a member of 
hospital research staff was aware of the time of the interview and the address that 
it was occurring at; I then contacted this person following completion of the 
interview to inform them that it had been completed.   
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5.10 ANALYSIS  
5.10.1 Rationale for the approach used  
Analysis was based on the principles of the constant comparative approach. 
Constant comparative analysis was originally an integral part of grounded theory, of 
Glaser and Strauss, as part of theory development, with emergent categories 
forming interrelations that ultimately form the emerging theory (Thorne, 2000; 
Bowen, 2008). Constant comparative analysis comprises four stages; comparing 
incidents applicable to each theme that emerges from the data, integrating themes 
and their properties, delimiting the theory, and writing the theory (Bowen, 2008). 
The comparing and contrasting of categories to see how they cluster or connect 
together helps to build, densify and saturate the categories and is a vital step in 
forming the scaffolding in the final substantive theory (Coyne and Cowley, 2006).     
Some qualitative analytic strategies have taken an approach using the principles of 
constant comparative analysis. Though constant comparison is associated with 
grounded theory, these other strategies draw from this analytic strategy to create 
knowledge that is generally descriptive or interpretative, this has been used in 
areas such as coping with cancer, or living with illness (Thorne, 2000). Studies using 
the constant comparison principles of analysis involve systematic coding 
procedures. Open codes serve to reduce textual data into manageable groupings, 
these are checked and rechecked across the data, codes are clustered into 
substantive categories that are compared across interview transcripts. There is 
continual comparison of newly gathered data with the codes that have been 
developed (Bowen, 2008). This procedure does not aim to generate theory but uses 
the constant comparative approach to develop categories from the data. This type 
of constant comparative approach has been used to continuously compare the 
views and experiences of respondents. Where the purpose is to generate 
knowledge about themes within the human experience this process compares each 
new interview or account until all have been compared with each other (Thorne, 
2000).     
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The use of constant comparison goes beyond content analysis to develop nuanced 
descriptions of the lived experience (Hsieh and Shannon, 2005). This type of 
analysis has been used to explore aspects of healthcare, such as in investigating 
ventilator-dependent children and adults (Dybwik et al., 2011), the use of 
complementary therapy by patients and parents of children with asthma (Shaw et 
al., 2006), or the impact of treatment demands on the patients and siblings of those 
with cystic fibrosis (Foster et al., 2001).      
Specifically in relation to children and their medicines, this method has been 
effectively used as part of a project that considered parents’ experiences of their 
child’s suspected adverse drug reaction (Arnott et al., 2012a) and enhancing 
parental participation in pharmacovigilance (Arnott et al., 2012b). This method has 
also been used to investigate the recruitment to randomised controlled trials 
involving children (Shilling et al., 2011a) and parents’ experiences of their child’s 
presence in discussions with physicians about leukaemia (Young et al., 2011).      
These studies exemplify the use of constant comparison principles, the continual 
review of data and emerging analysis throughout the study process. This does not 
lead to theory development as it would where grounded theory was being used. It 
does however provide detailed description and analysis of the views and 
experiences of those involved.  
Within healthcare research using a constant comparison approach through this 
cycling between the data and analysis through discussion can allow the developing 
analysis to also be judged on catalytic validity (Wright et al., 2004). Catalytic validity 
is that the analysis should not merely describe, but should have the potential to 
influence and change practice or research (Wright et al., 2004; Salmon et al., 2007; 
Arnott et al., 2012a). As observed by (Arnott et al., 2012a) where the aim is to 
inform practice and the methods applied should fit with this aim and the criterion 
of catalytic validity.  
Within these studies the analysis followed the general principles of the constant 
comparative method and was informed by several steps to ensure its quality. 
Within this parent/carer study analysis I followed these methods with specific 
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reference to those studies which included interviews with parents (Arnott et al., 
2012a; 2012b).   
 
5.10.2 Approach used in this study  
I entered the verbatim transcripts of the interviews and field notes recorded 
immediately following the interview were entered into NVivo 9, qualitative data 
analysis software, for analysis. Initially analysis was commenced through the 
repeated reading of transcripts, though I had completed the interviews this 
approach ensured in-depth familiarity with the interview data and assisted with the 
development of the coding process. Subsequently the coding process was 
developed. Initially through line-by-line open codes, this process provided a large 
numbers of initial codes that were then refined into broader more substantive 
categories. These codes were continually compared across each interview 
transcript and between interview transcripts. This comparison provided a 
framework for further categorisation into smaller and more specific coding 
categories which aimed to reflect the interview data. It ensured that similarities and 
differences across the transcripts could be recognised. The coding and subsequent 
comparison within and across categories was reflected on by clinical and research 
experts (Dr MA Turner and Professor AJ Nunn). A process of ‘cycling’ between the 
developing analysis and new data was used; this was refined and tested by periodic 
discussion with these experts. This discussion of the developing analysis helped to 
confirm and refine the categories. This discussion also provided the means to 
challenge and reform categories as new interview data was analysed. Quotes that 
correlate to the categories that arose through the analysis are used to illustrate 
these during the results. General issues relating to children requiring long-term 
medication were identified alongside the specific drug manipulation related issues. 
Though initially analysis focused on the participants’ accounts this progressed to 
interpreting the accounts and considering what they chose to focus on in their 
responses. The use of an interpretative view will allow for consideration of not only 
the content of the data but the overall focus of what participants viewed as 
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significant for them. The field notes recorded following the interviews were 
referred to further when reflecting on the context of the interview and the areas of 
medication administration that the parents considered important to them.        
In an area such as drug administration and manipulation for primary school aged 
children this exploration will provide a valuable insight both for those working 
within drug development and health care professionals. 
 
5.11 RESULTS   
Seven interviews were completed; all participants choose to be interviewed at 
home. I undertook all interviews which were between 24 and 67 minutes duration, 
with an average interview length of 39 minutes.     
This study aimed to approach parents/carers and stated no preference as to 
whether mothers, fathers or both were being invited to be interviewed. Six of the 
seven interviews were with mothers, with one interview involving both parents. In 
one case the father had been the one initially approached by the clinical team but 
he deferred being interviewed to his wife. There were eight children involved; in 
one interview the parent had twins both of whom had a chronic condition. The 
children of the parents interviewed comprised four boys and four girls and ranged 
across the primary-school age spectrum (Table 20). 
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Table 20: Details of the diagnosis of the children of the parents interviewed    
Interviews Diagnosis (as described by parents 
during the interview) 
Sex Current 
Age 
Age at 
diagnosis  
Interview 1 Systemic juvenile onset arthritis  Female  10 years  5 years  
Interview 2 Juvenile idiopathic arthritis  Female  5 years  2 years  
Interview 3 Polyarticular juvenile rheumatoid 
arthritis  
Female  10 years  3 years 
Interview 4 Juvenile idiopathic arthritis Male  8 years  5 years  
Interview 5 Renal transplant, registered blind, 
thalassemia  
Male  11 years  Birth  
Interview 6 Neurological condition secondary to 
cardiac arrest, hemophagocytic 
lymphohistiocytosis (HLH) 
Female  7 years  6 years  
Interview 7  Cystinosis  Male – 
twins  
9 years  6 years  
   
5.11.1 The overall impact of having a child requiring long-term medication  
It was evident from parents that the uncertain and probably on-going nature of 
their child’s condition has an impact on both their child and on them. They 
accepted that, in many cases, their child’s condition could be unpredictable and 
long-term.   
“Well no-one can give us a guarantee; if anyone could give us a guarantee 
then we would be able to tell her exactly what’s happening” (Int 2) 
“I don’t know we just take everyday as it comes to be honest. That’s just the 
best thing to do that’s the only way you can do it because you get things 
thrown at you every so often” (Int 7) 
The consequences of their child’s condition and their medication requirements 
pervade many aspects of everyday childhood. This can be seen when parents 
described issues that they have had to think through and discuss with their child’s 
school.  
“A lot of schools won’t give them medications will they while they are at 
school.  So I was running over to the school and having to give her 
medications” (Int 1) 
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“because of her compromised immune system you have got to be very 
careful about being around people who have had chicken pox or measles 
and I am really worried that I do actually need to go to school and make sure 
they are fully aware”  (Int 2) 
Parents highlighted the additional stress that is caused by always having to consider 
their child’s medication, which impacts on many aspects of everyday life; such as 
when going on holiday, the child going to a friend’s sleepover or going out for the 
evening.   
“Then of course we had the issue of if she went for tea at a friend’s house 
because you give the medication at a certain time, you don’t want to start 
moving times around, so if she had gone to a party that was going on all 
evening and was having a sleepover and then of course I had to turn up to 
give her the medication” (Int 6) 
 “So I get a bit fed up with it to be honest especially when it comes to going 
out for an evening and thinking, right ok have I got those with me, and 
holidays, when you go on holiday and you have to get all your prescriptions 
sorted and your letters sorted” (Int 5)  
“It’s a nightmare!  We went to Blackpool in July, we went in a caravan and 
we had to take everything!” (Int 7) 
Additionally some of these parents had to collect prescriptions and drugs from the 
tertiary hospital pharmacy and could not access them locally. For some parents this 
required travelling some distance and was considered to cause extra and 
unnecessary frustration.     
“So every eight weeks whether [child’s name] has an appointment or not 
somebody has got to trek to the hospital to get her prescription filled and it’s 
stressful……….I don’t think whoever makes these rules up really understands 
exactly what it is like ” (Int 1)  
These persisting issues need to be managed as part of everyday life for a child and 
their parents where long-term medications will be needed.  
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Parents considered that when it comes to administering medication it is the on-
going nature that can pose particular difficulties as unlike short-term prescriptions a 
child often cannot be told of a time when they will not need to take them.  
“I think you can get away for a short period for administering any type of 
medicine sweet or foul tasting” (Int 6) 
Parents also described how the relationship that they have with their child can be 
affected by the need to administer long-term medications to them. This 
relationship has already had to absorb and sustain the implications of their child’s 
condition.      
“It is hard, as a parent it is hard, you don’t want to see them ill but then you 
don’t want to start getting them upset because they’ve got to take 
medication on top of everything else, that’s what’s hard” (Int 1)  
“You have to be openly honest with them and just try and explain it to the 
best you can for them to understand why they have to do it. Because I 
suppose in a lot of ways of being a parent you have to be cruel to be kind 
don’t you!” (Int 4)  
 
5.11.2 Issues with change  
As described above there are wide-ranging effects on family and everyday life of a 
child taking long-term medications, often combined with uncertainties about the 
future of the child’s condition. Consequently, where families felt that they had 
achieved some stability in the current situation they found changes challenging. 
This wish not to disturb the status quo that they had reached may have caused 
some of the anxiety that was described when handling changes to the medications 
that their child is prescribed; unless there were evident benefits to the change. 
Parents, at times, found prescription modifications and the attendant uncertainty 
relating to the outcomes of this change difficult. The support of healthcare staff in 
effecting the change was important.    
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“I don’t like it when you start a new medication and then they say – this 
could lead to this, that and the other and because it’s not we don’t know if it 
will lead to this, that or the other” (Int 3) 
“I was really, really upset to be honest that he had to go on another 
medication that would lower his immune system even further than it was” 
(Int 5) 
“I was really, really upset about it to be honest that he had to go on another 
medication……..she [hospital nurse]  went away and she got me loads of 
information, she got me print-outs, she got me leaflets, she got me all sorts 
of information on it and they went through it with me” (Int 6)  
Parents expressed reluctance, at times, to change between dosage forms, notably 
where they were offered solid dosage forms like capsules or tablets in preference 
to oral liquids. Though, as some parents correspondingly commented on their own 
reticence when faced with taking tablets, this may have been a factor in their 
perception that their child is unable to or is very reluctant take tablets.      
“If I was to be asked to give [child’s name] capsules, I know for a fact she 
wouldn’t be able to swallow them because of the size of them” (Int 1) 
“I could just see it being sat in her mouth for ten minutes and still not being 
swallowed………it’s a different battle whereas we know the battle with the 
oral [liquid] side of it we know how to do it quite well now” (Int 2) 
“No he still hasn’t got the gist of it yet but I don’t think it helps because I’m 
not very good with it [swallowing tablets] either” (Int 4)  
Parents expressed a need for familiarity with their child’s treatment and usual drug 
products. They described their uneasiness with the disruption that could be caused 
when the prescribed drugs were unchanged but they were faced were 
unanticipated (often seemingly unwarranted) changes in the dispensed drug 
products that they receive.    
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“I mean by that point she was quite used to the medicines and so the fact 
that it had changed and we said it was the same medicine wasn’t sitting well 
with her really” (Int 2) 
“Then they changed the packaging and they changed how you fill it up…….I 
think the last one they did it was meant to be easier……….because you’ve got 
to mix it up and you just forget, you know I’ve slept since the last time I did 
it, I can’t remember how much ” (Int 3)  
“When I got a prescription filled two months ago they had no liquid so they 
gave me tablets and I just couldn’t dissolve them…..then a week later the 
medicine was back” (Int 5) 
 
5.11.2.1 Relationship with health care professionals 
These interviews revealed that parents generally found both the relationship with 
health care professionals and the information that parents received from them to 
be constructive. The main source of support was the tertiary hospital and the staff 
who work there are most likely to be contacted. The provision of support from this 
centre was highly regarded by parents. Local services, such as general practitioner 
(GP) surgeries, were viewed as not aware enough of either their child’s condition or 
the medications they were prescribed.   
“I’ve never been sat here waiting in limbo – are they [hospital staff] going to 
ring me back?  They have always rung me back and they’ve always answered 
every question I’ve ever wanted to know” (Int 1) 
 “I remember having issues, it must have been a couple of months after 
they’d started taking it and they’d given me an emergency number for the 
Saturdays……so I phoned the ward…..they were really helpful” (Int 7) 
“It’s been a bit of a battle this year to get our flu shots sorted out with the 
GP because I’ve had to explain numerous times [child’s condition] and she’s 
on [drug name] for that and therefore her immune system is compromised” 
(Int 2)  
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5.11.3 Adjustment over time 
The chronic nature of their child’s condition provided parents with a perspective on 
how their child had adjusted to taking medications over time. There were positive 
aspects, that the difficulties with administration had become more manageable as 
the child has increased understanding of their condition. Consequently, they had 
adjusted to taking their medications. Though for some the experience was negative 
that as time passed, though the child was accepting they had to take medication, 
they were increasingly exasperated or upset by it.   
“Now that she’s older she’s got used to having what she’s got it’s kind of 
like, she doesn’t bother now, she just takes it” (Int 1) 
“He gets fed up with them, he does say to me ‘here we go again’, and I can 
understand that because I feel the same” (Int 5) 
“The longer he was on it, it became more of a battle and it would be like the 
less he would have of it” (Int 4)  
Parents considered that as their child got older and therefore could better 
understand explanations about the reason for their medications and consequently 
be negotiated with, subsequent administrations became less challenging. 
“She’s been on a helluva lot of medicines and it has been hard, but I think we 
are coming to a point now that because she is older it’s easier to explain it to 
her because she understands that bit more now”  (Int 1) 
“But she’s at that age where we were able to try and do some 
negotiation……..it sounds awful doesn’t it, she almost resigns herself to the 
fact that she has to go through all of this” (Int 6) 
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5.11.4 Administration of medications 
5.11.4.1 ‘Battle’ 
It was evident from these interviews that parents do not, by and large, find the 
long-term administration of medications to their primary-school aged child a 
straightforward process. It was clear that this is true for both the child and their 
parents. Parents described that, at times, the interaction was seen as a ‘battle’.  
“It’s just always been hard thinking how am I going to and can I be bothered 
having this battle with her for her to have this tablet” (Int 3) 
“We had a few times when we’d have to battle with him because he’s crying 
because he doesn’t want to take them” (Int 4)  
“She knew, every morning we went through this – and she’d be going – no, I 
don’t want to take it………..it was a battle every morning” (Int 6)  
Though, this challenging set of circumstances was not true for all of the children 
involved, or for all medications. 
“It was just really the [name of the medicine] that we had trouble with, all 
the others were fine” (Int 4) 
“He’s never said to me ‘Mum I’m not taking them’, I don’t know what I’d do 
if he did to be honest!” (Int 5)    
In one interview the parent did note that there were occasions where the 
difficulties with administration had meant that the child had not had their 
medication7.  
“Again sometimes with the tablets we’re just right she’s not having them 
then, because it just wasn’t worth the battle with her, the fallout from it, the 
arguing and the upset” (Int 3) 
                                                          
7
 This parent was describing a medication that her child was no longer taking so discussion with the 
independent paediatrician was not required 
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Other parents described situations with where they struggled on with 
administration until they reached a crunch point where they turned to medical staff 
and, where possible, got the prescription changed.   
“We’d got to the stage where I’d had to go to [hospital name] and say – look 
we are having a real battle and she’s now saying that the medication is 
making her sick and you know, to the point where we thought well ok let’s 
just take her off it and see how she goes” (Int 6)  
5.11.4.2 Medication administration with food/drinks 
Parents described the use of food and/or drinks to try and assist with 
administration, either to mask the taste or to make it easier for the child to take, or 
both. For some this included attempting to disguise the medication and administer 
it without the child’s knowledge. Several parents had been advised to use food or 
drinks by health care professionals though others had independently decided to 
take this approach.    
“If she knew it [the tablet in the foodstuff] was in there then there would 
have been no way she would have taken it.  I might as well have stood there 
and had the argument with her about swallowing tablets” (Int1)  
“We tried to hide it in her drink but she wouldn’t drink anything” (Int 3) 
“It was the ward……it was them that said to me – use a bit of blackcurrant or 
orange if they won’t take it” (Int 7)  
“But I really think you are left to try and work out how you can give this child 
the medicine you know, and I don’t think at any point I even thought about 
saying to the nurses – well I’m mixing it with milk, do you think that’s ok?  
You just do anything to get that medication down your child really” (Int 6)  
Though the impact of this on the foodstuffs and the possibility of making their child 
suspicious of foods they were given was a concern for some parents.  
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“She loved her yoghurts so again to put it into her yoghurts but then of 
course your concern is that she’s going to relate that yoghurt afterwards to a 
disgusting medicine” (Int 6)  
“We also have an issue about trying to hide it in food and things because if 
she found out we were doing it we felt that she’s feel betrayed by us” (Int 2)  
5.11.4.3 Palatability 
When parents were asked about medication preferences or changes that would 
help their child, there was a strong feeling that improving the taste of medicines or 
more availability of liquid medicines would have the most impact. 
“If the volume was twice as much, if she had to have 10ml but it tasted nice, 
then I don’t think we would have the same problems” (Int 2)  
“I think most of the problems with medicines is that the taste is never very 
nice and I think that’s the main thing.  The [drug name] he’ll take that so 
easily because it was a sweet medicine and it was easy to take” (Int 4)  
“It’s got to be, make it palatable for kids hasn’t it so they don’t think – ugh, 
that tastes horrible” (Int 5)  
Taste was frequently mentioned, though it should be noted that this was not the 
only sensory aspect of medications that was mentioned as onerous for some 
children. 
“We tried different flavours and one was quite a thin liquid and another was 
quite a thick liquid, and that was even worse to get down because it didn’t 
blend with the juice very well because it was a thicker texture” (Int 4)  
“She said you need the powder from the thing [capsule] ……..so they said to 
put it in blackcurrant or orange if they wouldn’t drink it because it smells 
disgusting” (Int 7)  
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5.11.5 Drug manipulations 
In six of the seven interviews parents were currently, or had previously, undertaken 
drug manipulations prior to administering medications to their child. Descriptions 
given by parents included splitting of tablets and dispersing tablets. Two aspects of 
manipulations were evident in these interviews. Firstly, the information provided by 
healthcare professionals to parents on how to undertake manipulations was not 
consistent. Secondly these parents were predominantly not concerned about 
undertaking manipulations, though several described situations where the 
manipulation could have been perceived to have been problematic, such as tablets 
crumbling when they were split.  
“If it was like half a tablet I would cut the darn thing and pray the other one 
doesn’t fly away!..........We had shattered halves so we just kind of scooped it 
in.  No we didn’t have any major problems with it” (Int 2)  
“Well I had to put it in water, obviously in a cup then I’d pour it out, 
obviously what I didn’t need and then keep what I needed in the cup and 
then pour the juice in it to give to her” (Int 1)   
“We just tend to use a kitchen knife, if I remember rightly they’ve got a little 
line in the middle so it was quite easy to cut” (Int 4)  
“I had a pill cutter from the hospital which just used to cut your tablets in 
half………fine no problem with it” (Int 5)  
“I think the knife is better than using the tablet cutter to be honest! Although 
it’s handy because it stays there then, you can keep it there for the next 
morning the other half if it doesn’t cut straight.  I cut that one yesterday and 
that’s this morning’s one, it’s in three bits” [asked if the tablet often 
crumbled this parent replied Yes!](Int 7)  
It appeared that, in general, parents did not express concerns about undertaking 
manipulations. Although, one parent did consider the possible effect of the 
manipulation on the accuracy of the dose that was obtained and subsequently 
administered.  
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“I did notice on the odd occasion that you can see the edges crumbling off so 
you hadn’t actually got a full half, you’ve got bits and pieces.  So…..it’s not 
very accurate” (Int 6)  
This parent was also the only one who described concerns about the impact of 
mixing medications with foodstuffs. 
“Well if I’m mixing it with something acidic is that having an effect on the 
medication or if she’s taking it with dairy products, again is that having an 
effect” (Int 6)  
In all of the interviews when parents were asked about manipulations they 
provided brief factual answers even when asked supplementary questions. With 
many other questions parent provided answers that were expansive and provided 
topic areas for further exploration, this did not happen when they were asked 
about drug manipulation.  
The responses that parents gave to questions about drug manipulations provided a 
clear contrast to the very thoughtful descriptions that parents gave about other 
aspects of their experiences. This is illustrated where the brief responses about 
drug manipulations are reviewed alongside other depictions that parents gave of 
the quite meticulous approach they apply to other aspects of giving their child 
medications, such as; the care that they take to measure doses accurately, 
measures that they take to ensure that their child takes all of the dose or the 
actions they take to ensure that their child gets their medication at the correct 
time.   
“I’ve crushed it up and put it underneath her cereal and then stood over her 
shoulder – ‘now come on you’ve got to eat all that’” (Int 1)  
“You know as a child you are told a teaspoon is 5 ml…….teaspoons aren’t 
5ml, ours are all different amounts.  So I tried with a teaspoon and I was – oh 
there aren’t 5ml there” (Int 2)  
“It’s quite a viscous medicine, very, very, thick, very difficult to get the 
correct measurement” (Int 6)  
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“You do watch the clock all the time when you have to watch don’t you; you 
know for 12 hours, especially with anti-rejection drugs, they have to be 
within certain timescales” (Int 5)  
 
5.12 DISCUSSION  
This study used semi-structured interviews with parents of children who require 
long-term medication. There was no preference stated as to which parent was 
interviewed. It was interesting to note that six of the seven interviews were solely 
with the child/children’s mother; the remaining interview involved both parents. 
Even where it was the father who had been initially approached, this father chose 
to pass the option of being interviewed to his wife. This has been found in previous 
studies that considered care-giver time for children with chronic conditions and 
reported that there are substantial demands on maternal time (Ziaian et al., 2006).   
The situations of the parents within this study must be viewed as directly applicable 
only to their own unique context. Nonetheless there are many aspects of the 
outcomes of this study that are likely to have relevance for other parents/carers of 
children taking long-term medications. Many of the consequences of childhood 
health problems are independent of the specific diagnosis since these children and 
care-givers experience common challenges and life experiences (Kohen et al., 
2007). It is important to establish the parental view as parents model health 
behaviours and coping skills that will establish behavioural norms for their children 
(WHO, 2010).    
Using interviews meant that it was a small sample of parents that provided the data 
relating to drug manipulations within the context of how parents administer long-
term medications to their children. However, this approach ensured that topics that 
arose during the interviews and the nuances of drug administration to primary-
school aged children could be explored. This also aimed to safeguard the honesty 
and willingness of parents to provide information as they were interviewed at 
home and not in the presence of other parents.    The interviewer had no previous 
relationship with the participants and was not connected in any way to the clinical 
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teams responsible for their child’s care. This lack of a pre-existing relationship 
between the interviewer and interviewee, and that they were unlikely to encounter 
each other again, has previously been considered to enable mothers to voice fears 
and concerns without fear of recrimination of judgement (Hodgkinson and Lester, 
2002).   
The key themes arising from these interviews were around the impact of a primary-
school age child requiring long-term medication     
 
5.12.1 Impact of long-term medication  
Parents in this study described adjustments that were required in their family lives 
to adapt to their child requiring long-term prescribed medication and the uncertain 
nature of their child’s condition. Fisher (2001) reviewed the literature relating to 
parents of chronically sick children. This author noted that it is clear that a change 
of lifestyle occurs for parents when a diagnosis of chronic illness is made and that 
health care professionals should be alert to the fragile nature of the coping 
mechanisms developed by parents. Previous studies relating to the needs/impacts 
of chronic conditions on family life have often not included medication – except in 
the context of wider treatment needs, such as physiotherapy with cystic fibrosis. 
There were a number of practical issues raised in these interviews, issues that were 
not directly related to medication administration. Many children who have a 
chronic condition will be referred to, and have their major care decisions made in, 
large tertiary centres. For some this will require travelling some distance to attend 
clinic appointments. Participants in this study expressed frustration with disjointed 
links from the hospital to their local healthcare provision particularly with the need 
to obtain the prescribed medications from the hospital pharmacy which was some 
distance from where they live. These practical difficulties have been previously 
described as disruptive by a senior nurse writing on children and anti-epileptic 
drugs who considered that having to travel to a distant pharmacy to fulfil a 
prescription may represent an important obstacle for some families (Wilmot-Lee, 
2008). The continual need to plan for their child’s medication needs, such as in 
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relation to social occasions for child or parent, or going on holiday, or in discussions 
with their child’s school was illustrated by parents during the interviews in this 
study. Parents have previously described that their child’s condition had to come 
first, that any family activities required advanced planning and there is little 
opportunity for spontaneous activities (Hodgkinson and Lester, 2002). This study 
suggests that the effect of a child requiring long-term medication goes beyond 
medication administration and can impact across other aspects of normal life 
activities.   
 
5.12.2 Issues with change and support of health care professionals 
Parents in this study appeared ambivalent where prescription changes were 
required or new drugs needed to be introduced into the regimen. The support of 
health care professionals in supporting both the medication regimen and facilitating 
change was considered important. This supports previous findings that parents 
emphasised the value of information at the commencement of new therapy (Slatter 
et al., 2004). These interviews revealed the importance of the availability of health 
care professionals from the tertiary centre; this was especially notable where 
parents had questions or anxieties that they wanted to discuss without delay. The 
use of specialist secondary care as the first point for queries, in preference to 
primary care, has been previously described when the stresses and coping 
strategies of mothers of a child with cystic fibrosis were investigated (Hodgkinson 
and Lester, 2002). The importance to the parents in this study of effective 
communication between healthcare providers and patients/families is evident. 
Children and their families need to fully comprehend what they are being asked to 
do, and should be encouraged to question both to clarify understanding and to 
provide feedback about their experiences (Dimatteo, 2004). This may have 
implications beyond ensuring that families feel well supported and able to seek 
reassurance when required. Yin et al. (2010) investigated parents’ medication 
errors and described parental errors with measuring doses. These authors noted 
the importance of clearly informing and ensuring parental understanding. Research 
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evidence supports the important role of effective communication in fostering 
adherence to preventive and chronic disease treatment regimens in the care of 
children and adolescents (Dimatteo, 2004). This interview study found that parents 
were positive and felt that overall they were well supported and informed by the 
children’s hospital health care professionals. Nonetheless there did appear at times 
to be an ad hoc approach to how they received information about their child’s 
prescribed drugs. This was particularly evident when it came to information about 
drug manipulations and the addition of drugs to food or drinks.        
Some parents did express a misgiving as to whether primary healthcare services 
had sufficient understanding of either their child’s condition or their medication. 
This reliance and trust in only the tertiary centres has been previously described. 
Parents of children with cystic fibrosis perceived their GP had less knowledge and 
some regarded their GP as an irrelevance when it came to their child’s condition 
with all queries addressed to health care professionals in the tertiary centre (Slatter 
et al., 2004). It would be interesting to consider whether this is related to the 
process of achieving diagnosis and whether parents are more trusting of the health 
care professionals to whom their child was referred who provided the diagnosis and 
possible treatment options for their child. This reliance by parents on the tertiary 
centres may be further influenced by the requirement for some to collect 
prescribed drugs only from this centre with no more localised availability.       
  
5.12.3 Administration of medications  
Parents in this study described a range of methods used to administer their child’s 
medications, including using various food stuffs and drinks. It is not known with 
most of these drugs is whether this is an acceptable approach. It may be that using 
food or drinks to aid administration does not affect the drug and may be 
reasonable. The concern is that, for example, a crushed tablet or opened capsule 
may cause bioavailability changes either from the crushing or opening and/or from 
the mixing with food or drinks. The ‘Use of Melatonin in Children with 
Neurodevelopmental Disorders and Impaired Sleep’ (MENDS) trials considered 
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melatonin capsules mixed in water, orange juice, semi-skimmed milk, strawberry 
yoghurt and strawberry jam (Shah et al., 2008). This study reported a good 
percentage recovery of melatonin for all food products and considered that these 
results suggested that mixing melatonin in common beverages or foods is an 
acceptable method of drug administration to children, if they are unable to swallow 
capsules. This study considered the use of melatonin, a drug that is prescribed for 
children on a ‘named patient only’ basis, the conclusions had to be viewed with the 
caveat that the lowest and highest effective doses of melatonin in children have 
never been determined (Shah et al., 2008). Nevertheless, this study concluded the 
mixing of this drug into food or drinks to be acceptable, though they noted that 
there could be differences in bioavailability between those taking melatonin with 
food and those not (Shah et al., 2008).     
The MENDS study had surveyed parents of children with neurological disabilities to 
identify the commonly used food and drink vehicles (Shah et al., 2008). Similarly, 
Nissen et al. (2009) found that a variety of mixers were used where crushed or split 
tablets or opened capsules were added to food and drinks. These were jam, 
patient’s food, water, custard, yoghurt, thickened fluid, juice and honey. Parents 
reported using various types of food and drinks to assist with administration. In 
some cases this was done with the aim of disguising from the child that the 
medication was being taken, while in others it was to mask the medication and 
make it easier for the child to take. It may be, if it can be established that the food 
or drink does not have an impact, that this is a useful and viable method to assist 
with administration. However, this is not known as the effects on the stability and 
bioavailability of mixing drugs into food or beverages are mostly undetermined 
(Standing and Tuleu, 2005; Davies and Tuleu, 2008). If a formulation is to be mixed 
in beverages/food, the dose accuracy, reproducibility and physiochemical stability 
issues should be considered in these vehicles (Pandit et al., 2010). In this current 
study several parents had discussed using food or drinks and they had been 
informally advised to do this by health care professionals. A study that investigated 
paediatric nurses’ practice of mixing medication into foodstuffs found little 
consistency amongst those interviewed in how they actually undertook this (Akram 
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and Mullen, 2012). If there is no consistency within in-patient clinical areas then it is 
unsurprising that the advice and information that parents appear to be receiving is 
inconsistent and delivered on an ad hoc basis. Where the choice is balancing the 
use of food or drinks to administer the medication with the likelihood of non-
adherence then it is rational to take the view that ensuring the drug is taken is the 
priority. However, this may not be sanctioned by those producing the drug.  This 
also raises questions relating to the liability of the health care professionals 
involved either in mixing drug products into food/drinks themselves or advising 
parents to do so.   
 
5.12.4 Adjustment over time  
Parents portrayed that on-going administration of medications to their child could 
be problematic, with the word ‘battle’ used to describe the interaction between 
parent and child. Although this was not applicable to all drugs, with parents 
describing situations where it would be straightforward to get their child to take 
one medication but that a different one would prove challenging. It was also not 
pertinent for all parents and children as one parent described a child who had 
always taken the various medications he was prescribed without difficulty. Though, 
this parent did nonetheless describe her child as ‘fed up’ with the unremitting daily 
routine of taking medications. These descriptions provided by parents in this study 
revealed that the administration could be a stressful process. The spontaneous 
description that used the term ‘battle’ implies that this has an impact on both the 
child and their parent. Even where a child takes the medications with little protest 
the, often daily, repetitive nature of the process has an effect. It appears that, for 
some, with time the child may become accustomed to taking medications and with 
an increased understanding of why they need to take them administration can 
become easier. Fiese and Everhart (2006) reviewed medical adherence and 
childhood chronic illness and discussed that parents typically establish behavioural 
norms and model health behaviours and coping skills for their children. This study 
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indicates that the child and their parents take time both to adjust to the medication 
regimens and also, at times, to adapt to changes in this regimen.   
Parents in this study described how they engaged in negotiation with their child to 
ensure that their medication was taken. Only one parent acknowledged that there 
were occasions where their child had not taken their prescribed medication. The 
other parents described persisting and ensuring that their child took the medication 
or in some instances discussing their difficulties with medical staff and, where 
possible, changing the prescription. It is acknowledged that there may have been 
reluctance in interviews to admit occasions where their child did not have their 
treatment. Nonetheless there were considerable efforts being made by parents to 
ensure that their child was adherent to their medication regimen. Gardiner and 
Dvorkin (2006) used case studies to illustrate issues relating to medication 
adherence in children; they noted medication adherence to be a complex issue 
involving the child, family members and other care providers. These authors further 
noted the importance of the family’s cultural beliefs, their perceptions of disease 
severity, and their understanding of the benefits of treatment. Where the support 
needed by parents in managing treatment for children with cystic fibrosis was 
investigated parents described the stress of having to urge reluctant children to 
take medication, dealing with refusal and encouraging them to take some 
responsibility for their medication (Slatter et al., 2004). It is evident that the ease 
with which the child complies with their medication regimen needs consideration; 
although the medication may be being taken the impact of achieving adherence 
may be affecting the child and also their parents/carers.         
There may be a parental influence on the willingness of the child to take solid 
dosage forms. Parents in this study described hesitancy when contemplating 
changing to their child taking tablets or capsules. Though the reasons for this are 
not clear, it may be that they do not want to change the status quo with their 
child’s treatment that has been established. It may be that not only are they 
concerned about their child’s ability to take tablets, but that they may be 
influenced by their own personal unwillingness to take tablets. Parental, especially 
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maternal, influences on children’s expectations of taking medicines and their 
compliance have been previously shown to be strong (Yeung and Wong, 2005; 
Hameen-Anttila, 2011). While the evidence is limited, studies do imply that children 
can effectively learn to take tablets if appropriately supported. Yeung and Wong 
(2005) completed a retrospective survey of medical records on the age at which 
children converted from liquid to solid formulations of antiretroviral drugs, finding a 
wide age range of 2.9-8.1 years. Parental diffidence to their child taking tablets has 
been described in a study that investigated pill-swallowing training for children 
taking anti-HIV medications (Garvie et al., 2007). They found that when offered pill-
swallowing training for their child parents/guardians often expressed reticence, the 
reasons for their reservations were considered to be related to parental 
perceptions of the child’s ability to swallow pills or their own or their child’s 
previous difficulties with swallowing pills. The parents interviewed in this study 
described some of the anxieties associated with changes in the prescribed drugs for 
their child. Cohen (1995) considered the triggers of heightened parental uncertainty 
in chronic, life threatening childhood illness. This author found that a plan to 
implement a new therapy or a procedure of unknown or unpredictable 
effectiveness can be alarming for parents. Any change proposed when the child is 
doing well under the current management was considered to threaten the 
precarious emotional equilibrium that has been established Cohen (1995).    
 
5.12.5 Palatability  
The parents who contributed to this study strongly believed that the availability of 
palatable liquid formulations would make it significantly easier for children to take 
medicines. Though this may seem to parents like a reasonable request it can be 
more difficult to achieve in reality. The financial implications of the development of 
liquid formulations for drugs that are not frequently in use in paediatrics may be 
prohibitive. It can prove difficult to achieve good organoleptic characteristics with 
liquid formulations (Davies and Tuleu, 2008). These properties refer not only to 
taste but include other possible sensory experiences of the product, such as smell 
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or texture. If the drug has a bitter taste there is little possibility that within a liquid 
formulation the taste can be masked (Breitkreutz and Boos, 2007). Furthermore, 
solubility characteristics may not be suitable for the liquid dosage forms. 
Compounds with high solubility can be difficult to taste mask in liquid preparations 
as they often cannot be easily formulated as suspensions (Cram et al., 2009). 
Excipients may also be a restricting factor. As Choonara and Rieder (2002) noted it 
is important to remember that medicines contain not only the desired active 
compound but also numerous other chemicals which are added to make the drug 
more palatable, more soluble or more stable. Oral liquids often require 
substantially larger amounts of excipients to ensure stability and palatability. 
Furthermore neonates and infants may not be able to metabolise/eliminate an 
excipient due to immature renal and hepatic function (Pandit et al., 2010). Though 
it may seem that the dose flexibility of oral liquids is a clear advantage, there can be 
dose accuracy questions. Yin et al. (2010) found a considerable number of 
measurement errors made by parents using dosing cups, though the use of oral 
syringes helped with accuracy. Though the accuracy of measurement of the correct 
volume in oral syringes, while better than other measuring devices, has also been 
questioned (Sobhani et al., 2008). The lack of safety and stability data and inclusion 
of excipients with elevated toxicological risks might hinder the advantages of liquid 
formulations, and their use in paediatric age groups needs to be assessed first 
(Pandit et al., 2010). There may be other influences on the availability of liquid 
formulations; as where these are only available as ‘specials’ the increasing cost of 
these means that hospitals and primary care trusts need to carefully consider their 
use (Wright and Tomlin, 2011). Furthermore it needs to be remembered that how 
palatable a liquid formulation is perceived to be will vary between individuals. 
Breitkreutz and Boos (2007)  considered that the main problem with using liquids is 
the palatability of the solution, especially when considering that taste sensation 
differs age-dependently and between individuals.      
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5.12.6 Drug manipulations 
When drug manipulations were required, parents were generally guided by 
information they received from health care professionals on how to complete 
them. They did not seem to seek additional information from other sources. 
Referring to the summary of product characteristics (SPC) leaflet that is provided 
with drug product was not mentioned by parents as a source of information for 
manipulations. The reasons for this may be two-fold, firstly that the manipulation 
may not be sanctioned by the drug company and therefore will not be in the SPC. 
Secondly, it may be that the information is not clear. Breitkreutz and Boos (2007)   
noted that by simply reading the product labelling even experts cannot often 
elucidate whether the tablet may be split or not and that product information 
provided with the drugs is often unreadable for patients or caregivers. Furthermore 
parents did not mention consulting websites, such as the ‘Medicines for Children’ 
website8. Though this website provides useful information for parents about how to 
administer their child’s medication, much of the advice relating to possible 
manipulations notes that parents should discuss these with healthcare 
professionals.         
As the initial interview transcripts were reviewed and analysed with the 
experienced paediatrician the brevity of answers relating to drug manipulation 
provoked discussion. There was consideration during the initial analysis as to 
whether the addition of further questions or topics in this area would be 
appropriate in the forthcoming interviews. However apprehensions relating to the 
possibility of stimulating parental concern in this area, without prior discussion with 
the appropriate clinical team, were considered a risk of the addition of further 
questions. It was decided that during the interviews the process of exploring any 
issues raised by parents relating to manipulation would continue, without the 
addition of further planned questions, but with an awareness of the brevity of 
                                                          
8
 This website has been established for parents by the Royal College of Paediatrics and Child Health 
(RCPCH), the Neonatal and Paediatric Pharmacists Group (NPPG) and the child health WellChild, 
(http://www.medicinesforchildren.org.uk/) 
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answers in previous interviews.  Where parental needs and views about giving 
medicines to children are to be explored a delicate line of questioning may be the 
most appropriate (Sweis and Wong, 2004).    
The parents interviewed here were, in the main, unconcerned about undertaking 
manipulations. They did highlight areas of unreliability with manipulations, such as 
tablets crumbling or measuring proportions of a dispersed tablet. Parents had 
received inconsistent information from health care professionals. Some had been 
supplied with equipment (tablet splitters) and given careful instructions. Others had 
been informed that proportions of the intact dose were needed and given little 
further information on how to achieve this. It appears that if they are advised by 
healthcare professionals to manipulate parents do not generally feel that they need 
to ask further questions about this. There may be reasons that contribute to this, 
such as that they have been advised to do this by healthcare staff that they have a 
relationship of trust with. It may though be symptomatic of a general unawareness 
about the use of medicines in children, and a trust that that the medicines that are 
prescribed for children will have been through the same drug testing and safety 
process as those for adults. It may therefore be being assumed that the 
manipulation is a safe, effective and validated action. Mukattash et al. (2008) 
explored the awareness of the unlicensed use of medicines in children, finding that 
most participants were oblivious to the use of unlicensed medicines in children. 
These findings were not unexpected as these authors and others (Sweis and Wong, 
2004) have noted the preference by health care professionals not to explain that 
children are being prescribed off-label or unlicensed medicines. This may be 
indicative of a reluctance to discuss potential difficulties relating to their treatment 
with a child’s parents. Arnott et al. (2012a) investigated parents’ experiences of 
their child’s suspected adverse drug reactions and found that from the parents’ 
perspective clinicians’ communication about adverse drug reactions was poor.  
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5.13 CONCLUSIONS   
This study provides an exploratory analysis of the methods used by parents to 
administer medications required for long-term use and areas where they think 
changes would be helpful for both their children and themselves. In doing so it has 
highlighted that this can be challenging and may have a negative impact both on 
the child and their parents. Conversely some can find it wearisome but not 
problematic. Drug manipulation does not appear to unduly concern the parents 
undertaking it, though the reasons for this are not clear. There is a disconnect 
between professional concerns about manipulations and parental perspectives. 
This disconnect is likely to hamper efforts to address the case for research.  
Primary school age children are dependent on their parents or carers for their 
medication requirements. While priority has to be given to whether (or not) the 
child will take the medication it is nonetheless important to ensure that they and 
their parents/carers are supported with appropriate, timely and consistent 
information.  
Underpinning the approach used for this study was whether it could be judged on 
catalytic validity; the potential to influence or change practice or research. The 
outcomes from this study provide not solely description of parental views. They 
also highlight the importance to some parents of the support of healthcare 
professionals and question aspects of this, particularly of how healthcare 
professionals provide explanations relating to medications and drug manipulations 
to parents.       
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CHAPTER 6: DISCUSSION  
6.1 BACKGROUND LEADING TO THIS RESEARCH  
Infants and children were first described as therapeutic and pharmaceutical 
orphans over forty years ago (Shirkey, 1968). Nunn, in 2003, commented that little 
had changed (Nunn, 2003). This lack of progress in the availability of appropriate 
paediatric drug products may even be argued to be an evolving issue as the 
treatment and survival age for many chronic and/or life-threatening conditions of 
childhood have advanced. Changes implemented through the EMA and FDA and the 
development of the EuPFI have drawn attention to the need for medications that 
are designed to meet the dose requirements for administration to babies and 
children. It is recognised that children cannot be treated as small adults and their 
healthcare, treatment and services should be suitable for their needs. The 
prescription of off-label and unlicensed drugs in paediatric practice is known. This 
use is accepted as a current necessity; without it children would not be able to be 
prescribed drugs that may be the most applicable to their needs (Conroy and 
Peden, 2001; Hoppu, 2008). Previous studies have established that off-label or 
unlicensed use is endemic in practice (Conroy et al., 2000; Di Paolo et al., 2006). The 
availability of appropriate doses in products that are designed for paediatric use will 
impact on whether the drug is actually taken as the design of the drug product has 
intended it to be. If there is not sufficient dose flexibility, the dose required for 
paediatric use may require manipulation to attain the dose required. As with the 
need to prescribe off-label and unlicensed drugs drug manipulation is established in 
practice. However this has not previously been systematically explored.  
 
6.2 THESIS FINDINGS – SUMMARY  
The impetus leading to the work in this thesis was that while drug manipulation 
appeared to be an established feature of paediatric clinical practice, what drugs and 
dosage forms are being manipulated and how these manipulations are undertaken 
was not known.   
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This thesis has investigated and described drug manipulation across paediatric 
practice. It has included: what evidence is available relating to drug manipulation 
(Chapter 2), what drugs and dosage forms are manipulated and in which in-patient 
clinical settings, how manipulations are undertaken (Chapters 3 and 4), and how 
parents view undertaking manipulations at home (Chapter 5).  
This thesis has elucidated that drug manipulation is an intrinsic part of 
administering drugs to babies and children. There is a dearth of evidence to support 
drug manipulation. Findings have indicated that, while they may be more prevalent 
within the more high dependency clinical areas, drug manipulations occur 
throughout specialist and generalist in-patient areas, across a range of diagnoses 
and throughout all ages of childhood. Furthermore parents are undertaking 
manipulations prior to administering medications to their children at home. Despite 
the lack of evidence parents do not appear to be concerned.   
 
6.3 INTERNATIONAL PERSPECTIVES   
This research has focused on practice within the UK. Internationally there are liable 
to be cultural, traditional, regulatory or financial reasons for variances in the use of 
drugs and/or dosage forms in different countries. The issues relating to children’s 
medicines have an international basis. Consequently the outcomes of this 
investigation into drug manipulation in paediatric practice have implications that 
will be relevant beyond the UK. The description of the drug manipulations within 
this thesis has implications both for current practice and for future research.   
 
6.4 DRUG MANIPULATIONS – TABLETS  
It is apparent that the evidence base to support or refute drug manipulation is 
insubstantial (Chapter 2). What evidence is available relates principally to tablet 
manipulations. Throughout the observational study (Chapter 3) and questionnaire 
responses (Chapter 4) tablets were the largest dosage form group in which drug 
manipulations are carried out in paediatric practice. Tablets are split, crushed and 
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dispersed and a proportion of the intact tablet dose administered to patients. The 
conclusion that can be drawn from the evidence base in the systematic review 
relating to tablet manipulations is that this manipulation is unreliable. Though for 
some tablets manipulation to obtain a proportion of the original dose can achieve 
an accurate dose, for others this cannot be stated with any confidence. This is 
further complicated by the unfeasibility of inferring that a tablet of the same dose 
of the same drug will consistently give the same outcomes. There may be a variety 
of formulations of this drug that may give dissimilar outcomes when manipulated; 
that is, though the drug and dose may be the same, there may be several drug 
products that have been formulated differently by various manufacturers and thus 
the outcome of the manipulation may differ. Though the evidence is limited, it is 
clear that tablet manipulations can be unreliable and at worst potentially 
dangerous, such as where the dose achieved is outwith adapted pharmacopoeial 
limits.  
Many tablet manipulations involve the segmenting of a tablet. The inadequacy and 
ambiguity of the scorelines on some tablets has been recognised. Work is underway 
with the FDA and USP to scientifically define the term ‘functional score’ for tablets. 
This functional score will designate only tablets that reliably split into equal 
portions, American Society of Health-System Pharmacists 2012,  
(http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?id=3789#). 
Developments like this will be beneficial to both healthcare professionals and 
patients who are splitting tablets. However specific consideration on the usage in 
children is needed, as knowing a scoreline is functional for splitting in half will not 
prove sufficient should a smaller dose, such as a quarter, of the tablet be required.  
 
6.5 NON-TABLET MANIPULATIONS  
The dearth of non-tablet studies identified during the systematic review (Chapter 2) 
led to questions relating to the manipulations of other dosage forms. Is it that this 
lack of evidence is because they were not being manipulated or because they were 
they being manipulated but this practice had not been investigated? It is apparent 
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that, though tablets represent the highest proportion of manipulations, other 
dosage forms are being manipulated. Manipulations were described as being 
undertaken using a range of dosage forms: sachets, capsules, transdermal patches, 
nebuliser solutions, suppositories and enemas. With the paucity of evidence, any 
impact of manipulations on those receiving manipulated drugs is undetermined. It 
cannot be inferred that these manipulations are harmful and should not be 
undertaken; correspondingly it cannot be assumed that manipulations are effective 
in achieving the dose required and are safe.  
 
6.6 INTRAVENOUS MANIPULATIONS AND MEASUREMENT OF SMALL VOLUMES  
Most intravenous manipulations are occurring within neonatal units or high 
dependency areas, areas where experience has shown the value of guidance for 
drug preparation and administration. Much of this guidance is generated locally, 
though this may raise questions relating to the validation of guidance and whether 
all units are following optimal practice. Consequently for intravenous manipulations 
within neonatal units there are more reference materials available. What was 
identified during a concurrent quantitative review (Nunn et al., 2013)  is that it is 
not always evident where intravenous injections are required is whether a 
manipulation occurs or whether a small volume, such as <0.2mL, has been 
measured in the process of achieving the small dose required. If such small doses 
are being measured the accuracy of such measurements may not be reliable. 
Although any error in these measurements may appear to be very small, with doses 
of this size, even an apparently small error could nonetheless result in a substantial 
under or over dosage.  
The additional dilution of intravenous manipulations risks errors with calculations 
and/or measurements. This leads to the question of whether it is more accurate 
and less prone to error if a small volume is measured or if additional dilution is used 
allowing the measurement of a larger volume?   
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6.7 RESOURCE IMPLICATIONS  
The frequency of manipulations may have implications for clinical practice due to 
the time that may be involved in drug manipulation and the resulting pressures on 
busy wards. A study which considered the administration of oral medicines to 
children found that where tablets or capsules were crushed, cut or dispersed and 
either all or a proportion of the original dosage form administered, then the drug 
administration took a significantly longer time (median time 4 minutes compared 
with 2 minutes (p<0.001) (Skwierczynski and Conroy, 2008). With drug 
manipulation to obtain the required dose, this potential impact on clinical time may 
be increased by the need to calculate the proportion of the available strength. 
While these may appear to be small fractions of time, the practice in many 
paediatric areas is to require that all drugs are checked by two nurses, consequently 
manipulations may add considerably to the workload in already busy clinical areas. 
There are potential resource implications relating to manipulations, due to the time 
taken for manipulations. In addition, where manipulations need to be repeated 
there will be wastage of drug products. As discrete, individual events these will not 
have an impact, nonetheless there may be a cumulative impact.    
 
6.8 REFERENCE DOCUMENTATION AND PROFESSIONAL LIABILITY  
Further consideration needs to be given to ensuring that what is considered to be 
best practice in drug manipulation is used. A variety of manipulation methods have 
been described and it appears that practice may be inconsistent and best practice is 
not known. The BNF/BNFC is by far the most frequently consulted reference 
document, though in many cases the BNF/BNFC will not provide information that 
will assist with the manipulation. Within neonatal areas there appears to be much 
more reliance on local supportive documentation. This may be because many of the 
manipulations in this area are of intravenous injections and there is widespread use 
of intravenous drug administration guides.  
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There is a need for more formal recognition that manipulations occur and the 
development of suitable supportive documentation, such as protocols or policies. 
However, for this to be facilitated there will need to be some agreement or 
recognition of where the responsibility lies. Within prescribing in paediatrics it is 
accepted that off label and unlicensed prescribing may be necessary when no 
suitable alternative is available (Hill, 2005). It does not appear that similar thought 
has been given to the process of actually achieving the prescribed dose, the means 
of administering it and any implications that these actions may have professionally 
for those undertaking them. There has been some discussion within nursing 
journals relating to the possible legal implications of crushing tablets and opening 
capsules.  However, this has centred on adult and community care, and has 
involved cases where the whole dose is administered and thus the crushing or 
opening has been to assist with administration (Wright, 2002; Griffith and Davies, 
2003; Griffith et al., 2003; James, 2004). These authors have cautioned that any 
liability associated with the administration of crushed medication might lie with the 
administrating nurse (Wright, 2002) and that health professionals must be sure that 
their reasons for crushing tablets could be justified in a court of law (Griffith and 
Davies, 2003). The importance of relevant protocols has also been described 
(Wright, 2002). It does appear that drug manipulations are known and 
acknowledged in practice but that the possible legal and professional implications 
within paediatric practice have not been further considered. The Nursing and 
Midwifery Council (NMC) ‘Standards for Medicines Management’ notes that for the 
crushing of medicines pharmacy advice should be sought and that the patient’s best 
interests need to be determined. In considering good practice in the administration 
of medicines to children, Crawford (2012) noted that there are powerful and 
unlicensed drugs that are administered without parental knowledge of the lack of a 
licence, often with assumed parental consent. Furthermore, with these there are 
ethical and professional implications for the nurse who administers these 
medications (Crawford, 2012). Drug manipulations may not be sanctioned by those 
manufacturing the drug product. This raises questions of individual and corporate 
responsibility. Consideration could be given to discussing drug manipulation with 
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experienced practitioners; there may be an acceptance of what they view as usual 
practice that should be challenged. Drug manipulation has been a conventional 
feature of paediatric practice and may be accepted by practitioners as such. This 
acceptance of conditioned practice may mean that the need to develop reference 
documentation relating to drug manipulation has not been considered. Or it may be 
that there has been reticence relating to the development of supportive reference 
documentation, as the individual accountability and/or hospital liability relating to 
drug manipulation is unclear.     
 
6.9 GUIDELINES  
The outcomes from the systematic review (Chapter 2), observational study (Chapter 
3) and survey of paediatric nurses (Chapter 4) have been utilised by a group of 
clinical, research and pharmacy experts to develop guidelines relating to drug 
manipulation. However, though these guidelines have been produced, their generic 
nature and focus on the need to seek expertise prior to many manipulations is 
liable to make them unwieldy and impractical in clinical situations. Their value is 
more likely to be in decision-making with those who are making drug planning and 
purchasing decisions. In consultation with paediatric pharmacy experts, this 
planning could potentially avoid some manipulations. Additionally, these guidelines 
will provide a platform for the consideration of the priorities for future research. 
These guidelines epitomise the difficulties in making generic guidelines for a clinical 
practice like drug manipulation that spans dosage forms and encompasses many 
different drugs (each with potentially several available drug products and therefore 
formulations).      
 
6.10 IMPLICATIONS FOR KNOWLEDGE AND TRAINING  
The prescription of drugs within paediatrics can be complex and the appropriate 
doses and methods of administration may change frequently throughout childhood. 
Failure to make these adjustments may reduce the benefits of treatment (Menson 
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et al., 2006). The dose of many drugs is calculated on weight, age or surface area, 
alongside any clinical condition specific factors. When prescribers are calculating 
the dose required, the question arises as to whether they give any consideration to 
which dosage forms and/or drug products are available.  Concern has been 
expressed about the amount of pharmacology and prescribing teaching within 
medical training. Heaton et al. (2008) found that few medical students and recent 
graduates in medicine felt confident about prescribing and calculating drug doses 
and that less than a third (2413 respondents) considered that they met the 
standard expected of them at the point of graduation. In acknowledgement of the 
complexities involved, concern about the knowledge of prescribers has been 
specifically broached within paediatrics (Conroy et al., 2008; Conroy and Carroll, 
2009). For non-medical prescribers the NMC standards for prescribers note that 
only nurses with relevant knowledge, competence, skills and experience in nursing 
children should prescribe for children (www.nmc-uk.org/Documents/Standards). 
Increasing planning and teaching within postgraduate programmes, with possible 
further development of the role of trained paediatric clinical pharmacologists 
(Conroy and Carroll, 2009) and the development and use of electronic prescribing 
(Davis, 2011), have been suggested as means of increasing knowledge and 
awareness of paediatric prescribing and reducing prescribing errors.   
Furthermore the knowledge of, or teaching of, nurses administering medicines has 
been questioned. Akram and Mullen (2012) completed interviews with a small 
number of paediatric nurses working in general or psychiatric areas and considered 
that there is a lack of formal training on drug stability/degradation issues and/or 
possible clinical impact.  
If there was more pharmacological knowledge and increased awareness of what 
dosage forms and drug products are available, people who prescribe and/or 
administer medicines (or those who advise prescribers and/or those who 
administer) would be able to consider and offer alternatives that may not require 
manipulation. This could involve aspects of prescribing such as whether an 
alternative drug in the same class could be used.  Or it could involve the 
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appropriate use of dose rounding or dose ranges, if those prescribing had the 
knowledge and the confidence to calculate the drug doses and to appropriately use 
such flexibility where it is available. 
It appears that there may be a need for sustained and consistent implementation of 
pharmacology, prescribing and drug administration teaching for both students and 
health professionals working in paediatric practice. 
 
6.10.1 Avoidable manipulations  
It may be that to obtain the dose needed for some drugs and formulations 
manipulation is necessary. However, what has emerged from this work is that there 
may be manipulations that could potentially be avoided. Drugs were reported and 
observed being manipulated where several differing strengths and dosage forms 
exist.  Analgesics were a particular example of this, such as paracetamol or 
ibuprofen.  These drugs are available as tablets, capsules, soluble tablets and oral 
suspension of various strengths. With some drugs there may be dose ranges that 
can be used, or some flexibility with the number of occasions a dose can be divided 
into over 24 hours.  This provokes the question as to whether there is a lack of 
awareness of the different strengths and dosage forms that the drugs are available 
in. Or it may be that methods such as dose rounding or dose ranges are not being 
utilised. Or is the practice of manipulating so ingrained and habitual that in a busy 
clinical area it is not contested? If there has been acceptance that drug 
manipulation is a part of practice it may be that it has become habitual and not 
questioned or methods that could avoid it not implemented. With anecdotal 
descriptions of students having commented on registered practitioners showing 
them how to crush tablets (Wright, 2002), it may be that ingrained practice could 
be challenged with increased focus on training needs. The likelihood that there are 
drug manipulations that could be avoided raises questions such as the role of 
habitual practice and the potential of methods of prescription that could provide an 
appropriate dose that avoids the need to manipulate. However, further work is 
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needed in this area to consider education or training needs and potentially to 
challenge ingrained or accepted practice.          
 
6.10.1.1 Dosage form preferences   
Providing patient choice or meeting patient preference may influence the use of a 
drug manipulation. The observational study (Chapter 3) and questionnaire study 
(Chapter 4) provided examples where the preference was for segments of a tablet 
rather than a liquid formulation. It may seem that liquid formulations provide the 
solution to many difficulties with children’s medications. They provide greater dose 
flexibility and are generally considered easier to swallow than solid dosage forms. 
When parents who were interviewed (Chapter 5) advocated strongly for the 
availability of liquid medicines, they did so with the proviso that they would also be 
palatable. However, as Breitkreutz and Boos (2011) noted there is limited evidence-
based information on acceptability and preference of dosage forms in children, 
despite the fact that the therapeutic outcomes are closely linked to it. The 
development of suitable and palatable oral solutions is often problematic; many 
bitter tasting drugs cannot be effectively masked in a liquid formulation. 
Additionally, there have been safety concerns about the use of some excipients in 
children (Choonara and Rieder, 2002; Breitkreutz and Boos, 2011). Moreover liquid 
formulations can provide challenges due to shorter expiry dates once opened or 
storage issues. There may also be cost issues related to the liquid formulation 
development.    
Although parents may consider liquid formulations to be a solution, some children 
have shown preferences for taking halved tablets rather than liquids. It has been 
suggested that the large volumes needed to achieve some doses have been disliked 
by some children (Nunn, 2003). Tablet manipulations occur for reasons of patient 
choice in a way that other manipulations do not. There is inconsistency in the 
limited research about the age at which children can take solid dosage forms 
(Yeung and Wong, 2005). Expert consensus in the EMA is that children younger 
than six years have difficulty with solid oral dosage forms (Breitkreutz and Boos, 
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2011). The influence of parental preference will be a factor in this process, perhaps 
especially if the parents themselves dislike taking tablets. It is evident that children 
cannot be treated as a homogenous group and it is not going to be viable to have 
drug products that cater to what may be a wide range of possible preferences. 
Nevertheless, further research relating to the palatability and dosage form 
preferences of children taking long-term medication would provide valuable data 
for those manufacturing drug products, as well as those prescribing and 
administering them.       
 
6.11 MANIPULATIONS, DRUG ERRORS AND ADVERSE DRUG REACTIONS  
Drug manipulations add supplementary steps to drug administration; this can 
include the calculation of the proportion of the available dose that is required and 
additional volume measurements. This need for calculations and extra steps (such 
as dilution and measurements) where manipulation is required in drug 
administration replicates processes that have been implicated in increasing the risk 
of drug errors. If strategies to reduce risk are to be effectively targeted, it is 
necessary to identify the stages where errors are most likely (McDowell et al., 
2010). The potential for error with the additional steps used during drug 
manipulation may exacerbate risks that have been previously recognised with other 
known aspects of paediatric medication administration, such as the use of 
unlicensed/off label drugs. Reports of errors in a UK children’s hospital were 
analysed and it was found that 60% (12/20) of the errors that were considered to 
have caused moderate harm involved unlicensed/off label drugs (Conroy, 2011). 
Beyond the accuracy of the dose and safety issues that are directly related to the 
manipulated product, there is a further unknown implication. That is that babies 
and children may already be at increased risk of adverse drug events. It has 
previously been noted that medicines that are extemporaneously prepared are 
commonly given to some of the most vulnerable patients in hospitals (such as 
neonates, children, elderly patients and patients with feeding tubes)(Lowey and 
Jackson, 2008). These groups include individuals who may not be able to alert 
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carers or staff to any adverse events they are experiencing (Lowey and Jackson, 
2008). Therefore those administering drugs to them need to be aware of any 
potential adverse events.  Several studies suggest that about one-third of adverse 
drug events are associated with medication errors and are thus preventable 
(Kaushal et al., 2001). Furthermore, use of unlicensed medicines carries a greater 
risk of adverse drug reactions than the use of licensed medicines (Sutcliffe, 1999; 
Lowey and Jackson, 2008). It is not known if receiving a manipulated drug also 
increases the risk of an adverse drug reaction, a manipulation effectively renders 
the drug product to be unlicensed. There are associations of adverse drug reactions 
with medicines that have been prepared extemporaneously, medication errors and 
unlicensed medicines; as these have links with manipulated drugs the possibility of 
an increased risk of adverse drug reactions should be considered.    
 
6.12 IMPLICATIONS FOR PARENTS  
It appears that parents are trusting of the prescribed medications that they are 
advised to administer to their children. A previous study has found that there is 
limited public knowledge of the unlicensed use of medicines in children (Mukattash 
et al., 2008). The interviews I completed with parents here found that generally 
parents were unconcerned about undertaking a drug manipulation prior to 
administering a medication. The information and support provided by healthcare 
professionals to parents about undertaking manipulations appears to be 
inconsistent. If there is further focus on the need for all involved in paediatric drug 
prescribing and administration to have sufficient knowledge and training, then 
communication about drug related issues with children and parents should also 
improve. As has been previously noted by (Breitkreutz and Boos, 2007) when there 
is dependence on the abilities of the caregivers, drugs that are patient-adapted 
should be designed appropriately for caregivers as well.  
Ultimately provision of appropriate medicines depends on political will. Individual 
parents did not report concerns about manipulations. This was despite noticing 
problems such as unreliability in splitting tablets, variable measurements of 5mL 
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volumes and the oral liquid viscosity on the consistency of manipulations. In general 
parents did not further consider the potential consequences of their observations. 
As long as those concerns are not expressed by parents it will be difficult to develop 
public advocacy for improvements in the situation.          
6.12.1 Implications of long-term medication administration 
Parents described the conflict (spontaneously using the term ‘battle’) that can arise 
during the administration of some medications. The need to take long-term 
medications can have a substantial impact on some children and their parents. 
When administering medications some parents use a variety of methods. A widely-
used approach is to use foodstuffs and/or drinks to mask the taste, or in some cases 
to disguise from the child that a medication is being taken. This can help with 
ensuring that administration is achieved. As with drug manipulations a pragmatic 
decision-making process may be being used, where the importance of getting a 
child to take a medication takes priority over the methods used to achieve this. 
Again, this is reasonable and may not impact on the effectiveness or safety of the 
drug involved. However, for many drug products this is not known. Parents have 
reported that they were advised to use food or drinks by healthcare staff. This 
advice may help with the medication administration and be a helpful response to a 
parental query. However, those advising the use of food or drinks may need to 
consider how confident they are that this is the correct advice. The uncertainty of 
nurses about whether or not medication should be mixed into foodstuffs could be 
seen in a study by Akram and Mullen (2012) when they interviewed nurses about it. 
These authors found that they were unable to complete the number of interviews 
that they had intended as only a small number of nurses agreed to participate; it 
was considered that nurses were apprehensive about discussing a potentially 
‘pseudo-illegal’ practice with another health colleague. If it was well-defined where 
a drug product can be effectively and safely administered with foodstuffs and/or 
drinks, this would allow this method to be confidently used. It would not be feasible 
to test drug products in a variety of food or drinks but perhaps the testing of those 
205 
 
to be administered to children in a small number of selected foods or drinks should 
be considered.   
 
6.13 LIMITATIONS 
The methods used to explore drug manipulation within this thesis were selected 
with the aim of ensuring that the outcomes would provide a comprehensive 
depiction of current practice. This depiction provides a basis from which to 
contribute to the discussion about the provision of appropriate drugs for 
administration to babies and children. In scoping this practice it is accepted that 
there are related limitations.     
The systematic review completed in this thesis investigated a broad topic where 
potentially any drug and/or dosage form could be included. This proved a challenge 
with search strategy development and database searching. Though measures were 
included with the aim of ensuring the aptness of the search strategy, the generality 
of many of the terms that had to be used meant that to achieve a retrieval that was 
reasonable, some specificity of the search had to be forfeited. This review 
acknowledged and allowed for relevant research that was available from studies 
that were completed solely within laboratories and did not include administration 
of the drugs involved. The inclusion of these studies provided a challenge for the 
quality assessment and synthesis of the evidence found within the review. To 
accommodate these studies and the breadth of studies involved, a review-specific 
quality assessment tool had to be devised. The breadth of the studies involved in 
this review meant that definitive conclusions could not be drawn, though a 
comprehensive picture of the evidence relating to manipulations and the gaps 
within it were apparent.  
The observation of drug manipulations provided the initial data on the nature of 
manipulations occurring and on which drugs and dosage forms. Observing drug 
manipulations was feasible in in-patient areas, though the needs of the ward area 
always had to take precedence and there are practical difficulties with observing in 
these areas. Tools to enable the data recording of manipulations had to be devised. 
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These went through a considerable drafting and review process, were piloted and 
are considered to be fit for purpose. These tools did allow the recording of data 
that was considered to be valid, nonetheless there were adaptations that had to be 
made during data collection; notably where intravenous injections were being 
observed.  
The outcomes from both the observational study and the questionnaire depict drug 
manipulations are occurring throughout neonatal and paediatric practice, involving 
the administration of a range of drugs and dosage forms. However, though this 
provides rich data, the use of purposive sampling in these studies means that there 
can be no conclusions drawn about the incidence of drug manipulations.   
It is accepted that there may have been some care taken by participants in their 
answers to interview questions to conform to how they think a parent should 
respond. As with all studies where there is no attempt to sample representatively, 
the generalisability of the outcomes is a question. This study aimed purely to 
explore and in doing so provide outcomes that can illuminate areas where parents 
have concerns or issues and areas where they do not. To approach this study using 
more quantitative methods without any underlying understanding of the issues 
would have been inappropriate.   
  
6.14 FUTURE CONSIDERATIONS     
Those working within paediatric drug development, prescription and administration 
need to consider how feasible it is to resolve issues relating to drug manipulation. 
Ideally all drugs and dosage forms would be in child sized doses and in a 
formulation that was acceptable to children. Even allowing for the improbability of 
achieving a formulation that all children would find acceptable, this is unlikely. The 
FDA and EMA are promoting the development and availability of medicinal 
products for paediatric use. The importance of a syndicate approach in drug 
development has been discussed. It has been considered to be of paramount 
importance to strengthen the health system so that the individual child’s medical 
need is both scientifically and ethically addressed right from drug manufacturer to 
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its administration (Yewale and Dharmapalan, 2012). As there may be a wide range 
in the doses required or the drug may not be frequently prescribed for children, it 
may not be feasible for some drugs, practically or economically, to be provided in 
appropriate single unit doses.  
The focus may need to be not on preventing all drug manipulation, but in validating 
those manipulations that may be considered unavoidable. That is, to ensure that 
where manipulations cannot be avoided, the formulation is suitable, so that the 
efficacy and safety of the product are not compromised by the manipulation. There 
also should be consistency in practice. As has been previously identified, it is 
extremely important, particularly when the dosage form may have to be 
manipulated, to restrict the influence administration could have on intra- and inter-
individual variations (Pandit et al., 2010). With drug manipulations the inherent 
difficulty in assessing and producing collective guidance or advice is that the 
effectiveness of each manipulation will be specific to that formulation. To achieve 
consistency, there needs to be further consideration and agreement on the best 
practice for drug manipulations.  
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CHAPTER 7: FINAL CONCLUSIONS  
It is true that drug development has historically neglected the provision of drug 
products that within the required dose range and are suitable for administration to 
infants and children. The current professional and regulatory focus on improving 
this situation aims to provide improved access to appropriate paediatric 
medications. Alongside these developments it is appropriate to question paediatric 
drug prescription, preparation and administration practices such as drug 
manipulation.  
The crux of the issue that underlies this thesis and the need to consider drug 
manipulation is the effectiveness and safety of the drug treatment. The overarching 
conclusion that can be drawn from exploring drug manipulation is that it is relevant 
to current practice and impacts throughout general and specialist areas. In 
establishing that manipulation is intrinsic to practice the outcomes of this thesis 
have raised more questions about issues that need to be reflected on.  
To appropriately address drug manipulation there are a multiplicity of issues to be 
considered. Perhaps it is fitting to begin by considering situations where drug 
manipulation could be avoided. Prescribing within neonatal and paediatric practice 
is complex. It often requires child specific calculations relating to factors like age, 
weight or surface area, as well as any condition-specific considerations. Appropriate 
use of dose ranges or dose rounding following this calculation, and a awareness of 
the drug products available, may either avoid a manipulation or at least ensure that 
it is for a more easily calculable and measurable proportion. The onus for ensuring 
this cannot be solely that of the prescriber but requires a combination of the 
prescriber and the nurse administering the drug, with support and advice provided 
by pharmacists. For this to be effective there needs to be sufficient pharmacology 
related training of all healthcare professionals working within neonatal and 
paediatric areas.  
Where drug manipulation is unavoidable then it is important that the practice is 
consistent and appropriate. Drug manipulation has been a longstanding necessity 
within paediatric practice; as such it may have become habitual. There are 
209 
 
questions relating to the liability of practitioners both in completing manipulations 
themselves and advising patient or carers to do so. There needs to be recognition 
that manipulation may not be avoidable in some cases and that there needs to be 
consideration given to what is best practice. It is acknowledged that there are 
substantial gaps in the evidence-base to support drug manipulation. Nonetheless it 
is imperative that there are reference sources available relating to drug 
manipulation. Care had to be taken within this research to ensure that it was clear 
what drug manipulation was defined as. To develop appropriate source materials 
there needs to be a suitable nomenclature that ensures that where a manipulation 
is discussed it is consistently clear what it refers to. Furthermore there needs to be 
discussion and recognition of the personal and corporate liability aspects of drug 
manipulations, so that those undertaking them can feel supported and justified in 
their practice.       
This thesis has demonstrated the difficulties of investigating drug manipulation that 
is that the data about the manipulation of a particular dosage form provides 
reliable data only for that individual formulation. Testing and validation of all 
potential formulations is not possible. Therefore further consideration of this issue 
requires some prioritisation. Overall incidence of manipulations cannot be assumed 
from the outcomes in this thesis. Nevertheless expert review of the drugs 
manipulated would provide recommendations as to priorities of future work. This 
review should include health care professionals, children, parents/carers and 
research expertise alongside consultation with regulatory and industry 
representatives. While priority areas need to be discussed and decided by these 
relevant groups, they may include, for example, drugs that are frequently 
prescribed for children where the dose required will often render manipulation 
unavoidable or those which are less frequently used but there are specific 
effectiveness or safety concerns raised by the manipulation.         
With intravenous injection manipulations where dilutions are used to access doses 
that maybe a very small fraction of the dose in the vial there are further questions 
to be considered. With all drug manipulations there is a risk of miscalculation when 
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the dose needed is being calculated from the dose available. This may be 
particularly pertinent with intravenous drug manipulations as these may involve 
more complex fractions of the original dose. Moreover from review of the 
prescribed and available doses it is not always evident whether a manipulation is 
occurring or it may be that to avoid manipulating there may be attempts made to 
measure very small volumes. The accuracy of these possible small volume 
measurements may not be assured. There needs to be further consideration as to 
whether undertaking manipulations or measuring small volumes are acceptable and 
provide sufficient accuracy in the final dose that is administered to the patient.   
It is accepted that the provision of choices of paediatric formulations to encompass 
differing preferences and tastes will be impracticable. There are a variety of food 
and drink vectors used to assist with the administration of medications to children. 
Testing for the effectiveness of drug products across a variety of these is also likely 
to not be realistic. Nonetheless it may be feasible to consider whether the testing of 
effectiveness with a very small range of foodstuffs could be approached with 
paediatric drug development. This would assist with the appropriateness and 
confidence with which related advice could be provided to parents. It may also be 
worth reflecting on the development and validation of programmes which can 
applicably teach children how to take tablets or capsules.            
In exploring drug manipulation this thesis has added to the knowledge and 
discussion around the need for appropriate medication for paediatric use. The 
ultimate aim is to provide drugs that are effective, safe and tolerated and therefore 
can optimise patient treatment and outcomes. The thesis has identified specific 
gaps in the literature, scoped out the nature and practicalities of manipulations 
conducted by nurses and parents and indicated key areas for future work.       
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Appendix 1 
PubMed search strategy  
Example search strategy to find drug manipulation studies (any type of drug) – 
PUBMED: 
("Pharmaceutical Preparations/administration and dosage"[Mesh]) OR 
("Pharmaceutical Preparations/adverse effects"[Mesh]) OR ("Pharmaceutical 
Preparations/analysis"[Mesh]) OR ("Pharmaceutical 
Preparations/chemistry"[Mesh]) OR ("Pharmaceutical 
Preparations/economics"[Mesh]) OR ("Pharmaceutical 
Preparations/standards"[Mesh]) OR ("Dosage forms"[Mesh]) 
 
AND 
(cut OR cutting OR split OR splitting OR crush OR crushed OR crushing OR grind OR 
grinding OR halve OR halving OR halved OR halves OR quarter OR quartered OR 
quarters OR quartering OR suspend OR suspension OR suspending OR suspends OR 
manipulate OR manipulates OR manipulated OR manipulating OR segment OR 
segmented OR segmenting OR segments OR portion OR portions OR dissolve OR 
dissolves OR dissolved OR dissolving OR divides OR disperse OR disperses OR 
dispersing OR dispersed OR diluted OR dilution OR dilute OR dilutes) 
 
AND  
(((accuracy OR accurate OR accurately OR concentration OR repeatable OR 
repeatability OR reliable OR reliability OR reproducible OR reproducibility OR 
variable OR variability OR equal OR unequal OR equivalent OR inaccurate OR 
inaccuracies OR inaccuracy) AND (dose OR dosage OR volume)) OR (absorption OR 
bioavailability OR "drug stability" OR dissolution OR solubility OR soluble OR 
"particle size" OR quality OR interaction OR interacts OR "drug toxicity" OR "adverse 
effects" OR safety OR safe OR "adverse event" OR "adverse reaction" OR "adverse 
drug reaction" OR "adverse effects" OR harms OR error OR errors OR overdose OR 
over-dose OR underdose OR under-dose OR "dose delivery" OR "dose dumping" OR 
"dose uniformity" OR sub-therapeutic OR compliance OR comply OR adherence OR 
adhere OR taste OR palatable OR palatability OR tolerable OR tolerability OR cost 
OR waste OR contamination)) 
 
236 
 
Appendix 2 
Individual drug search strategy  
 
Example drug specific search strategy example (for warfarin) – EMBASE: 
 ((Aldocumar or Anasmol or Befarin or Circuvit or Coumadin or Coumadine or 
Cumar or Fargem or Jantoven or Lawarin or Marevan or Marfarin or Maforan or 
Orfarin or Panwarfin or Romesa or Simarc-2 or Sofarin or Tedicumar or Tufam or 
Uniwarfin or Varfine or Warf or Warfant or Warfarex or Warfilone or Warfin or 
Waran or warfarin or Zyfarin or adoisine or athrombin k or athrombine k or 
athrombinek or carfin or coumafene or coumaphene or kumatox or panwarfarin or 
prothromadin or sodium warfarinum or tintorane or wafarin or warfarine or 
warnerin or alpha acetonylbenzyl)  
adj15 
(cut or cutting or split or splitting or crush or crushed or crushing or grind or 
grinding or halve or halved or halving or halves or quarter or quartered or quarters 
or quartering or fourths or thirds or eighths or suspend or suspension or 
suspending or suspends or manipulate or manipulates or manipulated or 
manipulating or manipulation or segment or segmented or segmenting or segments 
or portion or portions or dissolve or dissolves or dissolved or dissolving or 
dissolution or divide or divides or divided or dividing or division or disperse or 
disperses or dispersing or dispersed or dispersion or diluted or dilution or dilute or 
dilutes or disintegrate or disintegrates or disintegrating or disintegration or 
disintegrated)).ti,ab 
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Author   Year     Paper title          
 N/A
9
 N/R
10
 
Yes  Further details (if req.) Descriptor  
Internal validity:       
      
Title summarises the study?      
Abstract: structured?      
Abstract: provides clear summary of the study?       
Are funding sources identified?      
Are any potential conflicts of interest identified and 
adequately explained? 
     
      
Introduction/background:     Rationale for the study to be identified 
- Population identified?     Patient groups to whom this manipulation may 
apply 
- Incidence?     Of the situation for the manipulation 
- Driver for study identified?     Reasons/explanation why this particular study is 
being undertaken 
      
Were eligibility criteria for participants clear?     Include in further details any possible concerns 
about bias  
Clear rationale for the selection of all the medications 
involved given? 
    To include both the medications under 
investigation and any controls (where used) 
Were concomitant medications/foods specified?      
Were adverse events considered?      
                                                          
9
 Not applicable  
10
 Not reported  
Appendix 3 
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 N/A
9
 N/R
10
 
Yes  Further details (if req.) Descriptor  
Were adverse events clearly reported?      
      
Methods:      
      
Medication details given? 
- Generic name 
- Brand name 
- Form 
- Strength  
- Shape 
- Scoring 
- Manufacturer  
- Lot number  
     
      
Primary aim/purpose of the study clearly stated?      
Any secondary aims clearly stated?      
Hypothesis clearly stated?      
      
Sample size determination completed?     Should include type 1 error, power, event rate in 
control group, treatment effect of interest  
      
RCTs/CCTs:      
- Sequence generation     Was there sequence generation and was it 
adequately described  
- Allocation concealment      Was there allocation concealment and was it 
adequately described  
- Blinding of participants, personnel and outcome 
assessors 
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 N/A
9
 N/R
10
 
Yes  Further details (if req.) Descriptor  
Crossover studies:      
- Has the order of receiving treatments been 
randomised? 
    Randomisation needed to avoid the risk of changes 
in outcome over time  
- Was it clear how many treatments or periods were 
being used?  
     
- Was a suitable wash-out period used?     Need to avoid the bias of a possible carry-over 
effect from the drug from one period to the next  
- Were drop-outs reported and considered 
acceptable? 
    Possible risk of bias where participants received 
one treatment but not the second  
- Paired analysis completed?     Needed to account for within person differences 
      
Surveys:       
- Is the sample considered to be representative of the 
population to be studied? 
     
- Is there evidence of matching of the questions to 
the concepts being measured and the population 
studies? 
     
- Was the questionnaire appropriately piloted?      
- Were interviewers trained on interviewing 
techniques and the subject matter of the survey? 
     
- Were measures taken to assess inter-interviewer 
agreement?  
     
- Were there appropriate attempts to maximise 
response rate? 
     
- Was there appropriate analysis and reporting 
techniques?  
     
      
Manipulation:       
- Is the manipulation clearly described? (could it be      
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 N/A
9
 N/R
10
 
Yes  Further details (if req.) Descriptor  
reproduced) 
- Was there a justification for any equipment used for 
the manipulation? 
    Such as reason for the choice of tablet splitter used  
- Was a description of the equipment given?     Note if manufacturer specified 
- Was there any effort made to ensure that all the 
drug was administered? 
    Additional effort relating to the manipulation  
- Were there adequate descriptions of any physical 
changes during the manipulation?  
    Qualitative descriptions e.g. powdering or 
crumbling or fragmentation or difficulties with 
dissolution? 
- Was the person undertaking the manipulation 
specified?  
    To include – health care professional; parent; 
student; training etc. 
- Were there measures to ensure 
consistency/reproducibility of the manipulations by 
the person undertaking the manipulation? 
    Such as, training of those doing the manipulations, 
all manipulations completed by the same person 
- Were there measures to ensure 
consistency/reproducibility of the technique used? 
    Such as orientation of the tablet, or methods of 
ensuring all of the tablet crushed? 
- Were any adverse events related to taking a 
manipulated drug reported? 
     
      
Measurement methodology:      
- Has the measurement methodology been reported 
as validated? 
    Stated that a valid method has been used  
- Could it be repeated?     Is there sufficient explanation of the method to 
allow for replication  
- Are sources of variability quantified; intra assay 
variability, inter assay variability?  
     
- Was the active ingredient measured to asses the 
accuracy of the manipulation or was a marker such 
as weight used? 
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 N/A
9
 N/R
10
 
Yes  Further details (if req.) Descriptor  
- Where weight was measured were there sufficient 
description of the measures used?  
    Details of the balance used including sensitivity and 
quality checks  
- Were regulatory criteria used for assessing tablet 
dose accuracy?  
    Such as adapted USP criteria for half tablets  
- Was there incomplete data reporting?     Yes if high drop-out rates, outcomes reported for 
some groups of participants, pre-specified 
outcomes not reported  
      
External validity:      
Are the results/conclusions relevant to the aims/objectives 
of the study? 
     
Are results critically appraised in relation to previous work?      
Are claims made for other situations?     Other clinical situations or other patient groups 
Is a target group of those liable to be using this manipulation 
identified? 
     
How are links made between the study and any application 
in other contexts? – literature, analogy/experience  
    Lines of argument form the literature 
Unsubstantiated lines of argument, relating to 
what is assumed to be expected practice  
Are pharmaceutical factors that impact on generalisability 
identified and discussed  
    e.g. excipients, manufacturing process and how 
they might affect the results 
Are the implications of therapeutic index of the drug and 
possible implications for manipulations identified and 
discussed? 
     
Is there consideration of whether the manipulation would 
require quality assurance in clinical practice?  
    Methods of ensuring consistency in manipulation in 
clinical situations  
Are manipulation risks to those manipulating the drug 
discussed? 
Are manipulation risks to those taking the manipulated drug 
discussed? 
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 N/A
9
 N/R
10
 
Yes  Further details (if req.) Descriptor  
Are the conclusions of the study supported by the results and 
the discussion?  
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Appendix 4 
 Observational study reference guide  
 
MODRIC – data observation forms: definitions of data to be collected  
Overall: where data is missing/unavailable at the time of the observation note in 
additional comments box if boxes on the form are left blank it will be assumed that 
this data has been accidentally not recorded and will be treated as missing data 
Section A: Background data 
Box on form  Data to be collected  
Date/Time  Date and time drug prescribed to be given at  
Time given  Time administered  
Patient ID  AH no. to be taken from drug kardex (if not on the drug kardex and 
taken from elsewhere or if the patient only has an NHS no. then 
record this and note in additional comments)  
Gestation age at birth   
HCP The HCP checking and giving the drug  
Weight  To be taken from the drug kardex (if not on kardex, take from notes 
and note in additional comments)  
Route of administration  Oral, rectal, IV etc. (where oral being given via PEG/NG tube note 
this additionally)  
Product name/manufacturer  To be taken from the packaging used 
Pharmacist comments  Note any pharmacy annotations to the drug kardex (if there are 
none note this or put a line through the box) 
Diagnosis  To be asked of the HCP giving the drug  
 
Section B: Tablets or Capsules  
Tablet cut or broken  
Box on form  Data to be collected  
Score line  Y/N also note number of score lines 
Tablet shape  Oval, round, square etc. (where the observer thinks that 
perceptions may differ e.g. between oval/round note in additional 
comments and an assessment can be made retrospectively) 
Number of segments  Where there is an odd number note the reason (e.g. 3 segments as 
the tablet has been split into 2 halves and 1 half split into quarters) 
Segments appeared equal in 
size 
Refers to the segment of which ½ is being given  
Powder generated Y/N (unintentionally generated fragments/particles as a result of 
the manipulation (regardless of size) i.e. fragments not intended to 
be administered) 
Approximate fraction of 
tablet given  
½, ¼ etc.  
Location of manipulation Where manipulation took place e.g. medicine trolley, treatment 
room, bedside (in ICU this includes preparation on the trolley in the 
bedside)  
Equipment used Specify e.g. syringe, medicine cup etc.  
Remaining segments  Discarded/retained (if retained where stored)  
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Tablet crushed  
Box on form  Data to be collected  
Enteric coated  Y/N (to be taken from product packaging, where Y check with HCP if 
this is routine/expected practice)  
Fraction of tablet given  ½, ¼ etc. 
Location of manipulation Where manipulation took place e.g. medicine trolley, treatment 
room, bedside  
Equipment used  Specify e.g. syringe, medicine cup etc.  
  
Tablet dispersed   
Box on form  Data to be collected  
Dispersible tablet  Y/N (to be taken from product packaging)  
Dispersed in(liquid & volume) Specify (e.g. water and 5mL, if volume unclear note In additional 
comments)  
Tablet split first? Powder? Y/N for both ( powder refers to powder generated i.e. 
unintentionally generated fragments/particles as a result of the 
manipulation) 
Powder included in dispersal?  Y/N (Y where any powder that has been generated by the splitting 
of the tablet has been dispersed, N where this residue has not been 
added to the liquid being used to disperse the tablet) 
Tablet appeared fully 
dispersed  
Y/N (if N add details)  
Mixed (specify) Y/N (note how mixed e.g. stirred with syringe, spoon etc.) 
Time: dispersal to 
administration 
Approximate time e.g. 1min, 10mins etc. 
Location of manipulation Where the manipulation took place e.g. medicine trolley, treatment 
room, bedside 
Equipment used  Specify e.g. syringe, medicine cup etc. 
Drawn from approx. what 
depth  
Note whether the portion to be administered was taken from the 
top, middle or bottom of the container  
  
Capsule dispersed   
Box on form  Data to be collected  
Dispersed in(liquid & volume) Specify (e.g. water and 5mL, if volume unclear note In additional 
comments) 
Contents appeared fully 
dispersed  
Y/N (if N add details) 
Mixed (specify) Y/N (note how mixed e.g. stirred with syringe, spoon etc.) 
Time: dispersal to 
administration 
Approximate time e.g. 1min, 10mins etc. 
Location of manipulation Where the manipulation took place e.g. medicine trolley, treatment 
room, bedside 
Equipment used  Specify e.g. syringe, medicine cup etc. 
Drawn from approx. what 
depth  
Note whether the portion to be administered was taken from the 
top, middle or bottom of the container  
 
Section C: Liquids, Suppositories, Enemas, Nebulisers  or Transdermal Patches   
Liquid diluted  
Box on form  Data to be collected  
Dispersed in(liquid & volume) Specify (e.g. water and 5mL, if volume unclear note In additional 
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comments) 
Mixed (specify) Y/N (note how mixed e.g. stirred with syringe, spoon etc.) 
Dilution appeared to change 
the appearance of the liquid 
Give details such as changes in colour or consistency  
Location of manipulation Where the manipulation took place e.g. medicine trolley, treatment 
room, bedside 
Equipment used  Specify e.g. syringe, medicine cup etc. 
Drawn from approx. what 
depth  
Note whether the portion to be administered was taken from the 
top, middle or bottom of the container  
  
Suppository  
Box on form  Data to be collected  
Cut direction Vertically (cut along the length of the suppository), horizontally (cut 
across the width of the suppository) 
Number of segments  Total number of pieces the suppository cut into  
Segments appeared equal in 
size  
Y/N, specify if N, or if cut horizontally give further details  
Approx. % of suppository 
given 
e.g. 25%, 50%, 66%, if other approx. % give details  
Direction suppository given End of the suppository inserted first; blunt or pointed 
Location of manipulation Where the manipulation took place e.g. medicine trolley etc.  
Cut with a knife Y/N  
Other equipment  Specify  
  
Enemas  
Box on form  Data to be collected  
Enema manipulation prior to 
or after administration 
Prior/after e.g. ½ an enema given by discarding ½ first or by giving 
½ to the patient and discarding the remainder  
Proportion enema contents 
removed (specify)? 
Approx. volume of enema contents removed e.g. 25mL, or if less 
accurately done ½, ¼ etc. specify how removed e.g. using syringe to 
measure, volume approximated by HCP  
Approx. % of enema given  e.g. 25%, 50%, 66%, if other approx. % give details 
Location of manipulation  Where the manipulation took place e.g. medicine trolley etc. 
Equipment used  Specify  
 Where there is any other type of manipulation of an enema e.g. a 
dilution, record the details as free text in additional comments  
  
Transdermal patches  
Box on form  Data to be collected  
Patch cut or covered  Cut/covered (specify if there are markings on the patch to guide 
cutting/covering) 
If cut, no. of segments  Where this is an odd number note the reason (e.g. 3 segments as 
the patch has been split into 2 halves and 1 half has been split into 
quarters) 
If covered approx. % of patch 
covered  
e.g. 25%, 50%, 66% 
Approx. % of patch applied  e.g. 25%, 50%, 66% 
Remainder of patch  Discarded/stored (if stored specify where) 
Location of manipulations  Where the manipulation took place e.g. medicine trolley etc. 
Equipment used  Specify  
Extra adhesion needed for 
patch 
If used specify what used and if it covered whole or part of the 
patch 
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Nebuliser  
Box on form  Data to be collected  
Dispersed in(liquid & volume)  Specify (e.g. water and 5mL, if volume unclear note In additional 
comments) 
Location  of manipulation Where the manipulation took place e.g. medicine trolley etc. 
Equipment used  Specify  
 
Section D: IVs  
IV bolus  
Box on form  Data to be collected  
Original drug  Powder for reconstitution/ready prepared solution/other (specify) 
Reconstitution details  e.g. mixed with 2mL water  
Volume and dose of 
reconstituted drug or ready 
prepared solution taken  
e.g. 1.2mL being 0.5mg of drug taken from the vial  
Diluted in(liquid & volume) e.g. saline, 100mL 
Volume given and dose Volume removed from diluted solution and the dose that this is 
presumed to contain (e.g. 2mL, 0.05mg of drug) 
Location of manipulation Where the manipulation took place e.g. medicine trolley etc.  
Equipment used Specify  
Syringe labelled  Y/N, note when e.g. as soon as drawn up, at bedside  
  
IV infusions (≥2 dilutions)  
Box on form  Data to be collected  
Original drug  Powder for reconstitution/ready prepared solution/other (specify) 
Reconstitution details  e.g. mixed with 2mL water  
Volume and dose of 
reconstituted drug or ready 
prepared solution taken  
e.g. 1.2mL being 0.5mg of drug taken from the vial  
First dilution, diluted in(liquid 
& volume) 
e.g. saline, 100mL 
Volume removed and dose  Volume removed from diluted solution and the dose that this is 
presumed to contain (e.g. 2mL, 0.05mg of drug) 
Second dilution, diluted 
in(liquid & volume) 
Volume and liquid used for the infusions e.g. saline 50mL 
Location of manipulation Where the manipulation took place e.g. medicine trolley etc.  
Equipment used Specify  
Syringe labelled  Y/N, note when e.g. as soon as drawn up, at bedside  
 
Sections B, C and D  
Box on form  Data to be collected  
Manipulation checked by 2 
HCPs 
Y/N (if N note if there was a reason for this) 
Manipulation expected 
practice by HCP 
Y/N, ask HCP giving the drug, if N ask for further details  
Manipulation repeated for 
any reason 
Note reason 
Any source of reference used  Note source if used  
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Appendix 5 
Parent/Carer interview prompt guide  
 
Background: Child’s age; Diagnosis; Current prescribed medication  
a) Were they taking medicines from a very young age/since babyhood 
b) Is the child taking a fairly regular set of medicines that they are almost 
always on, or do their prescriptions change regularly? 
c)  What are the medicines for? 
 
1) What do you feel about administering medicines to your child at home? 
 
2) What are the challenges you face when administering medicines to your 
child at home? 
 
3) What happens when your child is reluctant to/refuses to or is unable to take 
their medicines?   
a) Could you describe these situations and any methods that you use when 
they occur? 
b) Any reasons for refusal to take the meds?  Can you describe what 
happened? 
c) Could you describe a typical drug administration where this happens and 
the methods that you may use to ensure that the medicine is taken? 
d) Does your child ever have difficulties with swallowing medicines (if so – are 
there any particular medicines that this applies to and what methods do you use to 
ensure that the medicine is taken in this situation)? 
 
4) Some parents have told us that giving a child the prescribed dose is difficult. 
What is your experience about this?  
a) Have you had to give your child any medicines where getting this 
prescribed dose was difficult – such as where half a tablet/portion of a 
sachet/half of a nebuliser dose was needed? 
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b) Can you describe examples of this and methods that were used to get the 
dose prescribed? 
c) Do you have any concerns about this? 
d) Was there any advice on this that you received that was helpful, or would 
have been helpful, from healthcare professionals? 
 
5) Do you have any further thoughts/concerns about administering medicines 
to your child or children generally that may be helpful for those designing 
medicines for children? 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
